

## CURRICULUM VITAE

ROXANA MEHRAN, MD, FACC, FACP, FCCP, FESC, FSCAI

---

### CURRENT POSITIONS

2010-Present Professor of Medicine, Mount Sinai School of Medicine, New York, NY  
2010-Present Director of Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai School of Medicine, New York, NY  
2008-Present Chief Scientific Officer, Cardiovascular Research Foundation, New York, NY  
1999-Present Director of Clinical Research and Data Coordinating Center  
Cardiovascular Research Foundation, New York, NY  
1996-Present Course Co-Director, *Transcatheter Cardiovascular Therapeutics*, Washington, DC

### PREVIOUS POSITIONS

2004-2010 Associate Professor of Medicine in the Academic Track Department of Internal Medicine and Division of Cardiovascular Disease, Columbia University Medical Center, New York, NY  
2004-2010 Director, Outcomes Research, Data Coordination & Analysis, Center for Interventional Vascular Therapy, Columbia University Medical Center, New York, NY  
2002-2004 Associate Clinical Professor of Medicine, New York University School of Medicine  
1999-2004 Interventional Cardiologist, Lenox Hill Interventional Cardiology PC, Lenox Hill Hospital, New York, NY  
1997-1999 Assistant Clinical Professor of Medicine; George Washington University School of Medicine  
1996-1999 Director of Clinical Research and Data Coordinating Center  
Cardiology Research Foundation, Washington Hospital Center, Washington, DC  
1995-1999 Interventional Cardiologist, Washington Cardiology Center  
Washington Hospital Center, Washington, DC  
1994-1995 Instructor of Medicine, Mount Sinai School of Medicine, New York, NY

### POSTGRADUATE EXPERIENCE

1994-1995 Fellow, Interventional Cardiology, Cardiovascular Institute  
Mount Sinai Medical Center, New York, NY  
1991-1994 Fellow, Cardiology, Cardiovascular Institute  
Mount Sinai Medical Center, New York, NY  
1990-1991 Chief Resident, Internal Medicine, University of Connecticut School of Medicine  
Greater Hartford Integrated Internal Medicine Program, Hartford, Connecticut  
1988-1990 Resident, Internal Medicine, University of Connecticut School of Medicine  
Greater Hartford Integrated Internal Medicine Program, Hartford, Connecticut  
1987-1988 Medical Intern, Mount Sinai Hospital, Hartford, Connecticut

### POSTDOCTORAL FELLOWSHIPS

1990-1991 Postdoctoral Fellow, Department of Cardiology and Physiology  
University of Connecticut School of Medicine, Farmington, Connecticut  
1992-1993 Postdoctoral Fellow, Brookdale Center for Molecular Biology  
Mount Sinai School of Medicine, New York, NY

### EDUCATION

1987 St. George's University School of Medicine Grenada, WI **MD**  
1983 New York University, New York, NY **BA (Chemistry)**

### CERTIFICATIONS

1990 Diplomat, American Board of Internal Medicine  
1997 Diplomat, American Board of Internal Medicine, Cardiovascular Disease

1999 Diplomat, American Board of Internal Medicine, Interventional Cardiology  
 1985 Educational Commission for Foreign Medical Graduates [ECFMG #397-285-8]  
 1985 FLEX [# 621017500]

**HOSPITAL APPOINTMENTS**

2010 Mount Sinai Hospital, New York, NY  
 2004 Columbia University Medical Center/ New York Presbyterian Hospital, New York, NY  
 1999 Lenox Hill Hospital, New York, NY  
 1999 George Washington University, Washington, DC  
 1995 Washington Hospital Center, Washington, DC  
 1990 Mount Sinai Hospital, New York, NY

**MEMBERSHIPS and COMMITTEE APPOINTMENTS**

2012- Voting Member, Education Committee, SCAI  
 2011- Member, Technical Panel, American College of Cardiology/American Heart Association (ACCF/AHA) Appropriate Use Criteria for Diagnostic Catheterization  
 2011- Member, American College of Cardiology (ACC), Women in Cardiology Council  
 2011- Member, Society for Cardiac Angiography and Interventions (SCAI), Interventional Training Standards Committee  
 2011- Writing Committee, (SCAI), Reassessment of the Validity of the Universal Definition for MI following Coronary Revascularization  
 2011- Steering Committee Member, (SCAI), Gender Data Forum  
 2011- Strategic Committee, Advisory Board, SANOFI, Otamixaban  
 2010 Member, Writing Committee: ACCF/AHA Guidelines for Percutaneous Coronary Intervention (PCI)  
 2010- SCAI Representative, American College of Cardiology (ACC) Imaging Council  
 2009 Chair, Writing Committee for Bleeding Academic Research Consortium  
 2007-2010 Member, Conflict of Interest Committee Columbia University  
 2009 Lead, Standardized Definition for Cardiovascular Events in Clinical Trials, FDA- CDER  
 2009 Executive Operations Committee/Steering Committee- EXCEL Trial  
 2009- District 1 Councilor, New York State Chapter of the American College of Cardiology, NY State Cardiological Society  
 2009- Member, Business Development Advisory Panel, American College of Cardiology  
 2008- Chair, Women in Innovations (WIN). Society of Cardiac Angiography and Interventions (SCAI).  
 2008- Member of Board of Trustees: Society of Cardiac Angiography and Interventions (SCAI)  
 2005 Executive Committee Academic Research Consortium  
 2004 Member, Writing Group for Intravascular Echocardiography during Percutaneous Treatment of Adult Congenital Heart Disease: American Society of Echocardiography  
 2003 Member of Board of Directors: Society of Eradication of Heart Attacks: SHAPE  
 2003-2005 Member, Committee on Diagnostic & Interventional Cardiac Catheterization Council on Clinical Cardiology: American Heart Association  
 2003 Member, Advisory Board, [www.HeartHealthyWomen.org](http://www.HeartHealthyWomen.org): Women's Cardiovascular Health Initiative  
 2003 Member, Writing Group for Guidelines of Interventional Cardiovascular Treatment in Women: American Heart Association  
 2002 Fellow, Society for Cardiac Angiography and Interventions (FSCAI)  
 1999 Fellow, American College of Physicians (FACP)  
 1999 Fellow, American College of Cardiology (FACC)  
 1999 Fellow, European Society of Cardiology (FESC)  
 1999 Fellow, American College of Chest Physicians (FCCP)  
 1999 Fellow, Council on Arteriosclerosis, Thrombosis, and Vascular Biology (AHA)  
 1999 Member, Society for Cardiac Angiography and Interventions (SCAI)  
 1996 Member of the Angiographic committee; **Women's Angiographic Vitamin and Estrogen trial (WAVE Trial)**; NHLBI  
 1995 Member, American College of Cardiology  
 1995 Member, American College of Physicians  
 1995 Member, American Heart Association

### **EDITORIAL WORK**

1. Moderator, Expert Roundtable Discussion for *The Medical Roundtable Cardiovascular Edition*, Marvin Moser (ed), Topic "Antithrombotic Progress — Evolving Oral Agents ADP Inhibitors, Antithrombins, Fr Xa Inhibitors."
2. Guest Editor, *Interventional Cardiology Clinics on Coronary Interventions in Women*
3. Section Editor, *Textbook of Coronary Stenting*. Stone GW, Leon MB (eds). W.B. Saunders Co, Boston, MA; in press.
4. Editor, Transcatheter Cardiovascular Therapeutics Manual of Interventional Trials CD-ROM. 2002-2004.
5. Editor, Transcatheter Cardiovascular Therapeutics Syllabus. 1996-2002.
6. **Editorial Board**, *Circulation*.
7. Editorial Consultant (manuscript reviewer), *Journal of Kidney Disease*.
8. **Editorial Board**, *Journal of American College of Cardiology*.
9. Editorial Consultant, *American Journal of Cardiology*.
10. Editorial Consultant, *American Heart Journal*.
11. **Section Editor**, *Catheterization and Cardiovascular Interventions (Diagnosis)*.
12. Editorial Consultant, *Coronary Artery Disease*.
13. *Editorial Consultant*, *New England Journal of Medicine*
14. *Editorial Consultant*, *Journal of American Medical Association*

### **FACULTY APPOINTMENTS IN CONFERENCES & SOCIETIES**

1. Transcatheter Cardiovascular Therapeutics (TCT) Course Co-Director. 1996-Present.
2. American Heart Association Scientific Session (AHA) 1996 - present
3. American College of Cardiology (ACC). 1997-Present.
4. Interventional Cardiology Fellows' Course. 1998-present.
5. Joint Interventional Meeting (JIM) Rome, Italy 2000-present.
6. European Society of Cardiology (ESC). 2001-present
7. Sociedad Latino Americana de Cardiologia Intervencionista (SOLACI)
8. China Interventional Therapeutics (CIT)
9. Angioplasty Summit - TCT Asia Pacific- Korea
10. EuroPCR
11. Global Interventional Summit (GIS). 2010
12. Società Italiana di Cardiologia Invasiva (GISE)
13. Cardiological Society of Argentina, Buenos Aires, Argentina. October 1998.

### **INVITED LECTURES**

1. Cardiology Grand Rounds, Elmhurst Hospital, Elmhurst, NY: Impact of bleeding in patients with Cardiovascular Disease, April 12, 2011
2. Bleeding Academic Research Consortium: Definitions and Algorithms for Risk Prediction (ACC 2011 i2 Symposium, New Orleans, LA)
3. Bleeding: The New Risk Factor (ACC 2011, New Orleans, LA)
4. CKD in the Cardiac Cath Patient-African Americans Compared with Others (ACC 2011, New Orleans, LA)
5. Complication Management (ACC 2011 i2 Symposium, New Orleans, LA)
6. Dual Antiplatelet Therapy: Updates and Advancements (ACC 2011, New Orleans, LA)
7. Prevalence and Presentation: Differences and Similarities among Genders that Affect Patient Outcomes - A Western Perspective (ACC 2011, ACC Spotlight, New Orleans, LA)
8. Update on Left Main/Multivessel PCI: Lessons from SYNTAX, a View to Excel (ACC 2011, 2011 Women in Innovations Symposium, New Orleans, LA)
9. ATLAS ACS TIMI 51 Modeled Data (ACC 2011, ACS Roundtable, New Orleans, LA)
10. How to Prevent Contrast-Induced Nephropathy Now and in the Future (TCT 2010 Nurse-Technologist Symposium, Washington DC)
11. The Adjudicators: Role and Responsibilities of the CEC (TCT 2010 Comprehensive Training in Clinical Research Course, Washington DC)
12. Pros and Cons of Globally Conducted Studies (TCT 2010 Comprehensive Training in Clinical Research Course, Washington DC)
13. Should DES be used frequently in patients with STEMI? (TCT 2010, Washington DC)
14. Chronic Kidney Disease, Contrast Agents, and Radiocontrast Nephropathy (TCT 2010 Board Review Course with Self-Assessment, Washington DC)

15. Balancing the Risks of DAPT: The Yin and the Yang (TCT 2010, Washington DC)
16. Is there a need for improved anticoagulation during PCI? The balance of ischemia and bleeding (TCT 2010, Washington DC)
17. Hybrid Coronary Revascularization: What constitutes and abnormal immediate and early postoperative angiogram? (TCT 2010, Washington DC)
18. What type of bleed increases mortality? Access vs. non-access site-related? Transfusion vs. major vs. minor? (TCT 2010, Washington DC)
19. Contrast-Induced Nephropathy: A complication that can and must be minimized during all procedures (TCT 2010, Washington DC)
20. Individualizing pharmacologic decision-making based on clinical profiles: The ACUITY Example (TCT 2010, Washington DC)
21. Understanding and reversing the decline in US clinical research participation: Scope of the problem and root causes: the CRF perspective (TCT 2010 FDA Town Hall Meeting, Washington DC)
22. PCI Anti-Platelet Pharmacology: The Complex Integration of New Dosing Schemes, New Agents (Prasugrel and Ticagrelor) and Platelet Monitoring into Clinical Practice (SOLACI 2010, Buenos Aires)
23. New Antiplatelet Agents: What is New and Who is it For? (SOLACI 2010, Buenos Aires)
24. Revascularization Strategy for Patients with Left Main Coronary Disease and Chronic Total Occlusions: Do Randomized Trials Benefit Angioplasty? (SOLACI 2010, Buenos Aires)
25. Anti-Platelet drugs in 2010: What is currently available, what is surpassed, what is promising? (SIM 2010, Catania)
26. An evidence-based decision-making in Treatment of patients with Left Main Disease (SIM 2010, Catania)
27. The latest news from DES trials (SIM 2010, Catania)
28. Drivers of Mortality Following Primary PCI – Attributable Factors (EuroPCR 2010, Paris)
29. Bleeding Academic Research Consortium – Consensus on Event Definition (EuroPCR 2010, Paris)
30. Planning the Regulatory Process for Devices and Adjunct Pharmacology: How to Work Closely with CEDR and CDRH (CIT 2010, Beijing)
31. The Nuances of Superiority and Non-Inferiority Trials: Design Considerations and Choice of Endpoints (CIT 2010, Beijing)
32. Adjunctive Pharmacology: New Drugs, Important Clinical Trials, and Changing Treatment Strategies (CIT 2010, Beijing)
33. Latest Clinical Results on Contrast-Induced Nephropathy (CIT 2010, Beijing)
34. Safety Issues Related to Treating Bifurcation Lesions (TCT 2009, San Francisco)
35. Updates from Ongoing DAPT Studies: The PARIS Registry (TCT 2009, San Francisco)
36. Research in Women (TCT 2009, San Francisco)
37. Contrast-Induced Acute Kidney Injury: Latest Clinical Evidence (TCT 2009, San Francisco)
38. Chronic Kidney Disease, Contrast Agents, and Radiocontrast Nephropathy (Recertification and Board Review Course, TCT 2009, San Francisco)
39. Role of Risk Scores and Prognostic Models (TCT 2009, San Francisco)
40. Importance of Bleeding in STEMI: Insights from HORIZONS-AMI (TCT 2009, San Francisco)
41. Balancing Bleeding-Ischemic Risks in Relation to Duration of Anti-Platelet Therapy (TCT 2009, San Francisco)
42. Contrast-Induced Nephropathy: Incidence, Mechanisms, and Strategies for Prevention: A Systematic Analysis of What Works and What Does Not (TCT 2009, San Francisco)
43. IMA Angiography Soon After CABG: Findings and When To Intervene (TCT 2009, San Francisco)
44. Biomarkers for CIN – Role of NGAL (TCT 2009, San Francisco)
45. Determinants of Post-PCI Mortality – What are the Attributable Events? (ESC 2009, Barcelona)
46. Clinical Applications and Case Studies in Understanding a Patient's Antiplatelet Response (ESC 2009, Barcelona)
47. Mortality of Patients Treated with Bivalirudin Compared to Heparin Plus Glycoprotein IIb/IIIa Inhibitors After Clopidogrel Pre-Treatment: A Meta-Analysis from Randomized Trials (ESC 2009, Barcelona)
48. Summarizing the US Clinical Experiences with DES Treatment of Unprotected Left Main: Cedars, Columbia, Scripps, and Others (Left Main & Bifurcation Summit 2009, New York)
49. Balancing Ischemia and Bleeding Both Acutely and Long-Term (ACC/i2 2009, Orlando)
50. Results from the Prospective Milan-New York CTO Registry (CTO Summit 2009, New York)
51. TRITON-TIMI 38: The Future Role of Prasugrel (and other new antiplatelet agents) in PCI (Angioplasty Summit: TCT Asia Pacific 2009, Seoul)
52. Pharmacology Confusion: How to Choose Antithrombotic & Antiplatelets for STEMI and NSTEMI (6<sup>th</sup> Annual Innovations, Cardiac & Vascular Symposium 2009, Washington Adventist Hospital)
53. HORIZONS-AMI – A Prospective, Randomized Comparison of Bivalirudin vs. Heparin plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction: One Year Results (TCT 2008, Washington DC)
54. The Columbia DES Left Main Experience: Long Term Follow-Up (TCT 2008, Washington DC)

55. Identifying the Patient at High Risk for Bleeding vs Ischemia: Insights from ACUITY and HORIZONS (TCT 2008, Washington, DC)
56. Bivalirudin has Emerged as the New Gold Standard (TCT 2008, Washington DC)
57. HORIZONS-AMI: Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary PCI in STEMI (TCT 2008, Washington DC)
58. Does Major Bleeding Incite or Otherwise Correlate with Early and Late Stent Thrombosis? Insights from ACUITY and HORIZONS (TCT 2008, Washington DC)
59. Impact of Ischemic vs. Bleeding Endpoints: Lessons from ACUITY and HORIZONS (TCT 2008, Washington DC)
60. Chronic Kidney Disease, Contrast Agents and Radiocontrast Nephropathy (Recertification and Board Review Course, TCT 2008, Washington DC)
61. Lessons Learned From Surrogate Endpoints: From Periprocedural MI to Late Loss (TCT 2008, Washington DC)
62. Impact of Major Adverse Cardiac Events and Major Bleeding on Overall Mortality in Patients with STEMI: HORIZONS-AMI (ESC 2008, Munich)
63. Bivalirudin: HORIZONS-AMI Trial Update (ACC/i2 2008, Chicago)
64. Contrast Induced Nephropathy (ACC/i2 2008, Chicago)
65. Radiocontrast Considerations – Use, Abuse, and Helpful Management Tips for CIN (CTO Summit 2008, New York)
66. On-Label DES Use: Meta-Analyses of the Prospective, Double-Blind Trials (And the ARC Definitions) (TCT 2007, Washington DC)
67. Chronic Kidney Disease and Contrast Nephropathy: Prognostic Impact and the Hottest Data on Preventive Therapies (TCT 2007, Washington DC)
68. Causes, Patterns and Treatment Options for In-stent DES Restenosis (TCT 2007, Washington DC)
69. Factoring in Radiation Exposure, Contrast Utilization and Resource Consumption in the Decision to perform CTO Angioplasty (TCT 2007, Washington DC)
70. Restenosis and Thrombosis of Bare Metal and Drug-Eluting Stents (TCT 2007, Washington DC)
71. HORIZONS AMI: Harmonizing Outcomes with Revascularization and Stents In Acute Myocardial Infarction (SOLACI 2007, Buenos Aires)
72. Understanding DES Thrombosis: Clinical, Angiographic, and Procedural Correlates, and the New “ARC” Definitions (DES Summit at ACC/i2 2007, New Orleans)
73. Does the Type of DES Really Matter and Why? (ACC/i2 2007, New Orleans)
74. CTO Environmental Issues: Radiocontrast Considerations-Use, Abuse, and Helpful Management Strategies to Avoid CIN (CTO Summit 2007, New York)
75. A Critical View on the Current Clinical Data (EuroPCR 2007)
76. How to Interpret Primary Endpoint, Secondary Endpoint, and Statistical Information of Randomised Clinical Trials (EuroPCR 2007)

#### **AWARDS**

- |      |   |
|------|---|
| 1991 | NASPE Fellow; Chicago, IL   |
| 2001 | Innovation in Clinical Research: "Novel Approaches for the Inhibition of Stent Restenosis and Arteriopathy After Cardiac Transplantation" (Co-recipient: Steven O. Marx) Doris Duke Charitable Foundation, New York, NY |

#### **LICENSURE**

New York State	License # 185790-1
Connecticut	License # 30590
District of Columbia	License # MD 30649

#### **RESEARCH**

##### **ONGOING**

1. **Data Safety Monitoring Board:** OPTIMIZE Trial
2. **Data Safety Monitoring Board:** INFUSE-AMI Trial
3. **Data Safety Monitoring Board:** Resolute China RCT
4. **Member of Steering Committee:** The REMEDEE Trial: A Prospective, Randomized Study to Evaluate the Safety and Efficacy of an Abluminal Sirolimus Coated Bio-engineered Stent (Combo Bio-engineered Sirolimus Eluting Stent)
5. **Member of Steering Committee:** SAFE-PCI for Women: Protocol Launch
6. **National Co-PI:** RenalGuard US pivotal trial. Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The **RenalGuard** System in High-Risk Patients for Contrast-Induced Acute Kidney Injury
7. **Member of Executive Committee:** **EXCEL Trial:** Evaluation of XIENCE PRIME™ Everolimus Eluting Stent System (EECSS) or XIENCE V® EECSS Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization

8. **Co-Investigator:** Multidisciplinary Training in Translational Cardiovascular Research. Funding Institution: NHLBI, Current Award #5 T32 HL08-7745-01
9. **Co-Investigator:** Improving Med Adherence in Post-ACS Patients: Phase 1B Dose-Finding RCT. Funding Institution: NHLBI, Current Award # K24 HL084034
10. **Co-Investigator:** Depression, Biobehavioral Mechanisms, & CHD/Mortality Outcomes (PULSE). Funding Institution: NHLBI, Current Award # 5 P01 HL088117-02
11. **Co-Investigator: FREEDOM** Trial: Future Revascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease. Funding Institution: NHLBI.
12. **Co-Investigator:** Cardiac Caregiver Study. Funding Institution: NHLBI. Award #2R01 HL075101-05A1
13. **Member of Data Safety Monitoring Board:** European Ambulance ACS Angiox Trial (The **EUROMAX** study)
14. **Member of Executive Committee: RADAR:** A Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-Ranging Study Assessing the Safety, Efficacy, and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Heparin in Subjects With Acute Coronary Syndrome
15. **Principal Investigator: Patterns of Non-Adherence to Antiplatelet Regimens in Stented Patients:** An Observational Single-Arm Study (The **PARIS** Registry)
16. **Director of Data Coordination and Analysis and Chair, Clinical Events Committee (non-Voting Member):** Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (**HORIZONS-AMI**): A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using either anticoagulation with unfractionated heparin plus routine IIb/IIIa inhibition with bivalirudin and bail-out IIb/IIIa inhibition, and primary angioplasty with stent implantation with either a slow rate-release paclitaxel-eluting stent (TAXUS™) or an otherwise identical uncoated bare metal stent (EXPRESS™)
17. **Chair, Clinical Events Committee (Non-Voting Member) : Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES)**
18. **Chair, Clinical Events Committee (Non-Voting Member): XIENCE V USA:** A prospective, open-label, multicenter, observational, single-arm registry designed to evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings.
19. **Chair, Clinical Events Committee (Non-Voting Member) : XIENCE DAPT :** A prospective, multicenter, randomized, double-blind AV-DAPT cohort to assess the effectiveness and safety of 12 versus 30 months of DAPT in patients undergoing percutaneous coronary intervention (PCI) with XIENCE V placement for the treatment of coronary artery lesions
20. **Chair, Clinical Events Committee (Non-Voting Member): XIENCE India:** A prospective, open-label, multicenter, observational, single-arm registry designed to evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings.
21. **Chair, Clinical Events Committee (Non-Voting Member) : SPIRIT SV :** To evaluate the safety and effectiveness of the 2.25 mm XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS) in improving coronary luminal diameter in subjects with ischemic heart disease due to a maximum of two de novo native coronary artery lesions in small vessels, each in a different epicardial vessel
22. **Chair, Clinical Events Committee (Non-Voting Member) : SPIRIT PRIME :** To evaluate the safety and effectiveness of the XIENCE PRIME and XIENCE PRIME LL EECSS in improving coronary luminal diameter in subjects with symptomatic heart disease due to a maximum of two de novo native coronary artery lesions, each in a different epicardial vessel
23. **Chair, Clinical Events Committee (Non-Voting Member) : RESOLUTE International :** Evaluation of the Endeavor Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population
24. **Chair, Clinical Events Committee (Non-Voting Member): RESOLUTE Harmonization:** A research collaboration between three organizations for the purpose of uniform event adjudication in Medtronic-sponsored clinical trials and inspired by earlier work done within the Academic Research Consortium. The objective of this academically-based partnership is to come to a harmonization and consistency in clinical event adjudication to allow for longitudinal and cross-sectional comparison of study results.
25. **Chair, Clinical Events Committee (Non-Voting Member): INFUSE-AMI :** A two-by-two factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction
26. **Chair, Clinical Events Committee (Non-Voting Member): COMPASSION THV: Congenital Multicenter trial of Pulmonic valve regurgitation Studying the SAPIEN interventional THV (Implantation of the SAPIEN™ Transcatheter Heart Valve (THV) in the Pulmonic Position).**
27. **Chair, Clinical Events Committee (Non-Voting Member):**A randomized, multicenter study of the pimecrolimus-eluting and pimecrolimus/paclitaxel-eluting coronary stent system in patients with de novo lesions of the native coronary arteries (GENESIS)

28. **Chair, Clinical Events Committee** (Non-Voting Member): **BIOFREEDOM**: A prospective, single-blinded, randomized study to evaluate the safety and effectiveness of a low and standard dose BIOFREEDOM™ biolimus A9™ drug-eluting coronary stent delivery system compared with a TAXUS Liberte™ control arm for treatment of stenotic lesions in native coronary arteries
29. **Chair, Clinical Events Committee** (Non-Voting Member): Phase I feasibility, non-randomized, multicenter, prospective, consecutive registry. Clinical Evaluation Of the Edwards Lifesciences PercUtaneous Mitral AnnulOplasty System for the Treatment of Mitral RegurgitatioN (**EVOLUTION I**)
30. **Chair, Clinical Events Committee** (Non-Voting Member): Multicenter, prospective, non-randomized study. Clinical Evaluation Of the Edwards Lifesciences MONARC System for the treatment of Mitral RegUrgiTatION II (**EVOLUTION II**)
31. **Director of Data Coordination and Analysis**: Clinical Evaluation of the Concomitant Use of Bivalirudin (Angiomax®) and a Drug-Eluting Stent (**ADEST**)

**COMPLETED**

1. **Co-Investigator**: Family-Centered Intervention Trial for Heart Health (**FIT HEART II**). Funding Institution: NIH, Current Award # 2RO1HL075101-05A1
2. **Chair, Clinical Events Committee (Non-Voting Member)**: Providing Regional Observations to Study Predictors of Events in the Coronary Tree (**PROSPECT**): An imaging study in patients with unstable atherosclerotic lesions
3. **Director of Data Coordination and Analysis and Chair, Clinical Events Committee (Non-Voting Member)**: A Randomized Comparison of Angiomax® (bivalirudin) versus Lovenox®/Clexane®(enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation (**ACUITY**)
4. **Principal Investigator**: **BREF-CU** Cardio Pilot Study I: A Multi-Center Pilot Study Of The Feasibility Of Collecting,Data Warehousing, & Retrieving Patient Specific Intracoronary Stent Device Information For The Purposes Of Developing A National Real-Time Medical Device Registry
5. **Director of Data Coordination & Analysis and Chair, Clinical Events Committee (Non-Voting Member)**:Sirolimus-Eluting BX Velocity™ Balloon-Expandable Stent in a Compassionate Use Registry (**SECURE**)
6. **Director of Data Coordination and Analysis and Chair, Clinical Events Committee (Non-Voting Member)**: CoMprehensive AssessmenT of SiRolimus-Eluting Stents In CompleX Lesions (**MATRIX**)
7. **Principal Investigator**: Patency, Outcome, and Economics of Minimally Invasive Direct Coronary Bypass MIDCAB (**POEM**)
8. **Director, Data Coordination and Analysis**: Primary percutaneous intervention for acute myocardial infarction (**CADILLAC trial**)
9. **Director, Data Coordination and Analysis**: **TAXUS IV** subanalyses
10. **Director, Data Coordination and Analysis** : Early Ambulation Using Mechanical Compression (**C-Clamp**)
11. **Chair, Data Safety Monitoring Board**: Implantation of AVE Stent versus JJIS stent for the prevention of stenosis (**COSTAR**)
12. **Principal Investigator**: **FREEDOM Trial Registry Substudy**: RO-1 Grant (September 2004 submission) A multicenter trial of CABG surgery versus sirolimus drug-eluting stent implantation in diabetic patients with multivessel coronary artery disease. Sponsor: NHLBI, NIH.
13. **Principal Investigator**:Ionic Versus Nonionic Contrast to Obviate Worsening Nephropathy After Angioplasty in Chronic Renal Failure Patients (**ICON**)
14. **Director, Data Coordination and Analysis** :Stent Thrombosis Registry After Localized Radiation Therapy to Inhibit Restenosis After Stenting (**ROBOTICS**)
15. **Chair, Clinical Events Committee** (Non-Voting Member: **FORTRON** Trial: A prospective, multicenter study of the Cordis endovascular Quantum LP stent graft system for the treatment of abdominal aortic aneurysms (AAA)
16. **Director of Data Coordination & Analysis**: Washington Radiation In-stent Re-Stenosis Trial (**Beta WRIST**)
17. **Director of Data Coordination & Analysis**: The Long Washington Radiation In-stent Re-Stenosis Trial: A Two-Center Randomized Trial of Intravascular Radiation Therapy to Inhibit Restenosis After Stenting (**LongWRIST**)
18. **Director of Data Coordination & Analysis**: Washington Radiation In-stent Re-Stenosis Trial (**WRIST PLUS**)
19. **Chair, Clinical Events Committee (Non-Voting Member)**: A Randomized Feasibility Study of the Double Dose or Single Dose Sirolimus-Eluting Bx Velocity Balloon Expandable Stent for the Treatment of Diabetic Patients with *DeNovo* Native Coronary Artery Lesions (**3D [Double Dose Diabetes]**)
20. **Chair, Clinical Events Committee (Non-Voting Member)**: A Multicenter, Nonrandomized Study of the **4.0mm SIRolimUS**-Eluting Bx Velocity Balloon Expandable Stent (**SIRIUS 4.0**)
21. **Chair, Clinical Events Committee (Non-Voting Member)**: Investigational Device Exemption for the Jomed JOSTENT® Coronary Stent Graft System (**BARRICADE**)
22. **Chair, Clinical Events Committee (Non-Voting Member)**: **CARE I**: A prospective, non-randomized, feasibility study to evaluate the safety and performance of the CardiMind coronary stent system for treatment of stenotic lesions in small diameter native coronary arteries

23. **Chair, Clinical Events Committee (Non-Voting Member):** **Cardiomind/CARE II:** A prospective, randomized, multicenter study to evaluate the safety efficacy, and performance of the Cardiomind coronary stent systems for treatment of stenotic lesions in small diameter native coronary arteries
24. **Chair, Clinical Events Committee (Non-Voting Member):** **AXXENT:** A pilot study of the DEVAX Axxess™ Plus biolimus drug eluting stent for the treatment of de novo bifurcated lesions of the left main coronary artery
25. **Chair, Clinical Events Committee (Non-Voting Member):** **AXXESS PLUS:** Safety and performance evaluation of the DEVAX AXXESS™ PLUS biolimus drug eluting stent for the treatment of de novo bifurcated lesions in native coronary arteries
26. **Chair, Clinical Events Committee (Non-Voting Member):** **RESORB Trial:** Prospective, multi-center safety study (first in man experience) to evaluate the safety of the REVA medical bioabsorbable stent platform
27. **Chair, Clinical Events Committee (Non-Voting Member):** **HEALING-AMI:** A safety evaluation of the Genous Bio-engineered R Stent in the treatment of patients with ST-segment myocardial infarction
28. **Chair, Clinical Events Committee (Non-Voting Member):** **DIVERGE:** To evaluate the safety and efficacy of the AXXESS stent for the treatment of de novo bifurcation lesions in native coronary arteries
29. **Chair, Clinical Events Committee (Non-Voting Member):** **GENOUS-SING:** A safety evaluation of the Genous Bio-engineered R stent in the treatment of patients with ST-segment elevation myocardial infarction
30. **Chair, Clinical Events Committee (Non-Voting Member):** **COHEREX:** A multicenter study to evaluate the safety and efficacy of the Coherex FlatStent PFO closure system
31. **Chair, Clinical Events Committee (Non-Voting Member):** **CONCISE (CONOR):** A prospective, multicenter evaluation of the over-the-wire (OTW) CoStar coronary stent delivery system
32. **Chair, Clinical Events Committee (Non-Voting Member):** **PRECISE (CONOR):** A prospective, multicenter evaluation of the SRX (Short Rapid Exchange) CoStar coronary stent delivery system
33. **Chair, Clinical Events Committee (Non-Voting Member):** **ANGIOSCULPT:** A prospective, multicenter, nonrandomized, single arm investigation. AngioSculpt™ scoring balloon catheter multi-center clinical investigation
34. **Chair, Clinical Events Committee (Non-Voting Member):** **ETHOS I:** To evaluate safety and efficacy of stents coated with slow-release and moderate-release formulations of 17β
35. **Director of Data Coordination & Analysis:** Stent Thrombosis Registry After Localized Radiation Therapy to Inhibit Restenosis after Stenting (**SCRIPPS III**)
36. **Director, Data Coordination and Analysis** Bovine Pericardium Covered Stent Graft (BPCS Graft) (**SLEEVE I**)
37. **Director, Data Coordination and Analysis** Pharmacodynamic Assessment of Tirofiban Versus Abciximab During Coronary Interventions (**ATHENS**)
38. **Director, Data Coordination and Analysis** Association of Platelet Glycoprotein IIIa Polymorphism With Platelet Aggregation and Myonecrosis After Percutaneous Coronary Interventions (**BIOHEART**)
39. **Director, Data Coordination and Analysis** Carotid Angioplasty and Stenting Free of Emboli (**CAFÉ**)
40. **Director, Data Coordination and Analysis** A Nonrandomized, Multicenter Registry Study to Evaluate the Safety and Clinical Effectiveness of the X Technologies FX miniRAIL™ Coronary Dilatation Catheter in Dilating Coronary Stenosis and Improving Myocardial Perfusion (**FX miniRAIL™**)
41. **Director of Data Coordination & Analysis:** A Nonrandomized, Multicenter Registry Study to Evaluate the Safety and Clinical Effectiveness of the X Technologies FX miniRAIL™ Coronary Dilatation Catheter in Dilating Coronary Stenosis and Improving Myocardial Perfusion (**FX ISR**)
42. **Director, Data Coordination and Analysis** BX Velocity™ with Hepacoat™ Raptor Over-the-Wire Stent System – De Novo and Restenotic Lesions With an Antithrombotic Regimen of Aspirin Alone (**HOPE**)
43. **Director of Data Coordination & Analysis:** A Pilot Trial of Localized Radiation Therapy (Brachytherapy) to Inhibit Restenosis After Stenting (**SCRIPPS II**)
44. **Director of Data Coordination & Analysis:** Beta Radiation to Reduce In-stent Restenosis Study in Saphenous Vein Grafts (**SVG BRITE**)
45. **Director, Data Coordination and Analysis:** Radiation After PTA In De Novo Lesions in Peripheral Arteries (**RAPID**)
46. **Director, Data Coordination and Analysis :** Safety and Performance Evaluation of the Biosensors International's Drug-Eluting Stent (CHALLENGE-Stent) (**FUTURE I**)
47. **Director, Data Coordination and Analysis :** Safety and Performance Evaluation of the Biosensors International's Drug-Eluting Stent (CHALLENGE-Stent) (**FUTURE II**)
48. **Director, Data Coordination and Analysis :** Evaluate the Safety and Clinical Effectiveness of the Matrix VSG System compared to standard compression methods in achieving hemostasis of the femoral artery puncture sites following diagnostic and interventional endovascular procedures (**AMS [Matrix Reload]**)
49. **Director, Data Coordination and Analysis :** Avandia to Prevent Restenosis and CAD Progression Trial (**APRICOT**)



50. **Director, Data Coordination and Analysis** : **Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberalized Debris (EMERALD)**
51. **Director, Data Coordination and Analysis** : EPI Filter Wire™ During Transluminal Intervention of High Risk Saphenous Vein Grafts (EPI High Risk)
52. **Director, Data Coordination and Analysis** : Feasibility of stenting symptomatic and asymptomatic carotid artery stenoses using the WALLSTENT® Endoprosthesis and NeuroShield™ Cerebral Protection System (MEDNOVA)
53. **Director, Data Coordination and Analysis** : A study of oral Rapamycin after stenting for the prevention of the restenosis in the treatment of patients with *De Novo* coronary artery lesions (Oral Rapamycin)
54. **Director, Data Coordination and Analysis** : Peripheral Arterial Disease in Interventional Patients Study (PIPS)
55. **Director, Data Coordination and Analysis** : Protection during Saphenous Vein Graft Intervention to Prevent Distal Embolization Study (PRIDE)
56. **Director, Data Coordination and Analysis** : A Prospective Multicenter Study of the Ariba™ Stent Graft System for the Treatment of Abdominal Aortic Aneurysms (Quantum LP)
57. **Chair, Clinical Events Committee (Non-Voting Member)**: An Evaluation of Two Reduced Sirolimus Doses on the BX Velocity Balloon-Expandable Stent in the Treatment of Patients with *De Novo* Native Coronary Artery Lesions (REDOX)
58. **Director, Data Coordination and Analysis** : A registry evaluation of patients undergoing Palmaz stent implantation following failed balloon angioplasty of renal artery stenosis (Scripps IV)
59. **Director, Data Coordination and Analysis** : Shelhigh, Inc.™ Stentless Porcine Bioprostheses for Aortic Valve Replacement Model NR-2000 Plus™ and Model NR-2000C Plus No-React® Treated (Shelhigh SHI-501 Valve)
60. **Director, Data Coordination and Analysis** : Over & Under Bovine Pericardium Covered Stent Trial (SLEEVE II)
61. **Director, Data Coordination and Analysis** : Stent Eluting A9 bioLimus Trial in Human (STEALTH 1)
62. **Director, Data Coordination and Analysis** : An Evaluation of a Sirolimus-Eluting, Heparin-Coated Cobalt Chromium Balloon-Expandable Stent in the Treatment of Patients with *De Novo* Native Coronary Artery Lesions in Small Vessels (SVS)
63. **Director, Data Coordination and Analysis** : FIRE subanalyses
64. **Director, Data Coordination and Analysis** : HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study
65. **Director, Data Coordination and Analysis** : Post-Market Surveillance of Devices; clinical outcomes after use of devices in general population in concert with FDA
66. Angiographic and intravascular ultrasound patterns of in-stent restenosis
67. Intravascular ultrasound study of the mechanisms of balloon angioplasty and excimer laser angioplasty in in-stent restenosis
68. Treatment of in-stent restenosis utilizing devices including balloon angioplasty, laser, rotational atherectomy and stents
69. Intravascular ultrasound evaluation of intimal hyperplasia within stents in a porcine model treated with angiopentin
70. Patency of LIMA to LAD using MID-CAB technique vs. conventional CABG on cardiopulmonary bypass (PI: POEM trial)
71. Member of the Angiographic committee; Women's Angiographic Vitamin and Estrogen trial (WAVE); NHLBI
72. Contrast-Induced Nephropathy: Effect of Contrast Media (PI: ICON trial); on outcomes after PCI
73. Evaluation of the significance of Lp(a) in the atheromatous plaque in different clinical syndromes; an atherectomy study
74. Braunwald classification of unstable angina and angiographic lesion morphology
75. Structure/function relationships of the calcium release channel from skeletal & cardiac muscle (Expression of this receptor via in vitro transcribed RNA injection into *Xenopus* monocytes and incorporation of SR vesicles into lipid bilayer system)
76. Cloning and characterization of the FKBP-12 in the human heart and its association with the Ryanodine receptor in the heart. PI: Andrew R. Marks
77. Incorporation of SR vesicles from canine myocardium into lipid bilayer system for single channel recordings of calcium channels. PI: B. Ehrlich, A. Katz
78. Utilization of the intravascular ultrasound probe in human and animal model PI: L. Gillam, R. McKay

**PAPERS (peer-reviewed) [http://www.ncbi.nlm.nih.gov/pubmed?term=mehran\\_r\[au\]](http://www.ncbi.nlm.nih.gov/pubmed?term=mehran_r[au])**

1. Singh HS, Dargas GD, Guagliumi G, Yu J, Witzensbichler B, Kornowski R, Grines C, Gersh B, Dudek D, **Mehran R**, Stone GW. Comparison of Abciximab Versus Eptifibatid During Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). *Am J Cardiol*. 2012 Oct 1;110(7):940-7. Epub 2012 Jun 28. PubMed PMID: 22748356.
2. Cannon LA, Simon DI, Kereiakes D, Jones J, **Mehran R**, Kusano H, Zhang Z, Lombardi W, James Fleischhauer F, Costa MA. The XIENCE nano™ everolimus eluting coronary stent system for the treatment of small coronary arteries: The SPIRIT small vessel trial. *Catheter Cardiovasc Interv*. 2012 Oct 1;80(4):546-53. doi: 10.1002/ccd.23397. Epub 2012 Jan 12. PubMed PMID: 22121027.

3. Kovacic JC, **Mehran R**, Karajgikar R, Baber U, Suleman J, Kim MC, Krishnan P, Dangas G, Sharma SK, Kini A. Female gender and mortality after percutaneous coronary intervention: Results from a large registry. *Catheter Cardiovasc Interv*. 2012 Oct 1;80(4):514-21. doi: 10.1002/ccd.23338. Epub 2011 Nov 1. PubMed PMID:22045678.
4. Kappetein AP, Head SJ, Génèreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, **Mehran R**, Rodés-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *EuroIntervention*. 2012 Oct 1. pii 20120915-00. PubMed PMID: 23022744.
5. Vranckx P, McFadden E, Cutlip DE, **Mehran R**, Swart M, Kint PP, Zijlstra F, Silber S, Windecker S, Serruys PW. Clinical endpoint adjudication in a contemporary all-comers coronary stent investigation: Methodology and external validation. *Contemp Clin Trials*. 2012 Sep 10. pii: S1551-7144. PubMed PMID: 22975439.
6. Patel MR, Bailey SR, Bonow RO, Chambers CE, Chan PS, Dehmer GJ, Kirtane AJ, Wann LS, Ward RP, Douglas PS, Patel MR, Bailey SR, Altus P, Barnard DD, Blankenship JC, Casey DE Jr, Dean LS, Fazel R, Gilchrist IC, Kavinsky CJ, Lakoski SG, Le DE, Lesser JR, Levine GN, **Mehran R**, Russo AM, Sorrentino MJ, Williams MR, Wong JB, Wolk MJ, Bailey SR, Douglas PS, Hendel RC, Kramer CM, Min JK, Patel MR, Shaw L, Stainback RF, Allen JM. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization: American College of Cardiology Foundation Appropriate Use Criteria Task Force Society for Cardiovascular Angiography and Interventions American Association for Thoracic Surgery American Heart Association, American Society of Echocardiography American Society of Nuclear Cardiology Heart Failure Society of America Heart Rhythm Society, Society of Critical Care Medicine Society of Cardiovascular Computed Tomography Society for Cardiovascular Magnetic Resonance Society of Thoracic Surgeons. *Catheter Cardiovasc Interv*. 2012 Sep 1;80(3):E50-81. doi: 10.1002/ccd.24467. Epub 2012 Jun 7. PubMed PMID: 22678595.
7. Nikolsky E, McLaurin BT, Cox DA, Manoukian SV, Xu K, **Mehran R**, Stone GW. Outcomes of Patients With Prior Coronary Artery Bypass Grafting and Acute Coronary Syndromes: Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. *JACC Cardiovasc Interv*. 2012 Sep;5(9):919-26. PubMed PMID: 22995879.
8. Weisz G, Metzger DC, Liberman HA, O'Shaughnessy CD, Douglas JS, Turco MA Jr, **Mehran R**, Gershony G, Leon MB, Moses JW. A provisional strategy for treating true bifurcation lesions employing a scoring balloon for the side branch – final results of the AGILITY trial. *Catheter Cardiovasc Interv*. 2012 Aug 25. PubMed PMID: 22927100.
9. Yun KH, Mintz GS, Farhat N, Marso SP, Taglieri N, Verheye S, Foster MC, Margolis MP, Templin B, Xu K, Dressler O, **Mehran R**, Stone GW, Maehara A. Relation Between Angiographic Lesion Severity, Vulnerable Plaque Morphology and Future Adverse Cardiac Events (from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree Study). *Am J Cardiol*. 2012 Aug 15;110(4):471-7.
10. Claessen BE, Dangas GD, Godino C, Henriques JP, Leon MB, Park SJ, Stone GW, Moses JW, Colombo A, **Mehran R**; On behalf of the Multinational CTO Registry. Impact of target vessel on long-term survival after percutaneous coronary intervention for chronic total occlusions. *Catheter Cardiovasc Interv*. 2012 Aug 6. doi: 10.1002/ccd.24579.
11. Tobbia P, Brodie BR, Stuckey T, McLaurin BT, Cox DA, Fahy M, Xu K, **Mehran R**, Stone GW. Are adverse events following an invasive strategy in patients with non-ST-segment elevation acute coronary syndromes more frequent at US Sites versus non-US sites? analysis from the ACUITY trial. *Catheter Cardiovasc Interv*. 2012 Aug 6. doi: 10.1002/ccd.24587.
12. Povsic TJ, Vavalle JP, Aberle LH, Kasprzak JD, Cohen MG, **Mehran R**, Bode C, Buller CE, Montalescot G, Cornel JH, Rynkiewicz A, Ring ME, Zeymer U, Natarajan M, Delarche N, Zelenkofske SL, Becker RC, Alexander JH; on behalf of the RADAR Investigators. A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. *Eur Heart J*. 2012 Aug 2.
13. Brener SJ, Cristea E, Lansky AJ, Fahy M, **Mehran R**, Stone GW. Operator Versus Core Laboratory Assessment of Angiographic Reperfusion Markers in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction. *Circ Cardiovasc Interv*. 2012 Aug 1;5(4):563-9.
14. Claessen BE, Stone GW, **Mehran R**, Witzenbichler B, Brodie BR, Wöhrle J, Witkowski A, Guagliumi G, Zmudka K, Henriques JP, Tijssen JG, Sanidas EA, Chantziara V, Hakim D, Leon S, Xu K, Dangas GD. Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. *J Thromb Thrombolysis*. 2012 Aug;34(2):165-79.
15. Vranckx P, McFadden E, **Mehran R**, Cutlip DE. Clinical event committees in coronary stent trials: insights and recommendations based on experience in an unselected study population. *EuroIntervention*. 2012 Jul 20;8(3):368-74. doi: 10.4244/EIJV8I3A56.
16. Planer D, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Xu K, Fahy M, **Mehran R**, Stone GW. Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The HORIZONS-AMI trial. *Int J Cardiol*. 2012 Jul 11.

17. Schier R, Hinkelbein J, Marcus H, **Mehran R**, El-Zein R, Hofstetter W, Swafford J, Riedel B. Preoperative microvascular dysfunction: a prospective, observational study expanding risk assessment strategies in major thoracic surgery. *Ann Thorac Surg*. 2012 Jul;94(1):226-33.
18. Sergie Z, **Mehran R**, Stone GW. What is the optimal antithrombotic strategy in primary percutaneous coronary intervention? *Curr Opin Cardiol*. 2012 Jul;27(4):361-7.
19. Généreux P, Palmerini T, Caixeta A, Rosner G, Green P, Dressler O, Xu K, Parise H, **Mehran R**, Serruys PW, Stone GW. Quantification and Impact of Untreated Coronary Artery Disease After Percutaneous Coronary Intervention: The Residual SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) Score. *J Am Coll Cardiol*. 2012 Jun 12;59(24):2165-74.
20. Diagnostic Catheterization Writing Group, Patel MR, Bailey SR, Bonow RO, Chambers CE, Chan PS, Dehmer GJ, Kirtane AJ, Samuel Wann L, Parker Ward R; Technical Panel, Douglas PS, Patel MR, Bailey SR, Altus P, Barnard DD, Blankenship JC, Casey DE Jr, Dean LS, Fazel R, Gilchrist IC, Kavinsky CJ, Lakoski SG, Le DE, Lesser JR, Levine GN, **Mehran R**, Russo AM, Sorrentino MJ, Williams MR, Wong JB; Appropriate Use Criteria Task Force, Wolk MJ, Bailey SR, Douglas PS, Hendel RC, Kramer CM, Min JK, Patel MR, Shaw L, Stainback RF, Allen JM. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate use criteria for diagnostic catheterization: A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, Society of Thoracic Surgeons. *J Thorac Cardiovasc Surg*. 2012 Jul;144(1):39-71.
21. Patel MR, Bailey SR, Bonow RO, Chambers CE, Chan PS, Dehmer GJ, Kirtane AJ, Wann LS, Ward RP, Douglas PS, Patel MR, Bailey SR, Altus P, Barnard DD, Blankenship JC, Casey DE Jr, Dean LS, Fazel R, Gilchrist IC, Kavinsky CJ, Lakoski SG, Le DE, Lesser JR, Levine GN, **Mehran R**, Russo AM, Sorrentino MJ, Williams MR, Wong JB, Wolk MJ, Bailey SR, Douglas PS, Hendel RC, Kramer CM, Min JK, Patel MR, Shaw L, Stainback RF, Allen JM. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 Appropriate Use Criteria for Diagnostic Catheterization : American College of Cardiology Foundation Appropriate Use Criteria Task Force Society for Cardiovascular Angiography and Interventions American Association for Thoracic Surgery American Heart Association, American Society of Echocardiography American Society of Nuclear Cardiology Heart Failure Society of America Heart Rhythm Society, Society of Critical Care Medicine Society of Cardiovascular Computed Tomography Society for Cardiovascular Magnetic Resonance Society of Thoracic Surgeons. *Catheter Cardiovasc Interv*. 2012 Jun 7. doi: 10.1002/ccd.24467.
22. Singh HS, Dangas GD, Guagliumi G, Yu J, Witzensbichler B, Kornowski R, Grines C, Gersh B, Dudek D, **Mehran R**, Stone GW. Comparison of Abciximab Versus Eptifibatid During Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). *Am J Cardiol*. 2012 Jun 27.
23. Rokos IC, Farkouh ME, Reiffel J, Dressler O, **Mehran R**, Stone GW. Correlation between index electrocardiographic patterns and pre-intervention angiographic findings: Insights from the HORIZONS-AMI trial. *Catheter Cardiovasc Interv*. 2012 Jun 1;79(7):1092-8. doi: 10.1002/ccd.23262.
24. Wöhrle J, Merkle N, Kunze M, Cristea E, **Mehran R**, Rottbauer W, Stone GW. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: The horizons-AMI CMRI substudy. *Catheter Cardiovasc Interv*. 2012 Jun 1;79(7):1083-9. doi: 10.1002/ccd.23179.
25. Yu J, **Mehran R**. "CIN" No More: The Use of Contrast Volume to e-GFR Ratio to Predict and Prevent Contrast-Induced Acute Kidney Injury. *Catheter Cardiovasc Interv*. 2012 Jun 1;79(7):1201-2. doi: 10.1002/ccd.23372.
26. Chirumamilla AP, Maehara A, Mintz GS, **Mehran R**, Kanwal S, Weisz G, Hassanin A, Hakim D, Guo N, Baber U, Pyo R, Moses JW, Fahy M, Kovacic JC, Dangas GD. High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. *JACC Cardiovasc Imaging*. 2012 May;5(5):540-9.
27. Talati S, Kirtane AJ, Hassanin A, **Mehran R**, Leon MB, Moses JW, Weisz G. Direct infusion of fenoldopam into the renal arteries to protect against contrast-induced nephropathy in patients at increased risk. *Clin Exp Pharmacol Physiol*. 2012 Jun;39(6):506-9. doi: 10.1111/j.1440-1681.2012.05709.x.
28. Yun KH, Mintz GS, Farhat N, Marso SP, Taglieri N, Verheye S, Foster MC, Margolis MP, Templin B, Xu K, Dressler O, **Mehran R**, Stone GW, Maehara A. Relation Between Angiographic Lesion Severity, Vulnerable Plaque Morphology and Future Adverse Cardiac Events (from the Providing Regional Observations to Study Predictors of Events in the Coronary Tree Study). *Am J Cardiol*. 2012 May 11.
29. Sergie Z, **Mehran R**, Stone GW. What is the optimal antithrombotic strategy in primary percutaneous coronary intervention? *Curr Opin Cardiol*. 2012 Jul;27(4):361-7.
30. Rosner GF, Kirtane AJ, Genereux P, Lansky AJ, Cristea E, Gersh BJ, Weisz G, Parise H, Fahy M, **Mehran R**, Stone GW. Impact of the Presence and Extent of Incomplete Angiographic Revascularization After Percutaneous Coronary Intervention in Acute Coronary Syndromes: The ACUITY Trial. *Circulation*. 2012 May 29;125(21):2613-20.

31. Dangas GD, Claessen BE, **Mehran R**, Brener S, Brodie BR, Dudek D, Witzendichler B, Peruga JZ, Guagliumi G, Moses JW, Lansky AJ, Xu K, Stone GW. Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital: Results From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) Trial. *J Am Coll Cardiol*. 2012 May 15;59(20):1752-9.
32. McEntegart MB, Kirtane AJ, Cristea E, Brener S, **Mehran R**, Fahy M, Moses JW, Stone GW. Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Are Associated With Adverse Outcomes: Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. *J Am Coll Cardiol*. 2012 May 15;59(20):1745-51.
33. Sergie Z, **Mehran R**. NAC and CIN prevention: Mounting evidence of inefficacy. *Catheter Cardiovasc Interv*. 2012 May 1;79(6):927-8. doi: 10.1002/ccd.24424.
34. Stone GW, Maehara A, Witzendichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, **Mehran R**, Gibson CM; for the INFUSE-AMI Investigators. Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction: The INFUSE-AMI Randomized Trial. *JAMA*. 2012 May 2;307(17):1817-26.
35. Brener SJ, **Mehran R**, Dressler O, Cristea E, Stone GW. Diabetes Mellitus, Myocardial Reperfusion, and Outcome in Patients With Acute ST-Elevation Myocardial Infarction Treated With Primary Angioplasty (from HORIZONS AMI). *Am J Cardiol*. 2012 Apr 15;109(8):1111-6.
36. Kunadian V, Coats L, Kini AS, **Mehran R**. Cardiogenic shock in women. *Interventional Cardiology Clinics*. Apr 2012;1(2):231-43.
37. Kini AS, **Mehran R**. Coronary artery disease in women: Shyly bold? *Interventional Cardiology Clinics*. Apr 2012;1(2):ix-x.
38. Conroy J, Baber U, **Mehran R**. Future perspectives on percutaneous coronary interventions in women. *Interventional Cardiology Clinics*. Apr 2012;1(2):251-8.
39. Golinvaux N, Maehara A, Mintz GS, Lansky AJ, McPherson J, Farhat N, Marso S, de Bruyne B, Serruys PW, Templin B, Cheong WF, Aaskar R, Fahy M, **Mehran R**, Leon M, Stone GW. An intravascular ultrasound appraisal of atherosclerotic plaque distribution in diseased coronary arteries. *American heart journal*. 2012 Apr;163(4):624-31.
40. Rozenman Y, **Mehran R**, Witzendichler B, Dangas G, Desaga M, Kochman J, Nilsen DW, Finkelstein A, Mosseri M, Stone GW. Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction. *Catheter Cardiovasc Interv*. 2012 Apr 17. 45 (4) doi: 10.1002/ccd.24279.
41. Acharji S, Baber U, **Mehran R**, Fahy M, Kirtane AJ, Lansky AJ, Stone GW. Prognostic Significance of Elevated Baseline Troponin in Patients With Acute Coronary Syndromes and Chronic Kidney Disease Treated With Different Antithrombotic Regimens: A Substudy From the ACUITY Trial. *Circ Cardiovasc Interv*. 2012 Apr 1;5(2):157-65.
42. Vranckx P, Cutlip DE, McFadden EP, Kern MJ, **Mehran R**, Muller O. Coronary pressure-derived fractional flow reserve measurements: recommendations for standardization, recording, and reporting as a core laboratory technique. Proposals for integration in clinical trials. *Circ Cardiovasc Interv*. 2012 Apr 1;5(2):312-7.
43. Talati S, Kirtane AJ, Hassanin A, **Mehran R**, Leon MB, Moses JW, Weisz G. Direct Infusion of Fenoldopam into the Renal Arteries to Protect from Contrast-Induced Nephropathy in Patients at Increased Risk. *Clin Exp Pharmacol Physiol*. 2012 Apr 3. doi: 10.1111/j.1440-1681.2012.05709.x.
44. Claessen BE, Stone GW, **Mehran R**, Witzendichler B, Brodie BR, Wöhrle J, Witkowski A, Guagliumi G, Zmudka K, Henriques JP, Tijssen JG, Sanidas EA, Chantziara V, Hakim D, Leon S, Xu K, Dangas GD. Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. *J Thromb Thrombolysis*. 2012 Apr 1. pp. 1-15 [Epub ahead of print]
45. De Luca G, Brener SJ, **Mehran R**, Lansky AJ, McLaurin BT, Cox DA, Cristea E, Fahy M, Stone GW. Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: Insights from the ACUITY trial. *Int J Cardiol*. 2012 Mar 29. [Epub ahead of print]
46. Xu K, Mintz GS, Kubo T, Wu X, Guo N, Yang J, Witzendichler B, Guagliumi G, Brodie B, Dressler O, Cristea E, Parise H, **Mehran R**, Stone GW, Maehara A. Long-Term Follow-Up of Attenuated Plaques in Patients With Acute Myocardial Infarction: An Intravascular Ultrasound Substudy of the HORIZONS-AMI Trial. *Circ Cardiovasc Interv*. 2012 Apr 1;5(2):185-92.
47. Rao SV, **Mehran R**. Evaluating the Bite of the BARC. *Circulation*. 2012 Mar 20;125(11):1344-6. Feb 17.
48. **Mehran R**, Steg PG, White HD, Rao SV. Letter by Mehran regarding article, "Bleeding academic research consortium consensus report: the food and drug administration perspective". *Circulation*. 2012 Mar 13;125(10):e460. doi: 10.1161/CIRCULATIONAHA.111.065888
49. Baber U, **Mehran R**. Acute kidney injury: Prevention of contrast-induced AKI-the ongoing saga. *Nat Rev Nephrol*. 2012 Mar 13. doi: 10.1038/nrneph.2012.57.

50. Kovacic JC, Lee P, Baber U, Karajgikar R, Evrard SM, Moreno P, **Mehran R**, Fuster V, Dangas G, Sharma SK, Kini AS. Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions. *Atherosclerosis*. 2012 Mar;221(1):176-82.
51. Sergie Z, **Mehran R**. The optimal approach to coronary bifurcations: Systematic rather than simplified? *Catheter Cardiovasc Interv*. 2012 Mar 1;79(4):623-4. doi: 10.1002/ccd.24318.
52. Sergie Z, **Mehran R**. Survival benefit with PCI for chronic total occlusions: The Jury is still out. *Catheter Cardiovasc Interv*. 2012 Mar 1;79(4):613-4. doi: 10.1002/ccd.24345.
53. McPherson JA, Maehara A, Weisz G, Mintz GS, Cristea E, **Mehran R**, Foster M, Verheye S, Rabbani L, Xu K, Fahy M, Templin B, Zhang Z, Lansky AJ, de Bruyne B, Serruys PW, Stone GW. Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention. *JACC Cardiovasc Imaging*. 2012 Mar;5(3 Suppl):S76-85.
54. Baber U, Stone GW, Weisz G, Moreno P, Dangas G, Maehara A, Mintz GS, Cristea E, Fahy M, Xu K, Lansky AJ, Wennerblom B, Mathey DG, Templin B, Zhang Z, Serruys PW, **Mehran R**. Coronary plaque composition, morphology, and outcomes in patients with and without chronic kidney disease presenting with acute coronary syndromes. *JACC Cardiovasc Imaging*. 2012 Mar;5(3 Suppl):S53-61.
55. Stone GW, Clayton TC, **Mehran R**, Dangas G, Parise H, Fahy M, Pocock SJ. Impact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. *Am Heart J*. 2012 Mar;163(3):522-9.
56. Palmerini T, Caixeta A, Genereux P, Cristea E, Lansky A, **Mehran R**, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. *Am Heart J*. 2012 Mar;163(3):383-391.e1-5.
57. Claessen BE, Dangas GD, Weisz G, Witzenbichler B, Guagliumi G, Möckel M, Brener SJ, Xu K, Henriques JP, **Mehran R**, Stone GW. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. *Eur Heart J*. 2012 Mar;33(6):768-75.
58. Yu J, **Mehran R**. "CIN" No More: The Use of Contrast Volume to e-GFR Ratio to Predict and Prevent Contrast-Induced Acute Kidney Injury. *Catheter Cardiovasc Interv*. 2012 Jan 10. doi: 10.1002/ccd.23372.
59. Mehta RH, Yu J, Piccini JP, Tcheng JE, Farkouh ME, Reiffel J, Fahy M, **Mehran R**, Stone GW. Prognostic Significance of Postprocedural Sustained Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention (from the HORIZONS-AMI Trial). *Am J Cardiol*. 2012 Mar 15;109(6):805-12.
60. Nikolsky E, **Mehran R**, Dangas GD, Yu J, Parise H, Xu K, Pocock SJ, Stone GW. Outcomes of Patients Treated With Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial). *Am J Cardiol*. 2012 Mar 15;109(6):831-8.
61. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, **Mehran R**, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson W, Yancy CW. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Catheter Cardiovasc Interv*. 2012 Feb 15;79(3):453-95. doi: 10.1002/ccd.23438.
62. Choi SY, Maehara A, Cristea E, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Dressler O, Lansky AJ, Parise H, **Mehran R**, Mintz GS, Stone GW. Usefulness of Minimum Stent Cross Sectional Area as a Predictor of Angiographic Restenosis After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the HORIZONS-AMI Trial IVUS Substudy). *Am J Cardiol*. 2012 Feb 15;109(4):455-60.
63. Cannon LA, Simon DI, Kereiakes D, Jones J, **Mehran R**, Kusano H, Zhang Z, Lombardi W, Fleischhauer FJ, Costa MA. The XIENCE nano™ everolimus eluting coronary stent system for the treatment of small coronary arteries: The SPIRIT small vessel trial. *Catheter Cardiovasc Interv*. Jan 2012;45(4).
64. Möckel M, Vollert J, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Kornowski R, Dudek D, Farkouh ME, Parise H, **Mehran R**, Stone GW; Horizons-AMI Trial Investigators. Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. *Am J Cardiol*. 2011 Dec 15;108(12):1697-703.
65. Généreux P, **Mehran R**, Palmerini T, Caixeta A, Kirtane AJ, Lansky AJ, Brodie BR, Witzenbichler B, Mockel M, Guagliumi G, Peruga JZ, Dudek D, Fahy MP, Dangas G, Stone GW. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial. *EuroIntervention*. 2011 Dec 13;7(8):905-16. doi: 10.4244/EIJV7I8A144.
66. Writing Committee Members, Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, **Mehran R**, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011

- ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*. 2011 Dec 6;124(23):2574-609.
67. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, **Mehran R**, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*. 2011 Dec 6;124(23):e574-651.
68. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, **Mehran R**, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol*. 2011 Dec 6;58(24):2550-83.
69. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, **Mehran R**, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *J Am Coll Cardiol*. 2011 Dec 6;58(24):e44-e122.
70. Brener SJ, Cristea E, **Mehran R**, Dressler O, Lansky AJ, Stone GW. Relationship between angiographic dynamic and densitometric assessment of myocardial reperfusion and survival in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: The Harmonizing Outcomes with Revascularization and Stents in AMI (HORIZONS-AMI) trial. *Am Heart J*. 2011 Dec;162(6):1044-51.
71. Génereux P, Palmerini T, Caixeta A, Cristea E, **Mehran R**, Sanchez R, Lazar D, Jankovic I, Corral MD, Dressler O, Fahy MP, Parise H, Lansky AJ, Stone GW. SYNTAX Score Reproducibility and Variability Between Interventional Cardiologists, Core Laboratory Technicians, and Quantitative Coronary Measurements. *Circ Cardiovasc Interv*. 2011 Dec 1;4(6):577-84.
72. Palmerini T, Dangas G, **Mehran R**, Caixeta A, Genereux P, Fahy M, Xu K, Cristea E, Lansky A, Stone GW. Predictors and Implications of Stent Thrombosis in Non-ST-Segment Elevation Acute Coronary Syndromes: The ACUITY Trial. *Circ Cardiovasc Interv*. 2011 Dec 1;4(6):577-84.
73. Prasad A, Dangas G, Srinivasan M, Yu J, Gersh BJ, **Mehran R**, Stone GW. Incidence and angiographic characteristics of patients with apical ballooning syndrome (takotsubo/stress cardiomyopathy) in the HORIZONS-AMI trial: An Analysis from a Multicenter, International Study of ST-elevation Myocardial Infarction. *Catheter Cardiovasc Interv*. 2011 Nov 25. doi: 10.1002/ccd.23441.
74. Goto K, Nikolsky E, Lansky AJ, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, **Mehran R**, Stone GW. Impact of smoking on outcomes of patients with ST-segment elevation myocardial infarction (from the HORIZONS-AMI Trial). *Am J Cardiol*. 2011 Nov 15;108(10):1387-94.
75. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, **Mehran R**, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH, Jacobs AK, Anderson JL, Albert N, Creager MA, Ettinger SM, Guyton RA, Halperin JL, Hochman JS, Kushner FG, Ohman EM, Stevenson W, Yancy CW. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Catheter Cardiovasc Interv*. 2011 Nov 7. doi: 10.1002/ccd.23390.
76. Kovacic JC, **Mehran R**, Karajgikar R, Baber U, Suleman J, Kim MC, Krishnan P, Dangas G, Sharma SK, Kini A. Female gender and mortality after percutaneous coronary intervention: Results from a large registry. *Catheter Cardiovasc Interv*. 2011 Nov 1. doi: 10.1002/ccd.23338.
77. Suh JW, **Mehran R**, Claessen BE, Xu K, Baber U, Dangas G, Parise H, Lansky AJ, Witzenbichler B, Grines CL, Guagliumi G, Kornowski R, Wöhrle J, Dudek D, Weisz G, Stone GW. Impact of In-Hospital Major Bleeding on Late Clinical Outcomes After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. *J Am Coll Cardiol*. 2011 Oct 18;58(17):1750-6.
78. Planer D, **Mehran R**, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Reyes SL, Stone GW. Prognostic Utility of Left Ventricular End-Diastolic Pressure in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Am J Cardiol*. 2011 Oct 15;108(8):1068-74.
79. Baber U, **Mehran R**, Sharma SK, Brar S, Yu J, Suh JW, Kim HS, Park SJ, Kastrati A, de Waha A, Krishnan P, Moreno P, Sweeny J, Kim MC, Suleman J, Pyo R, Wiley J, Kovacic J, Kini AS, Dangas GD. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. *J Am Coll Cardiol*. 2011 Oct 4;58(15):1569-77.

80. Kandzari DE, Barker CS, Leon MB, Mauri L, Wijns W, Fajadet J, **Mehran R**. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. *JACC Cardiovasc Interv*. 2011 Oct;4(10):1119-28.
81. Kelly DJ, Gershlick T, Witzenbichler B, Guagliumi G, Fahy M, Dangas G, **Mehran R**, Stone GW. Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: The HORIZONS-AMI trial. *Am Heart J*. 2011 Oct;162(4):663-70.
82. Claessen BE, Dangas GD, Godino C, Lee SW, Obunai K, Carlino M, Suh JW, Leon MB, Di Mario C, Park SJ, Stone GW, Moses JW, Colombo A, **Mehran R**; Multinational Cto Registry. Long-term clinical outcomes of percutaneous coronary intervention for chronic total occlusions in patients with versus without diabetes mellitus. *Am J Cardiol*. 2011 Oct 1;108(7):924-31.
83. Brener SJ, **Mehran R**, Brodie BR, Guagliumi G, Witzenbichler B, Cristea E, Xu K, Lansky AJ, Stone GW. Predictors and Implications of Coronary Infarct Artery Patency at Initial Angiography in Patients With Acute Myocardial Infarction (from the CADILLAC and HORIZONS-AMI Trials). *Am J Cardiol*. 2011 Oct 1;108(7):918-23.
84. Baber U, **Mehran R**. The fine balance of quality and quantity: The time has come to define quality of PCI! *Catheter Cardiovasc Interv*. 2011 Oct 1;78(4):503-4. doi: 10.1002/ccd.23356.
85. Povsic TJ, Wargin WA, Alexander JH, Krasnow J, Krolick M, Cohen MG, **Mehran R**, Buller CE, Bode C, Zelenkofske SL, Rusconi CP, Becker RC; on behalf of the RADAR Investigators. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. *Eur Heart J*. Eur Heart J. 2011 Oct;32(19):2412-2419.
86. Baber U, **Mehran R**. Acute coronary syndromes: Antithrombotics in ACS-moving beyond unfractionated heparin. *Nat Rev Cardiol*. 2011 Sep 27;8(11):613-4. doi: 10.1038/nrcardio.2011.153.
87. Vlachojannis GJ, **Mehran R**. Post TAVI paravalvular regurgitation: Can we stop the leak? *Catheter Cardiovasc Interv*. 2011 Sep 1;78(3):444-5. doi: 10.1002/ccd.23317.
88. Saltzman AJ, Stone GW, Claessen BE, Narula A, Leon-Reyes S, Weisz G, Brodie B, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Metzger DC, Lansky AJ, Nikolsky E, Dangas GD, **Mehran R**. Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. *JACC Cardiovasc Interv*. 2011 Sep;4(9):1011-9. doi: 10.1016/j.jcin.2011.06.012.
89. Claessen BE, **Mehran R**, Mintz GS, Weisz G, Leon MB, Dogan O, de Ribamar Costa J Jr, Stone GW, Apostolidou I, Morales A, Chantziara V, Syros G, Sanidas E, Xu K, Tijssen JG, Henriques JP, Piek JJ, Moses JW, Maehara A, Dangas GD. Impact of intravascular ultrasound imaging on early and late clinical outcomes following percutaneous coronary intervention with drug-eluting stents. *JACC Cardiovasc Interv*. 2011 Sep;4(9):974-81.
90. **Mehran R**, Claessen BE, Godino C, Dangas GD, Obunai K, Kanwal S, Carlino M, Henriques JP, Di Mario C, Kim YH, Park SJ, Stone GW, Leon MB, Moses JW, Colombo A; Multinational Chronic Total Occlusion Registry. Long-term outcome of percutaneous coronary intervention for chronic total occlusions. *JACC Cardiovasc Interv*. 2011 Sep;4(9):952-61.
91. Goto K, Nikolsky E, Lansky AJ, Dangas G, Witzenbichler B, Parise H, Guagliumi G, Kornowski R, Claessen BE, Fahy M, **Mehran R**, Stone GW. Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from the HORIZONS-AMI Trial). *Am J Cardiol*. 2011 Aug 23.
92. Kornowski R, **Mehran R**, Dangas G, Nikolsky E, Assali A, Claessen BE, Gersh BJ, Wong SC, Witzenbichler B, Guagliumi G, Dudek D, Fahy M, Lansky AJ, Stone GW; HORIZONS-AMI Trial Investigators. Prognostic Impact of Staged Versus "One-Time" Multivessel Percutaneous Intervention in Acute Myocardial Infarction Analysis From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. *J Am Coll Cardiol*. 2011 Aug 9;58(7):704-11.
93. Baber U, Kovacic J, Kini AS, Sharma SK, Dangas G, **Mehran R**. How Serious a Problem is Bleeding in Patients with Acute Coronary Syndromes?. *Curr Cardiol Rep*. 2011 Aug;13(4):312-9.
94. Mosca L, Mochari-Greenberger H, Aggarwal B, Liao M, Suero-Tejeda N, Comellas M, Rehm L, Umann TM, **Mehran R**. Patterns of Caregiving Among Patients Hospitalized With Cardiovascular Disease. *J Cardiovasc Nurs*. 2011 July/August;26(4):305-311.
95. Cristea E, Stone GW, **Mehran R**, Kirtane AJ, Brener SJ. Changes in reference vessel diameter in ST-segment elevation myocardial infarction after primary percutaneous coronary intervention: Implications for appropriate stent sizing. *Am Heart J*. 2011 Jul;162(1):173-7.
96. Goto K, Lansky AJ, Nikolsky E, Fahy M, Feit F, Ohman EM, White HD, **Mehran R**, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Significance of Coronary Thrombus in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes A Subanalysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) Trial. *JACC Cardiovasc Interv*. 2011 Jul;4(7):769-77.
97. Witzenbichler B, **Mehran R**, Guagliumi G, Dudek D, Huber K, Kornowski R, Stuckey TD, Fahy M, Parise H, Stone GW. Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary

- Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) Trial. *JACC Cardiovasc Interv.* 2011 Jul;4(7):760-8.
98. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, **Mehran R**; HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. *Lancet.* 2011 Jun 25;377(9784):2193-204
99. Palmerini T, **Mehran R**, Dangas G, Nikolsky E, Witzenbichler B, Guagliumi G, Dudek D, Genereux P, Caixeta A, Rabbani L, Weisz G, Parise H, Fahy M, Xu K, Brodie B, Lansky A, Stone GW. Impact of leukocyte count on mortality and bleeding in patients with myocardial infarction undergoing primary percutaneous coronary interventions: analysis from the harmonizing outcome with revascularization and stent in acute myocardial infarction trial. *Circulation.* 2011 Jun 21;123(24):2829-37.
100. **Mehran R**, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. *Circulation.* 2011 Jun 14;123(23):2736-47.
101. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, **Mehran R**, Dangas G, Lazar D, Sanchez R, Fahy M, Xu K, Stone GW. Prognostic Value of the SYNTAX Score in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. *J Am Coll Cardiol.* 2011 Jun 14;57(24):2389-97.
102. Dangas GD, **Mehran R**, Nikolsky E, Claessen BE, Lansky AJ, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möckel M, Caixeta A, Parise H, White H, Stone GW; HORIZONS-AMI Trial Investigators. Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis. *J Am Coll Cardiol.* 2011 Jun 7;57(23):2309-16.
103. Choi SY, Witzenbichler B, Maehara A, Lansky AJ, Guagliumi G, Brodie B, Kellett MA Jr, Dressler O, Parise H, **Mehran R**, Dangas GD, Mintz GS, Stone GW. Intravascular Ultrasound Findings of Early Stent Thrombosis After Primary Percutaneous Intervention in Acute Myocardial Infarction: A Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Substudy. *Circ Cardiovasc Interv.* 2011 Jun 1;4(3):239-47.
104. **Mehran R**, Pocock S, Nikolsky E, Dangas GD, Clayton T, Claessen BE, Caixeta A, Feit F, Manoukian SV, White H, Bertrand M, Ohman EM, Parise H, Lansky AJ, Lincoff AM, Stone GW. Impact of Bleeding on Mortality After Percutaneous Coronary Intervention Results From a Patient-Level Pooled Analysis of the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trials. *JACC Cardiovasc Interv.* 2011 Jun;4(6):654-64.
105. **Mehran R**. The fork in the road: A dedicated turn or a provisional one?. *Catheter Cardiovasc Interv.* 2011 May 1;77(6):807-8. doi: 10.1002/ccd.23128.
106. Cutlip DE, Nakazawa G, Krucoff MW, Vorpahl M, **Mehran R**, Finn AV, Vranckx P, Kimmelstiel C, Berger C, Petersen JL, Palabrica T, Virmani R. Autopsy validation study of the academic research consortium stent thrombosis definition. *JACC Cardiovasc Interv.* 2011 May;4(5):554-9.
107. Rubboli A, Kovacic JC, **Mehran R**, Lip GY. Coronary stent implantation in patients committed to long-term oral anticoagulation therapy: successfully navigating the treatment options. *Chest.* 2011 May;139(5):981-7.
108. Wu X, Mintz GS, Xu K, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Dressler O, Parise H, **Mehran R**, Stone GW, Maehara A. The relationship between attenuated plaque identified by intravascular ultrasound and no-reflow after stenting in acute myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. *JACC Cardiovasc Interv.* 2011 May;4(5):495-502
109. Dangas GD, Caixeta A, **Mehran R**, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Dudek D, Möckel M, Stone GW; for the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators. Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. *Circulation.* 2011 Apr 26;123(16):1745-1756. Epub 2011 Apr 11.
110. **Mehran R**. The GRACE of staged revascularization after primary angioplasty st-elevation myocardial infarction. *Catheter Cardiovasc Interv.* 2011 Apr 1;77(5):623-4. doi: 10.1002/ccd.23081.
111. Witzenbichler B, Wöhrle J, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Hood KL, Parise H, Lansky AJ, Nikolsky E, **Mehran R**, Stone GW. Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction: The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. *Circ Cardiovasc Interv.* 2011 Apr 1;4(2):130-138. Epub 2011 Mar 1.



112. Sweeny JM, **Mehran R**. Gender outcomes in acute myocardial infarction: are women from Venus and men from Mars?. *EuroIntervention*. 2011 Apr;6(9):1029-31. doi: 10.4244/EIJV6I9A179
113. Diercks DB, Pollack CV Jr, Hollander JE, Blomkalns AL, Emerman CL, Rokos IC, Larson DM, Hoekstra JW, **Mehran R**, Stone GW. The Time Dependence of Antithrombin Initiation in Patients With Non-ST-segment Elevation Acute Coronary Syndromes: Subgroup Analysis From the ACUITY Trial. *Ann Emerg Med*. 2011 Mar;57(3):204-212.e6. Epub 2010 Oct 16. PMID:20952100
114. Stone GW, Goldberg S, O'Shaughnessy C, Midei M, Siegel RM, Cristea E, Dangas G, Lansky AJ, **Mehran R**. 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial. *JACC Cardiovasc Interv*. 2011 Mar;4(3):300-9.
115. Claessen BE, **Mehran R**, Leon MB, Heller EA, Weisz G, Syros G, Mintz GS, Franklin-Bond T, Apostolidou I, Henriques JP, Stone GW, Moses JW, Dangas GD. Two-year safety and effectiveness of sirolimus-eluting stents (from a prospective registry). *Am J Cardiol*. 2011 Feb 15;107(4):528-34. Epub 2010 Dec 31. PMID:21195378
116. Hakim DA, Dangas GD, Caixeta A, Nikolsky E, Lansky AJ, Moses JW, Claessen B, Sanidas E, White HD, Ohman EM, Manoukian SV, Fahy M, **Mehran R**, Stone GW. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. *Am Heart J*. 2011 Feb;161(2):391-6. PMID:21315224
117. Caixeta A, Dangas GD, **Mehran R**, Feit F, Nikolsky E, Lansky AJ, Aoki J, Moses JW, Steinhubl SR, White HD, Ohman EM, Manoukian SV, Fahy M, Stone GW. Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. *Am Heart J*. 2011 Feb;161(2):298-306.e1 PMID: 21315212
118. Povsic TJ, Cohen MG, **Mehran R**, Buller CE, Bode C, Cornel JH, Kasprzak JD, Montalescot G, Joseph D, Wargin WA, Rusconi CP, Zelenkofske SL, Becker RC, Alexander JH. A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. *Am Heart J*. 2011 Feb;161(2):261-268.e1-2. PMID: 21315207
119. Best PJ, Skelding KA, **Mehran R**, Chieffo A, Kunadian V, Madan M, Mikhail GW, Mauri F, Takahashi S, Honye J, Hernández-Antolín R, Weiner BH; Society for Cardiovascular Angiography & Interventions' Women in Innovations (WIN) group. SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel. *Catheter Cardiovasc Interv*. 2011 Feb 1;77(2):232-41. doi: 10.1002/ccd.22877. Epub 2011 Jan 28. PMID:21061249
120. Best PJ, Skelding KA, **Mehran R**, Chieffo A, Kunadian V, Madan M, Mikhail GW, Mauri F, Takahashi S, Honye J, Hernández-Antolín R, Weiner BH. SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel. *EuroIntervention*. 2011 Feb;6(7):866-74. doi: 10.4244/EIJV6I7A148. PMID:21252022
121. Best PJ, Skelding KA, **Mehran R**, Chieffo A, Kunadian V, Madan M, Mikhail GW, Mauri F, Takahashi S, Honye J, Hernández-Antolín R, Weiner BH; Women in Innovations (WIN) group of the Society of Cardiac Angiography and Intervention. SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel. *Heart Lung Circ*. 2011 Feb;20(2):83-90. PMID: 21241961
122. Caixeta A, Stone GW, **Mehran R**, Lee EA, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Ohman EM, Palmerini T, Syros G, Kittas C, Fahy M, Hooper WC, Lansky AJ, Dangas GD. Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial. *J Thromb Thrombolysis*. 2011 Feb;31(2):154-64. PMID:20953817
123. Campbell CL, Steinhubl SR, Hooper WC, Jozic J, Smyth SS, Bernstein D, De Staercke C, Syros G, Negus BH, Stuckey T, Stone GW, **Mehran R**, Dangas G. Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. *J Thromb Thrombolysis*. 2011 Feb;31(2):139-45. PMID:20872045
124. Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, **Mehran R**, Stone GW. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. *JACC Cardiovasc Interv*. 2011 Feb;4(2):191-7. PMID:21349458
125. Ambrosio G, Steinhubl S, Gresele P, Tritto I, Zuchi C, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, **Mehran R**, Stone GW. Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. *Eur J Cardiovasc Prev Rehabil*. 2011 Feb;18(1):121-8. PMID: 20523219
126. Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS, **Mehran R**, McPherson J, Farhat N, Marso SP, Parise H, Templin B, White R, Zhang Z, Serruys PW; PROSPECT Investigators. A prospective natural-history study of coronary atherosclerosis. *N Engl J Med*. 2011 Jan 20;364(3):226-35. PMID: 21247313
127. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, **Mehran R**, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW. Standardized

- endpoint definitions for transcatheter aortic valve implantation clinical trials a consensus report from the valve academic research consortium. *J Am Coll Cardiol*. 2011 Jan 18;57(3):253-69. Epub 2011 Jan 7. PMID: 21216553
128. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, Kappetein AP, Krucoff MW, Mack M, **Mehran R**, Miller C, Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium.
129. Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N, Matiashvili A, Lortkipanidze N, Mihalcsik L, Trivisonno A, Valsecchi O, Mintz GS, Dressler O, Parise H, Maehara A, Cristea E, Lansky AJ, **Mehran R**, Stone GW. Strut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction: Optical Coherence Tomography Substudy of the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. *Circulation*. 2011 Jan 25;123(3):274-81. Epub 2011 Jan 10. PMID: 21220730
- Eur Heart J*. 2011 Jan;32(2):205-17. Epub 2011 Jan 6. PMID: 21216739
130. Claessen BE, **Mehran R**, Leon MB, Heller EA, Weisz G, Syros G, Mintz GS, Franklin-Bond T, Apostolidou I, Henriques JP, Stone GW, Moses JW, Dangas GD. Two-Year Safety and Effectiveness of Sirolimus-Eluting Stents (from a Prospective Registry). *Am J Cardiol*. 2010 Dec 30. [Epub ahead of print] PMID: 21195378
131. **Mehran R**, Kini AS. Sex-related outcomes after drug-eluting stent: should we "never mind" or "mind" the gap?. *JACC Cardiovasc Interv*. 2010 Dec;3(12):1260-1. PMID: 21232719
132. Cutlip DE, **Mehran R**, Vranckx P. FAME and coronary stent investigations: is there a kink in the wire? *J Am Coll Cardiol*. 2011 Jan 4;57(1):115-6; author reply 116. 2010 Dec 28;57(1):115-6. PMID: 21185512
133. Blankenship JC, Skelding KA, Scott TD, Berger PB, Parise H, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ, Lansky AJ, **Mehran R**, Stone GW. Predictors of Reperfusion Delay in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention from the HORIZONS-AMI Trial. *Am J Cardiol*. 2010 Dec 1;106(11):1527-33. Epub 2010 Oct 14. PMID: 21094350
134. Dangas GD, Sharma SK, **Mehran R**. Acute myocardial infarction and multivessel disease: some vessels are more equal than others. *Heart*. 2010 Dec;96(24):1955-6. Epub 2010 Oct 29. No abstract available. PMID:21036804
135. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, **Mehran R**. In-stent restenosis in the drug-eluting stent era. *J Am Coll Cardiol*. 2010 Nov 30;56(23):1897-907. PMID: 21109112
136. Stone GW, Parise H, Witzenbichler B, Kirtane A, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Lansky AJ, **Mehran R**. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. *J Am Coll Cardiol*. 2010 Nov 2;56(19):1597-604. Epub 2010 Oct 1. PMID: 20888162
137. Wöhrle J, Desaga M, Metzger C, Huber K, Suryapranata H, Guetta V, Guagliumi G, Witzenbichler B, Parise H, **Mehran R**, Stone GW. Impact of transfer for primary percutaneous coronary intervention on survival and clinical outcomes (from the HORIZONS-AMI Trial). *Am J Cardiol*. 2010 Nov 1;106(9):1218-24. Epub 2010 Sep 9. PMID: 21029816
138. Capranzano P, **Mehran R**, Tamburino C, Stone GW, Dangas G. Clinical Impact of Enhanced Inhibition of P2Y<sub>12</sub>-Mediated Platelet Aggregation in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention *Hosp Pract (Minneap)*. 2010 Nov;38(4):38-43. PMID:21068525
139. Doi H, Maehara A, Mintz GS, Tsujita K, Kubo T, Castellanos C, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Parise H, **Mehran R**, Leon MB, Moses JW, Stone GW. Intravascular ultrasound findings of stent fractures in patients with Sirolimus- and Paclitaxel-eluting stents. *Am J Cardiol*. 2010 Oct 1;106(7):952-7. Epub 2010 Aug 11. PMID: 20854956
140. Kumar D, Dangas G, **Mehran R**, Kirtane A, Bertrand M, Ebrahimi R, Guagliumi G, Brar S, Fahy M, Heller E, Moses J, Stone G. Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators). *Am J Cardiol*. 2010 Oct 1;106(7):941-5. Epub 2010 Aug 17. PMID: 20854954
141. Guo N, Maehara A, Mintz GS, He Y, Xu K, Wu X, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Dressler O, Parise H, **Mehran R**, Stone GW. Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. *Circulation*. 2010 Sep 14;122(11):1077-84. Epub 2010 Aug 30. PMID: 20805433
142. Parodi G, Antoniucci D, Nikolsky E, Witzenbichler B, Guagliumi G, Peruga JZ, Stuckey T, Dudek D, Kornowski R, Hartmann F, Lansky AJ, **Mehran R**, Stone GW. Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. *JACC Cardiovasc Interv*. 2010 Aug;3(8):796-802. PMID: 20723849

143. Brodie BR, Gersh BJ, Stuckey T, Witzendichler B, Guagliumi G, Peruga JZ, Dudek D, Grines CL, Cox D, Parise H, Prasad A, Lansky AJ, **Mehran R**, Stone GW. When is Door-to-Balloon Time Critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trials. *J Am Coll Cardiol*. 2010 Jul 27; 56(5):407-413. PMID: 20650362
144. Kirtane AJ, Parise H, **Mehran R**, Moses JW, Fahy M, Bertrand ME, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Ware JH, Pocock SJ, Lansky AJ, Stone GW. Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy). *Am J Cardiol*. 2010 Jul 15;106(2):180-6. PMID: 20599000
145. Saltzman AJ, **Mehran R**, Dangas GD. Safety issues related to treating bifurcation lesions. *Rev Cardiovasc Med*. 2010;11 Suppl 1:S3-10. PMID: 20495524
146. **Mehran R**, Pocock SJ, Nikolsky E, Clayton T, Dangas GD, Kirtane AJ, Parise H, Fahy M, Manoukian SV, Feit F, Ohman ME, Witzendichler B, Guagliumi G, Lansky AJ, Stone GW. A risk score to predict bleeding in patients with acute coronary syndromes. *J Am Coll Cardiol*. 2010 Jun 8;55(23):2556-66. PMID: 20513595
147. **Mehran R**, Brar S, Dangas G. Contrast-induced acute kidney injury. Underappreciated or a new marker of cardiovascular mortality? *J Am Coll Cardiol*. 2010 May 18;55(20):2210-1. PMID: 20466201
148. Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, **Mehran R**, Stone GW. Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). *Am J Cardiol*. 2010 May 15;105(10):1385-94. Epub 2010 Apr 2. PMID: 20451683
149. He Y, Maehara A, Mintz GS, Bharaj H, Castellanos C, Kesanakurthy S, Wu X, Guo N, Choi SY, Leon MB, Stone GW, **Mehran R**, Rabbani LE, Moses JW. Intravascular ultrasound assessment of cobalt chromium versus stainless steel drug-eluting stent expansion. *Am J Cardiol*. 2010 May 1;105(9):1272-5. PMID: 20403478
150. Davidson KW, Burg MM, Kronish IM, Shimbo D, Dettenborn L, **Mehran R**, Vorchheimer D, Clemow L, Schwartz JE, Lespérance F, Rieckmann N. Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome. *Arch Gen Psychiatry*. 2010 May;67(5):480-8. PMID: 20439829
151. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tchong JE, **Mehran R**, Lansky AJ, Grines CL, Stone GW. Impact of Delay to Angioplasty in Patients With Acute Coronary Syndromes Undergoing Invasive Management Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) Trial. *J Am Coll Cardiol*. 2010 Apr 6;55(14):1416-1424. PMID: 20359590
152. Oviedo C, Maehara A, Mintz GS, Tsujita K, Kubo T, Doi H, Castellanos C, Lansky AJ, **Mehran R**, Dangas G, Leon MB, Stone GW, Templin B, Araki H, Ochiai M, Moses JW. Is accurate intravascular ultrasound evaluation of the left circumflex ostium from a left anterior descending to left main pullback possible? *Am J Cardiol*. 2010 Apr 1;105(7):948-54. Epub 2010 Feb 13. *Am J Cardiol*. 2010 Apr 1;105(7):948-54. Epub 2010 Feb 13.
153. Tsujita K, Maehara A, Mintz GS, Lansky AJ, Kubo T, Doi H, Yang J, Bharaj H, Witzendichler B, Guagliumi G, Brodie BR, Kellett MA Jr, Parise H, **Mehran R**, Stone GW. Serial Intravascular Ultrasound Analysis of the Impact of Myocardial Bridge on Neointimal Proliferation After Coronary Stenting in Patients with Acute Myocardial Infarction. *J Interv Cardiol*. 2010 Mar 2. [Epub ahead of print] PMID: 20236216
154. Caixeta A, **Mehran R**. Evidence-based management of patients undergoing PCI: contrast-induced acute kidney injury. *Catheter Cardiovasc Interv*. 2010 Mar 1;75 Suppl 1:S15-20. PMID: 20333702
155. Lasala JM, **Mehran R**, Moses JW, Popma JJ, Reiner JS, Sharma SK, Vetrovec GW. Evidence based management of patients undergoing PCI. Conclusion. *Catheter Cardiovasc Interv*. 2010 Mar 1;75 Suppl 1:S43-5. PMID: 20333707
156. Vranckx P, Cutlip DE, **Mehran R**, Kint PP, Silber S, Windecker S, Serruys PW. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. *EuroIntervention*. 2010 Feb;5(7):871-4. PMID: 20142206
157. Chieffo A, Hoye A, Mauri F, Mikhail GW, Ammerer M, Grines C, Grinfeld L, Madan M, Presbitero P, Skelding KA, Weiner BH, **Mehran R**. Gender-based issues in interventional cardiology: a consensus statement from the Women in Innovations (WIN) initiative. *EuroIntervention*. 2010 Feb;5(7):773-9. PMID: 20142190
158. Sanborn TA, Ebrahimi R, Manoukian SV, McLaurin BT, Cox DA, Feit F, Hamon M, **Mehran R**, Stone GW. Impact of Femoral Vascular Closure Devices and Antithrombotic Therapy on Access Site Bleeding in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial. *Circ Cardiovasc Interv*. 2010 Feb 1;3(1):57-62. Epub 2010 Jan 26. PMID: 20118151
159. Goto K, Lansky AJ, Fahy M, Cristea E, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, **Mehran R**, Stone GW. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an acute catheterization and urgent intervention triage strategy (ACUITY) substudy. *Circulation*. 2010 Feb 23;121(7):853-62. Epub 2010 Feb 8. PMID: 20142447

160. Chieffo A, Hoye A, Mauri F, Mikhail G, Ammerer M, Grines C, Grinfeld L, Madan M, Presbitero P, Skelding KA, Weiner BH, **Mehran R**. Cuestiones relativas al sexo en cardiología intervencionista: declaración de consenso de la iniciativa Women in Innovations (WIN). *Rev Esp Cardiol*. 2010 Feb;63(2):200-208. English, Spanish. PMID: 20109417
161. Chieffo A, Hoye A, Mauri F, Mikhail GW, Ammerer M, Grines C, Grinfeld L, Madan M, Presbitero P, Skelding KA, Weiner BH, **Mehran R**; on behalf of the WIN Group. Gender-based issues in interventional cardiology: A consensus statement from the Women in Innovations (WIN) Initiative. *Catheter Cardiovasc Interv*. 2010 Jan 21;75(2):145-152. Epub ahead of print. PMID: 20095009
162. Pocock SJ, **Mehran R**, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications. Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial. *Circulation*. 2010 Jan 5;121(1):43-51. Epub 2009 Dec 21. PMID: 20026777
163. **Mehran R**, Caixeta A. N-acetylcysteine in Preventing Contrast-Induced Nephropathy. To Give, or Not To Give: That is the Question. *Rev Esp Cardiol*. 2010 Jan;63(1):9-11. English, Spanish. PMID: 20089220
164. Saltzman AJ, **Mehran R**, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. *J Invasive Cardiol*. 2010 Jan;22(1):2-6. PMID: 20048389
165. Ambrosio G, Steinhilb S, Gresele P, Tritto I, Zuchi C, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, **Mehran R**, Stone GW. Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. *Eur J Cardiovasc Prev Rehabil*. 2010 Jun 2. [Epub ahead of print] PMID: 20523219
166. Tsujita K, Nikolsky E, Lansky AJ, Dangas G, Fahy M, Brodie BR, Dudek D, Möckel M, Ochala A, **Mehran R**, Stone GW. Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). *Am J Cardiol*. 2010 May 15;105(10):1385-94. Epub 2010 Apr 2. PMID: 20451683
167. He Y, Maehara A, Mintz GS, Bharaj H, Castellanos C, Kesanakurthy S, Wu X, Guo N, Choi SY, Leon MB, Stone GW, **Mehran R**, Rabbani LE, Moses JW. Intravascular ultrasound assessment of cobalt chromium versus stainless steel drug-eluting stent expansion. *Am J Cardiol*. 2010 May 1;105(9):1272-5. PMID: 20403478
168. Davidson KW, Burg MM, Kronish IM, Shimbo D, Dettenborn L, **Mehran R**, Vorchheimer D, Clemow L, Schwartz JE, Lespérance F, Rieckmann N. Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome. *Arch Gen Psychiatry*. 2010 May;67(5):480-8. PMID: 20439829
169. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tchong JE, **Mehran R**, Lansky AJ, Grines CL, Stone GW. Impact of Delay to Angioplasty in Patients With Acute Coronary Syndromes Undergoing Invasive Management Analysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) Trial. *J Am Coll Cardiol*. 2010 Apr 6;55(14):1416-1424. PMID: 20359590
170. Oviedo C, Maehara A, Mintz GS, Tsujita K, Kubo T, Doi H, Castellanos C, Lansky AJ, **Mehran R**, Dangas G, Leon MB, Stone GW, Templin B, Araki H, Ochiai M, Moses JW. Is accurate intravascular ultrasound evaluation of the left circumflex ostium from a left anterior descending to left main pullback possible? *Am J Cardiol*. 2010 Apr 1;105(7):948-54. Epub 2010 Feb 13. *Am J Cardiol*. 2010 Apr 1;105(7):948-54. Epub 2010 Feb 13.
171. Tsujita K, Maehara A, Mintz GS, Lansky AJ, Kubo T, Doi H, Yang J, Bharaj H, Witzenbichler B, Guagliumi G, Brodie BR, Kellett MA Jr, Parise H, **Mehran R**, Stone GW. Serial Intravascular Ultrasound Analysis of the Impact of Myocardial Bridge on Neointimal Proliferation After Coronary Stenting in Patients with Acute Myocardial Infarction. *J Interv Cardiol*. 2010 Mar 2. [Epub ahead of print] PMID: 20236216
172. Lasala JM, **Mehran R**, Moses JW, Popma JJ, Reiner JS, Sharma SK, Vetrovec GW. Evidence based management of patients undergoing PCI. Conclusion. *Catheter Cardiovasc Interv*. 2010 Mar 1;75 Suppl 1:S43-5. PMID: 20333707 [PubMed - in process] Related citations
173. Oviedo C, Maehara A, Mintz GS, Araki H, Choi SY, Tsujita K, Kubo T, Doi H, Templin B, Lansky AJ, Dangas G, Leon MB, **Mehran R**, Tahk SJ, Stone GW, Ochiai M, Moses JW. Intravascular Ultrasound Classification of Plaque Distribution in Left Main Coronary Artery Bifurcations: Where Is the Plaque Really Located? *Circ Cardiovasc Interv*. 2010 Mar 2. [Epub ahead of print] PMID: 20197513
174. Vranckx P, Cutlip DE, **Mehran R**, Kint PP, Silber S, Windecker S, Serruys PW. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. *EuroIntervention*. 2010 Feb;5(7):871-4. PMID: 20142206
175. Sanborn TA, Ebrahimi R, Manoukian SV, McLaurin BT, Cox DA, Feit F, Hamon M, **Mehran R**, Stone GW. Impact of Femoral Vascular Closure Devices and Antithrombotic Therapy on Access Site Bleeding in Acute Coronary Syndromes: The Acute

- Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial. *Circ Cardiovasc Interv*. 2010 Feb 1;3(1):57-62. Epub 2010 Jan 26. PMID: 20118151
176. Goto K, Lansky AJ, Fahy M, Cristea E, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, **Mehran R**, Stone GW. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an acute catheterization and urgent intervention triage strategy (ACUITY) substudy. *Circulation*. 2010 Feb 23;121(7):853-62. Epub 2010 Feb 8. PMID: 20142447
177. Pocock SJ, **Mehran R**, Clayton TC, Nikolsky E, Parise H, Fahy M, Lansky AJ, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Stone GW. Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications. Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial. *Circulation*. 2010 Jan 5;121(1):43-51. Epub 2009 Dec 21. PMID: 20026777
178. Rao SV, Eikelboom J, Steg PG, Lincoff AM, Weintraub WS, Bassand JP, Rao AK, Gibson CM, Petersen JL, **Mehran R**, Manoukian SV, Charnigo R, Lee KL, Moscucci M, Harrington RA; on behalf of the Academic Bleeding Consensus Multidisciplinary Working Group. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group. *Am Heart J*. 2009 Dec; 158(6): 881-886. el. PMID: 19958852
179. Nayak KR, Mehta HS, Price MJ, Russo RJ, Stinis CT, Moses JW, **Mehran R**, Leon MB, Kandzari DE, Teirstein PS. A novel technique for ultra-low contrast administration during angiography or intervention. *Catheter Cardiovasc Interv*. 2009 Dec 22. [Epub ahead of print] PMID: 20146209
180. Maehara A, Mintz GS, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Parise H, **Mehran R**, Stone GW. Volumetric intravascular ultrasound analysis of Paclitaxel-eluting and bare metal stents in acute myocardial infarction: the harmonizing outcomes with revascularization and stents in acute myocardial infarction intravascular ultrasound substudy. *Circulation*. 2009 Nov 10;120(19):1875-82. Epub 2009 Oct 26. PMID: 19858413
181. **Mehran R**, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW; HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. *Lancet*. 2009 Oct 3;374(9696):1149-59. Epub 2009 Aug 28.
182. Doll JA, Nikolsky E, Stone GW, **Mehran R**, Lincoff AM, Caixeta A, McLaurin B, Cristea E, Fahy M, Kesanakurthy V, Lansky AJ. Outcomes of Patients with Coronary Artery Perforation Complicating Percutaneous Coronary Intervention and Correlations with the Type of Adjunctive Antithrombotic Therapy: Pooled Analysis from REPLACE-2, ACUITY, and HORIZONS-AMI Trials. *J Interv Cardiol* 2009 Oct;22(5):453-9. Epub 2009 Aug 20. PMID: 19702677
183. Syros G, **Mehran R**, Weisz G, Kittas C, Moses JW, Leon M, Dangas G. Role of PLA2 polymorphism on clinical events after percutaneous coronary intervention. *Acute Card Care*. 2009;11(2):88-91. PMID: 19526385
184. Dangas G, **Mehran R**, Guagliumi G, Caixeta A, Witzenbichler B, Aoki J, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Rabbani LE, Parise H, Stone GW; HORIZONS-AMI Trial Investigators. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. *J Am Coll Cardiol*. 2009 Oct 6;54(15):1438-46. PMID: 19796737
185. Liu X, Tsujita K, Maehara A, Mintz GS, Weisz G, Dangas GD, Lansky AJ, Kreps EM, Rabbani LE, Collins M, Stone GW, Moses JW, **Mehran R**, Leon MB. Intravascular ultrasound assessment of the incidence and predictors of edge dissections after drug-eluting stent implantation. *JACC Cardiovasc Interv*. 2009 Oct;2(10):997-1004. PMID: 19850262
186. Nikolsky E, Stone GW, Kirtane AH, Dangas GD, Lansky AJ, McLaurin B, Lincoff AM, Feit F, Moses JW, Fahy M, Manoukian SV, White HD, Ohman EM, Bertrand ME, Cox DA, **Mehran R**. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial. *J Am Coll Cardiol*. 2009 Sep 29;54(14):1293-302. PMID: 19778672
187. Caixeta A, Nikolsky E, **Mehran R**. Prevention and treatment of contrast-associated nephropathy in interventional cardiology. *Curr Cardiol Rep*. 2009 Sep;11(5):377-83. PMID: 19709498
188. **Mehran R**, Nikolsky E, Lansky AJ, Kirtane AJ, Kim YH, Feit F, Manoukian S, Moses JW, Ebrahimi R, Ohman EM, White HD, Pocock SJ, Dangas GD, Stone GW. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) substudy. *JACC Cardiovasc Interv*. 2009 Aug;2(8):748-57.
189. Tsujita K, Maehara A, Mintz GS, Franklin-Bond T, **Mehran R**, Stone GW, Leon MB, Moses JW. In vivo intravascular ultrasonic assessment of anomalous right coronary artery arising from left coronary sinus. *Am J Cardiol*. 2009 Mar 1;103(5):747-51. Epub 2009 Jan 23. PMID: 19231346
190. Aoki J, Lansky AJ, **Mehran R**, Moses J, Bertrand ME, McLaurin BT, Cox DA, Lincoff AM, Ohman EM, White HD, Parise H, Leon MB, Stone GW. Early Stent Thrombosis in Patients with Acute Coronary Syndromes Treated with Drug-Eluting and Bare Metal Stents.

- The Acute Catheterization and Urgent Intervention Triage Strategy Trial. *Circulation*. 2009 Jan 26. [Epub ahead of print]PMID: 19171852
191. G n reux P, **Mehran R**. Are drug-eluting stents safe in the long term? *CMAJ*. 2008 Dec 23
  192. Tsujita K, Maehara a, Mintz GS, Doi H, Kubo T, Castellanos C, Liu J, Yang J, Oviedo C, Franklin-Bond T, Dasgupta N, Biro S, Dani L, Dangas GD, **Mehran R**, Kirtane AJ, Lansky AJ, Kreps EM, Collins MB, Stone Gw, Moses JW, Leon MB. Comparison of angiographic and intravascular ultrasonic detection of myocardial bridging of the left anterior descending coronary artery. *Am J Cardiol*. 2008 Dec 15;102(12):1608-13 Epub 2008 Sep 20.
  193. Moussa ID, Jaff MR, **Mehran R**, Gray W, Dangas G, Lazic Z, Moses JW. Prevalence and prediction of previously unrecognized peripheral arterial disease in patients with coronary artery disease: The peripheral arterial disease in Interventional Patients Study. *Catheter Cardiovasc Interv*. 2008 Dec 30 PMID: 19213068
  194. Moses JW, Dangas G, **Mehran R**, Mintz GS. Drug-eluting stents in the real world: how intravascular ultrasound can improve clinical outcome. *Am J Cardiol* 2008 Nov 3;102(9A): 24-J-8J.
  195. Jeffrey W. Moses, George Dangas, **Roxana Mehran**, and Gary Mintz. Drug-Eluting Stents in the Real World: How Intravascular Ultrasound Can Improve Clinical Outcome. Assessing the Landscape of Stent Thrombosis: The Drug-Eluting Versus Bare-Metal Stent Controversy. *J Am Coll Cardiol*. 2008 Nov 3; Vol 102 (9).
  196. Pinto DS, Stone GW, Shi C, Dunn BS, Reynolds MR, York M, Waszczak J, Berezin RH, **Mehran R**, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ; ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibitor for early invasive management of acute coronary syndromes. *J Am Coll Cardiol*. 2008 Nov 25;52(22): 1758-68
  197. Pinto DS, Stone GW, Shi C, Dunn ES, Reynolds MR, York M, Walczak J, Berezin RH, **Mehran R**, McLaurin BT, Cox DA, Ohman EM, Lincoff AM, Cohen DJ, ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators. Economic Evaluation of Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibition Versus Heparin With Routine Glycoprotein IIb/IIIa Inhibition for Early Invasive Management of Acute Coronary Syndromes. *J Am Coll Cardiol*. 2008 Nov 25;52(22):1758-1768.
  198. Tamburino C, Di Salvo ME, Capodanno D, Capranzano P, Parisi R, Mirabella F, Scardaci F, Ussia G, Galassi AR, Fiscella D, **Mehran R**, Dangas G. Real world safety and efficacy of the Janus tacrolimus-eluting stent: Long-term clinical outcome and angiographic findings from the tacrolimus-eluting stent (TEST) registry. *Catheter Cardiovasc Interv*. 2008 Oct 27;73(2):243-248. PMID: 19156896
  199. Nikolsky E, **Mehran R**. Hydration Protocols to reduce the incidence of contrast-induced nephropathy *J Invasive Cardiol* 2008 Oct 20 (10):527-38. PMID: 18829997
  200. White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, **Mehran R**, Moses JW, Stone GW. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) trial *J Am Coll Cardiol*. 2008 Sept 2;52(10):807-14
  201. Solinas E, Dangas G, Kirtane AJ, Lansky AJ, Franklin-Bond T, Boland P, Syros G, Kim YH, Gupta A, Mitz G, Fahy M, Collins M, Kodali S, Stone GW, Moses JW, Leon MB, **Mehran R**. Angiographic patterns of drug-eluting stent restenosis and one-year outcomes after treatment with repeated percutaneous coronary intervention. *Am J Cardiol* 2008 Aug 1;102(3): 311-5 Epub 2008 May 24
  202. **Mehran R**, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW. The Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. *Am Heart J*. 2008 Jul;156(1):44-56. PMID: 18585496
  203. Kereiakes DJ, Petersen JL, Batchelor WB, Fitzgerald PJ, **Mehran R**, Lansky A, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MW. Clinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. *J Invasive Cardiol*. 2008 Jul;20(7):335-41.
  204. Missel E, Mintz GS, Carlier SG, Sano K, Qian J, Kaple RK, Castellanos C, Dangas G, **Mehran R**, Moses JW, Stone GW, Leon MB. Necrotic Core and Its Ratio to Dense Calcium are Predictors of High Risk Non ST-Elevation Acute Coronary Syndrome. *Am J Cardiol* 2008 Mar 1;101(5) 573-8 Epub 2007 Dec 21 PMID 183080001
  205. Kim YH, Dangas GD, Solinas E, Aoki J, Parise H, Kirmura M, Franklin-Bond T, Dasgupta NK, Kirtane AJ, Moussa I, Lansky AJ, Collins M., Stone GW, Leon MB, Moses JW, **Mehran R**. Effectiveness of drug eluting stent implantation for patients with unprotected left main coronary artery stenosis. *Am J Cardiol* 2008 Mar 15; 101(6) 801-6 Epub 2008 Jan 18 PMID 18328844
  206. Kirtane AJ, Ellie SG, Dawkins KD, Colombo A, Grube E, Popma JJ, Fahy M, Leon MB, Moses JW, **Mehran R**, Stone GW. Paclitxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials. *J Am Coll Cardiol* 2008 Feb 19;51(7) 708-15 PMID: 18279734
  207. Aoki J, Kirtane AJ, Dangas GD, Lansky AJ, Morales A, Kimura M, Kim YH, Moussa I, Weisz G, Kreps EM, Collins M, Franklin-Bond T, Stone GW, Moses JW, Leon MB, **Mehran R**. Clinical outcomes after heterogeneous overlap stenting with drug-eluting stents and

- bare metal stents for de novo coronary artery narrowings. *Am J Cardiol*. 2008 Jan 1;101(1):58-62-Epub 2007 Nov 26 PMID 18157966
208. Pucelikova T, **Mehran R**, Kirtane AJ, Kim YH, Fahy M, Weisz G, Lansky AJ, Moussa I, Gray WA, Collins MB, Kodali SK, Stone GW, Moses JW, Leon MB, Dangas G. Short and long term outcomes after stent assisted percutaneous treatment of saphenous vein grafts in the drug eluting stent era. *Am J Cardiol*. 2008 Jan 1;101(1):63-8 Epub 2008 Nov 9; PMID: 18157967
209. Pocock SJ, Lansky AJ, **Mehran R**, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Pucelikova T, Kandzari DE, Ellis SG, Leon MB, Stone GW. Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. *J Am Coll Cardiol*. 2008 Jan 1;51(1) 23-32.
210. Nikolsky E, **Mehran R**, Stone GW. Gastrointestinal bleeding in percutaneous coronary intervention and acute coronary syndromes. *Am J Cardiol*. 2009 Sep 7;104(5 Suppl):22C-9C. Review. PMID: 19695357
211. Moses JW, Dangas G, **Mehran R**, Mintz GS. Drug-eluting stents in the real world: how intravascular ultrasound can improve clinical outcome. *Am J Cardiol*. 2008 Nov 3;102(9 Suppl):24J-8J. Review. PMID: 18928789
212. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, **Mehran R**, Moses JW, ACUITY Investigators. Bivalirudin in Patients with Acute Coronary Syndromes Undergoing Percutaneous Intervention: The ACUITY Trial. *LANCET*: 2007: 369(9565):907-19
213. Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, **Mehran R**, Pocock SJ: ACUITY Investigator. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY TRIAL. *JAMA* 2007 Dec 5 298(21) 2497-506
214. Sano K, Mintz GS, Carlier SG, de Ribamar Costa J Jr, Qian J, Missel E, Shan S, Franklin-Bond T, Boland P, Weisz G, Mousa I, Dangas GD, **Mehran R**, Lansky AJ, Kreps EM, Collins MB, Stone GW, Leon MB, Moses JW. Assessing intermediate left main coronary lesions using intravascular ultrasound. *Am Heart J* 2007 Nov; 154 (5) 983-8
215. Pucelikova T, Dangas G, **Mehran R**. Contrast-induced nephropathy. *Catheter Cardiovasc Interv* 2007 Nov 1
216. Sano K, Mintz GS, Carlier SG, Solinas E, Costa J de R Jr, Qian J, Missel E, Shan S, Franklin-Bond T, Boland P, Weisz G, Moussa I, Dangas G, **Mehran R**, Lansky AJ, Kreps E, Collins M, Stone GW, Moses JW, Leon MB. Treatment of restenotic drug-eluting stents: an intravascular ultrasound analysis. *J Invasive Cardiol* 2007 Nov 19 (11) 464-8
217. Abizaid A, Chaves AJ, Leon MB, Hauptmann K, **Mehran R**, Lansky AJ, Baumbach W, Shankar H, Muller R, Feres F, Sousa AG, Sousa JE, Grube E. Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-eluting stent for treatment of native coronary artery lesions :six month results of the ETHOS I trial. *Catheter Cardiovasc Interv*, 2007, Nov : 1 ;70(50) : 654-60 PMID 17932898
218. Sorajja P, Gersh BJ, **Mehran R**, Lansky AJ, Krucoff MW, Webb J, Cox DA, Brodie BR, Stone GW. Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction. *Am Heart J* 2007;154(2):379-84
219. Solinas E, Nikolsky E, Lansky AJ, Kirtane AJ, Morice MC, Popma JJ, Schofer J, Schampaert E, Pucelikova T, Aoki J, Fahy M, Dangas GD, Moses JW, Cutlip DE, Leon MB, **Mehran R**. Gender-specific outcomes after sirolimus-eluting stent implantation. *J Am Coll Cardiol*. 2007 Nov 27;50(22):2111-6
220. Stone GW, Dixon SR, Grines CL, Cox DA, Webb JG, Brodie BR, Griffin JJ, Martin JL, Fahy M, **Mehran R**, Miller TD, Gibbons RJ, O'Neill WW. Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials. *Am J Cardiol* 2007 Nov 1;100(9) 1370-5
221. Kereiakes DJ, Teirstein PS, Sarembock IJ, Holmes DR JR, Krucoff MW, O'Neill WW, Waksman R, William DO, Popma JJ, Buchbinder M, **Mehran R**, Meredith IT, Moses JW, Stone GW. The Truth and consequences of the COURAGE Trial. *J Am Coll Cardiol*. 2007 Oct 16;50 (16): 1598-603
222. Manoukian SV, Feit F, **Mehran R**, Voeltz M, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB 3<sup>rd</sup>, Ohman EM, Stone GW. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. *J Am Coll Cardiol*. 2007; 49(12):1362
223. Sorajja P, Gersh BJ, Cox DA, McLaughlin MG, Zimetbaum P, Costantini C, Stuckey T, Tchong JE, **Mehran R**, Lansky AJ, Grines CL, Stone GW. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary Percutaneous coronary intervention for acute myocardial infarction. *Eur Heart J*. 2007 Jul;28(14): 1709-16 Epub 2007 Jun 7 PMID 17556348
224. **Mehran R**. Contrast-Induced Nephropathy Remains a Serious Complication of PCI. *J Interv Cardiol*. 2007 Jun;20(3):236-40
225. Young JJ, Cox DA, Stuckey T, Babb J, Turco M, Lansky AJ, **Mehran R**, Stone GW. Prospective, Multicenter Study of Thrombectomy in Patients with Acute Myocardial Infarction: The X-Tract AMI Registry. *J Interv Cardiol* 2007: 20(1):44-50

226. Grube E, Buellfeld L, Neumann FJ, Verheye S, Abizaid A, McClean D, Mueller R, Lansky A, **Mehran R**, Costa R, Gerckens U, Trauthen B, Fitzgerald PJ. Six Month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. *Am J Cardiol* 2007 Jun 15;99(12):1691-7
227. Nikolsky E, **Mehran R**, Dangas G, Fahy M, Na Y, Pocock SJ, Lincoff AM, Stone G. Development and validation of a prognostic risk score for major bleeding in patients undergoing Percutaneous Coronary Intervention via the femoral approach. *Eur Heart J*. 2007 June
228. Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Leieber IH, Cohen DJ, **Mehran R**, White HD. Routine Upstream Initiation vs Deferred Selective Use of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes: The ACUITY Timing Trial. *JAMA* 2007; 14: 297: 591-602.
229. Brodie BR, Webb J, Cox DA, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford B, Antonucci D, Stucky T, Krucoff M, Gibbons R, Lansky A, Na Y, **Mehran R**, Stone GW, EMERALD Investigators. Impact of time to treatment on myocardial reperfusion and infarct size with primary Percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial). *Am J Cardiol*. 2007 Jun 15;99(12):1680-6
230. Cutlip DE, Windecker S, **Mehran R**, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation* 2007 May 1;115(17):2344-51.
231. Nikolsky E, Pucelikova T, **Mehran R**, Balter S, Kaufman L, Fagy M, Lansky AJ, Leon MB, Moses JW, Stone GW, Dangas G. An evaluation of fluoroscopy time and correlations with outcomes after Percutaneous coronary intervention. *J Invasive Cardiol*. 2007 May; 19(5):208-13
232. Prasad A, Stone GW, Stuckey TD, Constanini CO, **Mehran R**, Garcia E, Tcheng JE, Cox DA, Grines CL, Lansky AJ, Gersh BJ. Relation between leucocyte count, myonecrosis, myocardial perfusion and outcomes following primary angioplasty. *Am J Cardiol*. 2007; 99(8): 1067-71
233. Nikolsky E, Grines CL, Cox DA, Garcia E, Tcheng JE, Sadeghi M, **Mehran R**, Lansky AJ, Na Y, Stone GW. Impact of Baseline Platelet Count in Patients Undergoing Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the CADILLAC trial). *Am J Cardiol* 2007;99(8): 1055-61
234. Harjai KJ, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Na Y, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Rutherford BD, Lansky AJ, **Mehran R**. Usefulness of Routine Unfractionated Heparin Infusion Following Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction in Patients Not Receiving Glycoprotein IIb/IIIa Inhibitors. *Am J Cardiol*. 2007; 99(2):202-207
235. **Mehran R**, Dangas G. Off-label use of drug-eluting stents: assessing the risk. *Nat Clin Pract Cardiovasc Med*. 2007
236. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, **Mehran R**, Leon MB. Safety and Efficacy of Sirolimus and Paclitaxel Eluting Coronary Stents. *N Engl J Med* 2007:
237. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, **Mehran R**, Ohman EM, ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. *N Engl J Med* 2006;355(21):2203-16.
238. Baim DS, **Mehran R**, Kereiakes DJ, Gross TP, Simons M, Malenka D, Kaplan AV. Postmarket surveillance for drug-eluting coronary stents: a comprehensive approach. *Circulation* 2006;113:897-897.
239. Jonas M, Stone GW, **Mehran R**, Hermiller J, Feldman R, Herrmann HC, Cox DA, Kuntz RE, Popma JJ, Rogers C. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. *Eur Heart J* 2006;27:920-8.
240. Iakovou I, **Mehran R**, Dangas G. Thrombosis after implantation of drug-eluting stents. *Hellenic J Cardiol* 2006;47:31-38.
241. Jensen LO, Mintz GS, Carlier SG, Fujii K, Moussa I, Dangas G, **Mehran R**, Stone GW, Leon MB, Moses JW. Intravascular Ultrasound assessment of fibrous cap remnants after coronary plaque rupture. *Am Heart J* 2006;152(2):327-32
242. Kandzari DE, Tcheng JE, Gersh BJ, Cox DA, Stuckey T, Turco M, **Mehran R**, Garcia E, Zimetbaum P, McGlaughlin MG, Lansky AJ, Costantini CO, Grines CL, Stone GW; CADILLAC investigators. Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction. *Am Heart J* 2006;151:1288-1295.
243. Brodie BR, Stone GW, Cox DA, Stuckey TD, Turco M, Tcheng JE, Berger P, **Mehran R**, McLaughlin M, Costantini C, Lansky AJ, Grines CL. Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial. *Am Heart J* 2006;151:1231-1238.
244. Halkin A, Masud AZ, Rogers C, Hermiller J, Feldman R, Hall P, Haber RH, Cambier PA, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA, **Mehran R**, Stone GW. Six-month outcomes after percutaneous intervention



- for lesions in aortocoronary saphenous vein grafts using distal protectin devices: results from the FIRE trial. *Am Heart J* 2006;151:915.
245. Nikolsky E, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Negoita M, Lansky AJ, Mehran R. Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. *Am Heart J* 2006;151:168-175.
246. Pinto DS, Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, **Mehran R**, Na Y, Turco M, Caputo R, Popma JJ, Cutlip DE, Russell ME, Cohen DJ; TAXUS-IV Investigators. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. *J Am Coll Cardiol* 2006;48:32-36.
247. Moses JW, Stone GW, Nikolsky E, Mintz GS, Dangas G, Grube E, Ellis SG, Lansky AJ, Weisz G, Fahy M, Na Y, Russell ME, Donohoe D, Leon MB, **Mehran R**. Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials. *J Am Coll Cardiol* 2006;47:2164-2171.
248. Halkin A, Stone GW, Grines CL, Cox DA, Rutherford BD, Esente P, Meils CM, Albertsson P, Farah A, Tcheng JE, Lansky AJ, **Mehran R**. Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction. *J Am Coll Cardiol* 2006;47:951-961
249. Price MJ, Moses JW, Leon MB, **Mehran R**, Negoita M, Lansky AJ, Collins M, Giap H, Lin R, Jani S, Steuterman S, Balter S, Dalton J, Lipsztein R, Tripuraneni P, Tierstein PS. A multicenter, randomized, does-finding study of gamma intracoronary radiation therapy to inhibit recurrent restenosis after stenting. *J Invasive Cardiol* 2006;18:169-173.
250. Lansky AJ, Yang YM, Khan Y, Costa RA, Pietras C, Tsuchiya Y, Cristea E, Collins M, **Mehran R**, Dangas GD, Moses JW, Leon MB, Stone GW. Treatment of coronary artery perforations complicating Percutaneous coronary intervention with a polytetrafluoroethylene-covered stent graft. *Am J Cardiol*. 2006;98(3):370-4
251. Kimura M, Mintz GS, Carlier S, Takebayashi H, Fujii K, Sano K, Yasuda T, Costa RA, Costa JR Jr., Quen J, Tanaka K, Lui J, Weisz g, Moussa I, Dangas G, **Mehran R**, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Outcome after acute incomplete Sirolimus-Eluting Stent apposition as assessed by serial intravascular ultrasound. *Am J Cardiol* 2006;98(4):436-42
252. Tsuchiya Y, Lansky AJ, Costa RA, **Mehran R**, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Muller R, Storger H, Hauptmann, KE, Grube E. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). *Am J Cardiol* 2006;98:464-9
253. Moses JW, Nikolsky E, **Mehran R**, Cambier PA, Bachinsky WB, Leya F, Kuntz RE, Popma JJ, Schleckser P, Wang H, Cohen SA, Leon MB, SIRIUS 2.25 Investigators. Safety and Efficacy of the 2.25-mm Sirolimus-Eluting Bx Velocity Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: the SIRIUS 2.25 Trial. *Am J Cardiol* 2006;98(11):1455-60
254. Sano K, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Kimura M, Costa JR Jr., Tanaka K, Costa RA, Lui J, Weisz G, Moussa I, Dangas GD, **Mehran R**, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Volumetric intravascular ultrasound assessment of neointimal hyperplasia and nonuniform stent strut distribution in Sirolimus-Eluting Stents restenosis. *Am J Cardiol* 2006;98(12):1559-62.
255. Lansky AJ, Yang YM, Khan Y, Costa RA, Pietras C, Tsuchiya Y, Cristea E, Collins M, **Mehran R**, Dangas GD, Moses JW, Leon MB, Stone GW. Treatment of coronary artery perforations complication percutaneous coronary intervention with a polytetrafluoroethylene-covered stent graft. *Am J Cardiol* 2006;98:370-374.
256. Cox DA, Stone GW, Grines CL, Stuckey T, Zimetbaum PJ, Tcheng JE, Turco M, Garcia E, Guagliumi G, Iwaoka RS, **Mehran R**, O'neill WW, Lansky AJ, Griffin JJ; CADILLAC Investigators. Comparative Early and Late Outcomes After Primary Percutaneous Coronary Intervention in ST-Segment Elevation and Non-ST-Segment Elevation Acute Myocardial Infarction (from the CADILLAC Trial). *Am J Cardiol* 2006;98:331-337.
257. Sano K, Mintz GS, Carlier SG, Fujii K, Yasuda T, Kimura M, Costa JR Jr, Costa RA, Lui J, Weisz G, Moussa I, Dangas GD, **Mehran R**, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Intravascular ultrasonic differences between aorto-ostial and shaft narrowing in saphenous veins used as aortocoronary bypass grafts. *Am J Cardiol* 2006;97:1463-1466.
258. Moussa I, Costa RA, Leon MB, Lansky AJ, Lasic Z, Cristea E, Trubelja N, Carlier SG, **Mehran R**, Dangas GD, Weisz G, Kreps EM, Collins M, Stone GW, Moses JW. A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique". *Am J Cardiol* 2006;97:1317-1321.
259. **Mehran R**, Dangas G. Can manual thrombus aspiration improve myocardial reperfusion? *Nat Clin Pract Cardiovasc Med* 2006;3:68-69
260. Sorajja P, Gersh BJ, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, Garcia E, Tcheng JE, **Mehran R**, Lansky AJ, Kandzari DE, Grines CL, Stone GW. Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. *Eur Heart J* 2005;26:667-674.
261. Stone GW, Colombo A, Teirstein PS, Moses JW, Leon MB, Reifart NJ, Mintz GS, Hoye A, Cox DA, Baim DS, Strauss BH, Selmon M, Moussa I, Suzuki T, Tamai H, Katoh O, Mitsudo K, Grube E, Cannon LA, Kandzari DE, Reisman M, Schwartz RS, Bailey S, Dangas G,

- Mehran R**, Abizaid A, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: procedural techniques, devices, and results. *Catheter Cardiovasc Interv* 2005;66:217-236.
262. **Mehran R**, Nikolsky E, Camenzind E, Zelizko M, Kranjec I, Seabra-Gomes R, Negoita M, Slack S, Lotan C. An Internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation. *Am Heart J* 2005;150:1171-1176.
263. Halkin A, **Mehran R**, Casey CW, Gordon P, Matthews R, Wilson BH, Leon MB, Russell ME, Ellis SG, Stone GW. Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. *Am Heart J* 2005;150:1163-1170.
264. Stone GW, Reifart NJ, Moussa I, Hoyer A, Cox DA, Colombo A, Baim DS, Teirstein PS, Strauss BH, Selmon M, Mintz GS, Katoh O, Mitsudo K, Suzuki T, Tamai H, Grube E, Cannon LA, Kandzari DE, Reisman M, Schwartz RS, Bailey S, Dangas G, **Mehran R**, Abizaid A, Moses JW, Leon MB, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II. *Circulation* 2005;112:2530-2537.
265. Stone GW, Kandzari DE, **Mehran R**, Colombo A, Schwartz RS, Bailey S, Moussa I, Teirstein PS, Dangas G, Baim DS, Selmon M, Strauss BH, Tamai H, Suzuki T, Mitsudo K, Katoh O, Cox DA, Hoyer A, Mintz GS, Grube E, Cannon LA, Reifart NJ, Reisman M, Abizaid A, Moses JW, Leon MB, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. *Circulation* 2005;112:2364-2372.
266. Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, **Mehran R**, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation* 2005;111:1611-1618.
267. Lansky AJ, Hochman JS, Ward PA, Mintz GS, Fabunmi R, Berger PB, New G, Grines CL, Pietras CG, Kern MJ, Ferrell M, Leon MB, **Mehran R**, White C, Mieres JH, Moses JW, Stone GW, Jacobs AK. Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women. A Statement for Healthcare Professionals From the American Heart Association. *Circulation* 2005;111:940-953.
268. Weisz G, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Rutherford BD, **Mehran R**, Aymong E, Lansky A, Grines CL, Stone GW. Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited. *Am Heart J* 2005;150:358-364.
269. Carlier S, Kakadiaris IA, Dib N, Vavuranakis M, Stefanadis C, O'Malley SM, Hartley CJ, Metcalfe R, **Mehran R**, Falk E, Gul K, Naghavi M. Vasa vasorum imaging: a new window to the clinical detection of vulnerable atherosclerotic plaques. *Curr Atheroscler Rep* 2005;7:164-169.
270. Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoniucci D, Krucoff MW, Gibbons RJ, Jones D, Lansky AJ, **Mehran R**; Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. *JAMA* 2005;293:1063-1072.
271. Costa RA, Mintz GS, Carlier SG, Lansky AJ, Moussa I, Fujii K, Takebayashi H, Yasuda T, Costa JR Jr, Tsuchiya Y, Jensen LO, Cristea E, **Mehran R**, Dangas GD, Iyer S, Collins M, Kreps EM, Colombo A, Stone GW, Leon MB, Moses JW. Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis. *J Am Coll Cardiol* 2005;46:599-605.
272. Nikolsky E, Sadeghi HM, Efron MB, **Mehran R**, Lansky AJ, Na Y, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD, Grines CL, Stone GW. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. *Am J Cardiol* 2005;96:474-481.
273. Halkin A, Singh M, Nikolsky E, Grines CL, Tcheng JE, Garcia E, Cox DA, Turco M, Stuckey TD, Na Y, Lansky AJ, Gersh BJ, O'Neill WW, **Mehran R**, Stone GW. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. *J Am Coll Cardiol* 2005;45:1397-1405.
274. Prasad A, Stone GW, Stuckey TD, Costantini CO, Zimetbaum PJ, McLaughlin M, **Mehran R**, Garcia E, Tcheng JE, Cox DA, Grines CL, Lansky AJ, Gersh BJ. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. *J Am Coll Cardiol* 2005;45:508-514.
275. Dangas G, Ellis SG, Shlofmitz R, Katz S, Fish D, Martin S, **Mehran R**, Russell ME, Stone GW; TAXUS-IV Investigators. Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery. *J Am Coll Cardiol* 2005;45:1186-1192.
276. Lansky AJ, Costa RA, Mooney M, Midei MG, Lui HK, Strickland W, **Mehran R**, Leon MB, Russell ME, Ellis SG, Stone GW; TAXUS-IV Investigators. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. *J Am Coll Cardiol* 2005;45:1180-1185.
277. Hermiller JB, Riazner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, **Mehran R**, Stone GW; TAXUS-IV Investigators. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. *J Am Coll Cardiol* 2005;45:1172-1179.

278. Moses JW, **Mehran R**, Nikolsky E, Lasala JM, Corey W, Albin G, Hirsch C, Leon MB, Russell ME, Ellis SG, Stone GW. Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. *J Am Coll Cardiol* 2005;45:1165-1171.
279. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, Dangas G, **Mehran R**, Lansky AJ, Kreps EM, Collins M, Stone GW, Moss JW, Leon MB. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. *J Am Coll Cardiol* 2005;45:995-998.
280. **Mehran R**, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. *Kidney Int Suppl* (100):S11-15.
281. Nikolsky E, **Mehran R**, Dangas G. Reply from the authors. *Kidney Int* 2005;68:1372.
282. Nikolsky E, **Mehran R**, Lasic Z, Mintz GS, Lansky AJ, Na Y, Pocock S, Negoita M, Moussa I, Stone GW, Moses JW, Leon MB, Dangas G. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. *Kidney Int* 2005;67:706-713.
283. Teirstein PS, Kao J, Watkins M, Tannenbaum MA, Laufer N, Chang M, **Mehran R**, Dangas G, Russell ME, Ellis SG, Stone GW. Impact of platelet glycoprotein IIb/IIIa inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provokable myocardial ischemia (a TAXUS IV substudy). *Am J Cardiol* 2005;96:500-505.
284. Halkin A, Stone GW, Grines CL, Cox DA, Stuckey TD, Garcia E, Guagliumi G, **Mehran R**, Rutherford BD, Griffin JJ, Na Y, Tcheng JE, Turco M. Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry). *Am J Cardiol* 2005;96:1649-1655.
285. Moussa I, Ellis SG, Jones M, Kereiakes DJ, McMartin D, Rutherford B, **Mehran R**, Collins M, Leon MB, Popma JJ, Russell ME, Stone GW. Impact of coronary culprit lesion calcium in patients undergoing paclitaxel-eluting stent implantation (a TAXUS-IV sub study). *Am J Cardiol* 2005;96:1242-1247.
286. Dangas G, Lasic Z, **Mehran R**, Cox D, Ghali MG, Henry TD, Teirstein PS, Stella JF, Browne KF Jr, Lewis SA, Knopf W, Leon MB, Moses JW, Stone GW. Effectiveness of the concomitant use of bivalirudin and drug-eluting stents (from the prospective, multicenter bivalirudin and Drug-Eluting Stents [ADEST] study). *Am J Cardiol* 2005;96:659-663.
287. Teirstein PS, Kao J, Watkins M, Tannenbaum MA, Laufer N, Chang M, **Mehran R**, Dangas G, Russell ME, Ellis SG, Stone GW. Impact of platelet glycoprotein IIb/IIIa inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provokable myocardial ischemia (a TAXUS IV substudy). *Am J Cardiol* 2005;96:500-505.
288. Nikolsky E, Sadeghi HM, Efron MB, **Mehran R**, Lansky AJ, Na Y, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD, Grines CL, Stone GW. Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. *Am J Cardiol* 2005;96:474-481.
289. Fujii K, Carlier SG, Mintz GS, Takebayashi H, Yasuda T, Costa RA, Moussa I, Dangas G, **Mehran R**, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Intravascular ultrasound study of patterns of calcium in ruptured coronary plaques. *Am J Cardiol* 2005;96:352-357.
290. Halkin A, Stone GW, Dixon SR, Grines CL, Tcheng JE, Cox DA, Garcia E, Brodie B, Stuckey TD, **Mehran R**, Lansky AJ. Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction. *Am J Cardiol* 2005;96:325-331.
291. de Ribamar Costa J Jr, Mintz GS, Carlier SG, Costa RA, Fujii K, Sano K, Kimura M, Lui J, Weisz G, Moussa I, Dangas G, **Mehran R**, Lansky AJ, Kreps EM, Collins M, Stone GW, Moses JW, Leon MB. Intravascular ultrasonic assessment of stent diameters derived from manufacturers' compliance charts. *Am J Cardiol* 2005;96:74-78.
292. Wong SC, Hong MK, Ellis SG, Buchbinder M, Reisman M, Delago A, Kellett M, Popma JJ, Russell ME, **Mehran R**, Moses JW, Stone GW. Influence of stent length to lesion length ratio on angiographic and clinical outcomes after implantation of bare metal and drug-eluting stents (the TAXUS-IV Study). *Am J Cardiol* 2005;95:1043-1048.
293. Nikolsky E, Koskinski E, Mishke GJ, Kimmelstiel C, McGarry TF Jr, **Mehran R**, Leon MB, Russell ME, Ellis SG, Stone GW. Impact of obesity on revascularization and restenosis rates after bare metal and drug-eluting stent implantation (from the TAXUS-IV trial). *Am J Cardiol* 2005;95:709-715.
294. Swaminathan A, Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud AR, Cambier P, Caputo RP, Cox DA, **Mehran R**, Herrmann HC. Influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft intervention. *Am J Cardiol* 2005;95:651-654.
295. Takebayashi H, Kobayashi Y, Mintz GS, Carlier SG, Fujii K, Yasuda T, Moussa I, **Mehran R**, Dangas GD, Collins MB, Kreps E, Lansky AJ, Stone GW, Leon MB, Moses JW. Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. *Am J Cardiol* 2005;95:498-502.

296. Fujii K, Carlier SG, Mintz GS, Kobayashi Y, Jacoboff D, Nierenberg H, Takebayashi H, Yasuda T, Moussa I, Dangas G, **Mehran R**, Lansky AJ, Kreps EM, Collins M, Stone GW, Leon MB, Moses JW. Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque. *Am J Cardiol* 2005;95:355-359.
297. Costa RA, Lansky AJ, Mintz GS, **Mehran R**, Tsuchiya Y, Negoita M, Gilutz Y, Nikolsky E, Fahy M, Pop R, Cristea E, Carlier S, Dangas G, Stone GW, Leon MB, Muller R, Techen G, Grube E. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). *Am J Cardiol* 2005;95:113-116.
298. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, Lansky AJ, Moussa I, Stone GW, Moses JW, Leon MB, **Mehran R**. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. *Am J Cardiol* 2005;95:13-19.
299. Stuckey TD, Stone GW, Cox DA, Tcheng JE, Garcia E, Carroll J, Guagliumi G, Rutherford BD, Griffin JJ, Turco M, Lansky AJ, **Mehran R**, Fahy M, Brodie BR, Grines CL; for the CADILLAC Investigators. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial). *Am J Cardiol* 2005;95:1-7.
300. **Mehran R**, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas GD. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary interventions: development and initial validation. *J Am Coll Cardiol* 2004;44:1393-1399.
301. McLaughlin MG, Stone GW, Aymong E, Gardner G, **Mehran R**, Lansky AJ, Grines CL, Tcheng JE, Cox DA, Stuckey T, Garcia E, Guagliumi G, Turco M, Josephson ME, Zimetbaum P; Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications trial. Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *J Am Coll Cardiol* 2004;44:1215-1223.
302. Nikolsky E, **Mehran R**, Halkin A, Aymong ED, Mintz GS, Lasic Z, Negoita M, Fahy M, Krieger S, Moussa I, Moses JW, Stone GW, Leon MB, Pocock SJ, Dangas G. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. *J Am Coll Cardiol* 2004;44:1200-1209.
303. Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, **Mehran R**, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Lansky AJ, Stone GW. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. *J Am Coll Cardiol* 2004;44:547-553.
304. Costantini CO, Stone GW, **Mehran R**, Aymong E, Grines CL, Cox DA, Stuckey T, Turco M, Gersh BJ, Tcheng JE, Garcia E, Griffin JJ, Guagliumi G, Leon MB, Lansky AJ. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. *J Am Coll Cardiol* 2004;44:305-312.
305. Halkin A, Grines CL, Cox DA, Garcia E, **Mehran R**, Tcheng JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong E, Lansky AJ, Stone GW. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. *J Am Coll Cardiol* 2004;43:1780-1787.
306. **Mehran R**, Dangas GD, Kobayashi Y, Lansky AJ, Mintz GS, Aymong ED, Fahy M, Moses JW, Stone GW, Leon MB. Short- and long-term results after multivessel stenting in diabetic patients. *J Am Coll Cardiol* 2004;43:1348-1354.
307. Pellizzon GC, Grines CL, Cox DA, Stuckey T, Tcheng JE, Garcia E, Guagliumi G, Turco M, Lansky AJ, Griffin JJ, Cohen DJ, Aymong E, **Mehran R**, O'Neill WW, Stone GW. Importance of mitral regurgitation in patients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. *J Am Coll Cardiol* 2004;43:1368-1374.
308. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujii K, Yasuda T, Costa RA, Moussa I, Dangas GD, **Mehran R**, Lansky AJ, Kreps E, Collins MB, Colombo A, Stone GW, Leon MB, Moses JW. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. *Circulation* 2004;110:3430-3434.
309. Guagliumi G, Stone GW, Cox DA, Stuckey T, Tcheng JE, Turco M, Musumeci G, Griffin JJ, Lansky AJ, **Mehran R**, Grines CL, Garcia E. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction. Results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. *Circulation* 2004;110:1598-1604.
310. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Jacoboff D, Yasuda T, Moussa I, Dangas G, **Mehran R**, Lansky AJ, Reyes A, Kreps E, Collins M, Stone GW, Leon MB, Moses JW. Vascular remodeling and plaque composition between focal and diffuse coronary lesions assessed by intravascular ultrasound. *Am J Cardiol* 2004;94:1067-1070.
311. Kandzari DE, Tcheng JE, Grines CL, Cox DA, Stuckey T, Griffin JJ, Turco M, Garcia E, Carroll JD, Fahy M, Lansky AJ, **Mehran R**, Stone GW; CADILLAC Investigators. Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction. *Am J Cardiol* 2004;94:1029-1033.

312. Nikolsky E, **Mehran R**, Aymong ED, Mintz GS, Lansky AJ, Lasic A, Negoita M, Fahy M, Pocock SJ, Na Y, Krieger S, Moses JW, Stone GW, Leon MB, Dangas G. Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. *Am J Cardiol* 2004;94:1023-1027.
313. Dangas G, Aymong ED, **Mehran R**, Tcheng JE, Grines CL, Cox CA, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Lansky AJ, Stone GW, for the CADILLAC Investigators. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). *Am J Cardiol* 2004;94:983-988.
314. Sadeghi HM, Grines CL, Chandra HR, **Mehran R**, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Lansky AJ, O'Neill WW, Stone GW. Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the CADILLAC trial). *Am J Cardiol* 2004;94:637-640.
315. Nikolsky E, **Mehran R**, Turcot D, Aymong ED, Mintz GS, Lasic Z, Lansky AJ, Tsounias E, Moses JW, Stone GW, Leon MB, Dangas GD. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. *Am J Cardiol* 2004;94:300-305.
316. Nikolsky E, **Mehran R**, Dangas GD, Lasic Z, Mintz GS, Negoita M, Lansky AJ, Stone GW, Moussa I, Iyer S, Na Y, Moses JW, Leon MB. Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions. *Am J Cardiol* 2004;93:1536-1539.
317. Iakovou I, Dangas G, Mintz GS, **Mehran R**, Kobayashi Y, Aymong ED, Hirose M, Ashby DT, Lansky AJ, Stone GW, Leon MB, Moses JW. Relation of final lumen dimensions in saphenous vein grafts after stent implantation to outcome. *Am J Cardiol* 2004;93:963-968.
318. Shirai K, Lansky AJ, **Mehran R**, Dangas GD, Costantini CO, Fahy M, Slack S, Mintz GS, Stone GW, Leon MB. Minimally invasive coronary artery bypass grafting versus stenting for patients with proximal left anterior descending coronary artery disease. *Am J Cardiol* 2004;93:959-962.
319. Lansky AJ, **Mehran R**, Dangas G, Cristea E, Shirai K, Costa R, Costantini C, Tsuchiya Y, Carlier S, Mintz G, Cotting Y, Stone G, Moses J, Leon MB. Comparison of differences in outcome after percutaneous coronary intervention in men versus women <40 years of age. *Am J Cardiol* 2004;93:916-919.
320. Halkin A, Aymong E, Cox DA, **Mehran R**, Lansky AJ, Fahy M, Weisz G, Garcia E, Tcheng JE, Grines CL, Stone GW. Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial). *Am J Cardiol* 2004;93:349-353.
321. Iakovou I, Dangas G, Mintz GS, **Mehran R**, Lansky AJ, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, Stone GW, Leon MB, Moses JW. Comparison of frequency of hemorrhagic stroke in patients <75 years versus ≥75 years of age among patients receiving glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. *Am J Cardiol* 2004;93:346-349.
322. **Mehran R**, Leon MB, Feigal DA, Jefferys D, Simons M, Chronos N, Fogarty TJ, Kuntz RE, Baim DS, Kaplan AV. Post-market approval surveillance: a call for a more integrated and comprehensive approach. *Circulation* 2004;109:3073-3077.
323. Fujii K, Mintz GS, Kobayashi Y, Carlier SG, Takebayashi H, Yasuda T, Moussa I, Dangas G, **Mehran R**, Lansky AJ, Reyes A, Kreps E, Collins M, Colombo A, Stone GW, Teirstein PS, Leon MB, Moses JW. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. *Circulation* 2004;109:1085-1088.
324. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, **Mehran R**, Moses JW, Ohman M, White HD. Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial: study design and rationale. *Am Heart J* 2004;148:764-775.
325. Moses JW, **Mehran R**. Cardiac safety and tolerability of angiographic contrast media. *Cath Lab Digest* 2004;16:1S-6S.
326. Yang YM, **Mehran R**, Dangas G, Reyes A, Qin J, Stone GW, Leon MB, Moses JW. Successful use of the frontrunner catheter in the treatment of in-stent coronary chronic total occlusions. *Catheter Cardiovasc Interv* 2004;63:462-468.
327. Iakovou I, **Mehran R**, Dangas G, Lansky AJ, Stone GW, Mintz GS, Aymong E, Ashby DT, Pichard AD, Satler LF, Kent K, Leon MB, Waksman R. Favorable effect of gamma-radiation for in-stent restenosis: effect of diabetes on angiographic and clinical outcomes. *Catheter Cardiovasc Interv* 2004;62:303-307.
328. Kipshidze NN, Iversen P, Kim HS, Yazdi H, Dangas G, Seaborn R, New G, Tio F, Waksman R, **Mehran R**, Tsapenko M, Stone GW, Roubin GS, Iyer S, Leon MB, Moses JW. Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. *Catheter Cardiovasc Interv* 2004;61:518-527.
329. **Mehran R**, Iakovou I, Dangas G, Lansky AJ, Stone GW, Mintz GS, Kent KM, Pichard AD, Satler LF, Fahy M, Leon MB, Waksman R. Gamma radiation for in-stent restenosis: effect of lesion length on angiographic and clinical outcomes. *Catheter Cardiovasc Interv* 2004;61:354-359.
330. Prasad A, Stone GW, Aymong E, Zimetbaum PJ, McLaughlin M, **Mehran R**, Garcia E, Tcheng JE, Cox DA, Grines CL, Gersh BJ. Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial. *Am Heart J* 2004;147:669-675.

331. Sharma SK, Kini A, **Mehran R**, Lansky A, Kobayashi Y, Marmur JD. Randomized trial of Rotational Atherectomy Versus Balloon Angioplasty for Diffuse In-stent Restenosis (ROSTER). *Am Heart J* 2004;147:16-22.
332. Abizaid A, Albertal M, Costa MA, Abizaid AS, Staico R, Feres F, Mattos LA, Sousa AG, Moses J, Kipshidze N, Roubin GS, **Mehran R**, New G, Leon MB, Sousa JE. First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial. *J Am Coll Cardiol* 2004;43:1118-1121.
333. Nikolsky E, **Mehran R**, Mintz GS, Dangas GD, Lansky AJ, Aymong ED, Negoita M, Fahy M, Moussa I, Roubin GS, Moses JW, Stone GW, Leon MB. Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions. *J Endovasc Ther* 2004;11:60-70.
334. Lasic Z, **Mehran R**, Dangas G, Mintz G, Nikolsky E, Tsounias E, Udani PC, Adamian M, Adamian J, Moussa I, Collins M, Stone G, Moses J. Comparison of safety and efficacy between first and second generation of Angio-seal closure devices in interventional patients. *J Invasive Cardiol* 2004;16:356-358.
335. Shirai K, Lansky AJ, Mintz GS, Costantini CO, Fahy M, **Mehran R**, Dangas G, Moses JW, Stone GW, Waksman R, Leon MB. Comparison of the angiographic outcomes after beta versus gamma vascular brachytherapy for treatment of in-stent restenosis. *Am J Cardiol* 2003;92:1409-1413.
336. Kobayashi Y, **Mehran R**, Mintz GS, Dangas G, Moussa I, Collins M, Brara P, Moussavian M, Lansky AJ, Stone GW, Leon MB, Moses JW, Teirstein PS. Acute and long-term outcomes of cutting balloon angioplasty followed by gamma brachytherapy for in-stent restenosis. *Am J Cardiol* 2003;92:1329-1331.
337. Iakovou I, Mintz GS, Dangas G, Abizaid A, **Mehran R**, Lansky AJ, Kobayashi Y, Hirose M, Ashby DT, Stone GW, Moses JW, Leon MB. Optimal fine lumen area and predictors of target lesion revascularization after stent implantation in small coronary arteries. *Am J Cardiol* 2003;92:1171-1176.
338. Costantini CO, Lansky AJ, Mintz GS, Shirai K, Dangas G, **Mehran R**, Stone GW, Leon MB. Usefulness of the angiographic pattern of in-stent restenosis in predicting the success of gamma vascular brachytherapy. *Am J Cardiol* 2003;92:1214-1217.
339. Ashby DT, Aymong EA, Grines CL, Cox DA, Garcia E, **Mehran R**, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Carroll JD, Turco M, Lansky AJ, Stone GW; CADILLAC trial. Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial). *Am J Cardiol* 2003;92:1095-1098.
340. Ashby DT, Aymong EA, Tcheng JE, Grines CL, Cox DA, **Mehran R**, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Lansky AJ, Stone GW; CADILLAC Trial. Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial). *Am J Cardiol* 2003;92:1091-1094.
341. Iakovou I, Dangas G, **Mehran R**, Mintz GS, Lansky AJ, Aymong ED, Nikolsky E, Vagaonescu T, Glasser LA, Stone GW, Leon MB, Moses JW. Comparison of effect of glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions on risk of hemorrhagic stroke in patients  $\geq 75$  years of age versus those  $< 75$  years of age. *Am J Cardiol* 2003;92:1083-1086.
342. Ashby DT, **Mehran R**, Aymong EA, Lansky AJ, Iakovou I, Weisz G, New G, Moussa, Dangas G, Moses JW, Stone GW, Leon MB. Comparison of outcomes in men versus women having percutaneous coronary interventions in small coronary arteries. *Am J Cardiol* 2003;91:979-981.
343. Kandzari DE, Tcheng JE, Cohen DJ, Bakhai A, Grines CL, Cox DA, Effron M, Stuckey T, Griffin JJ, Turco M, Carroll JD, Fahy M, **Mehran R**, Stone GW; CADILLAC Investigators. Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). *Am J Cardiol* 2003;92:779-784.
344. Kobayashi Y, **Mehran R**, Mintz GS, Dangas G, Moussa I, Lansky AJ, Stone GW, Moses JW, Leon MB. Comparison of in-hospital and one-year outcomes after multiple coronary arterial stenting in patients  $\geq 80$  years old versus those  $< 80$  years old. *Am J Cardiol* 2003;92:443-446.
345. Ashby DT, Dangas G, Aymong EA, Farkouh ME, **Mehran R**, Lansky AJ, Moses JW, Leon MB, Stone GW. Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. *Am J Cardiol* 2003;92:319-322.
346. Stone GW, **Mehran R**, Midei M, Waksman R, Schaer GL, Negoita M, Lansky AJ, Buchbinder M; SVG BRITE Investigators. Usefulness of beta radiation for de novo and in-stent restenotic lesions in saphenous vein grafts. *Am J Cardiol* 2003;92:312-314.
347. Limpijankit T, **Mehran R**, Mintz GS, Dangas G, Lansky AJ, Kao J, Ashby DT, Moussa I, Stone GW, Moses JW, Leon MB, Teirstein PS. Long-term follow-up of patients after gamma intracoronary brachytherapy failure (from GAMMA-I, GAMMA-II, and SCRIPPS-III). *Am J Cardiol* 2003;92:315-318.
348. El-Omar MM, Dangas G, **Mehran R**, Lansky AJ, Kipshidze NN, Polena S, Fahy M, Moussa I, Glasser L, Moses JW, Stone GW, Leon MB. Usefulness of atrial fibrillation as a marker of outcome after percutaneous coronary intervention. *Am J Cardiol* 2003;91:232-234.
349. Hirose M, Kobayashi Y, Mintz GS, Moussa I, **Mehran R**, Lansky AJ, Dangas G, Kreps EM, Collins MB, Stone GW, Colombo A, Leon MB, Moses JW. Correlation of coronary arterial remodeling determined by intravascular ultrasound with angiographic diameter reduction of 20% to 60%. *Am J Cardiol* 2003;92:141-145.

350. Fujii K, Kobayashi Y, Mintz GS, Hirose M, Moussa I, **Mehran R**, Dangas G, Lansky AJ, Kreps E, Collins M, Colombo A, Stone GW, Leon MB, Moses JW. Dominant contribution of negative remodeling to development of significant coronary bifurcation narrowing. *Am J Cardiol* 2003;92:59-61.
351. Chekanov VS, Nikolaychik V, Maternowski MA, **Mehran R**, Leon MB, Adamian M, Moses J, Dangas G, Kipshidze N, Akhtar M. Deferoxamine enhances neovascularization and recovery of ischemic skeletal muscle in an experimental sheep model. *Ann Thorac Surg* 2003;75:184-189.
352. Bhargava B, Karthikeyan G, Abizaid AS, **Mehran R**. New approaches to preventing restenosis. *BMJ* 2003;327: 274-279.
353. Sadeghi HM, Stone GW, Grines CL, **Mehran R**, Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tchong JE, Griffin JJ, Stuckey TD, Turco M, Carroll JC. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. *Circulation* 2003;108:2769-2775.
354. Fujii K, Kobayashi Y, Mintz GS, Takebayashi H, Dangas G, Moussa I, **Mehran R**, Lansky AJ, Kreps E, Collins M, Colombo A, Stone GW, Leon MB, Moses JW. Intravascular ultrasound assessment of ulcerated ruptured plaques: a comparison of culprit and nonculprit lesions of patients with acute coronary syndromes and lesions in patients without acute coronary syndromes. *Circulation* 2003;108:2473-2478.
355. Tchong JE, Kandzari DE, Grines CL, Cox DA, Effron MB, Garcia E, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Fahy M, Lansky AJ, **Mehran R**, Stone GW; CADILLAC Investigators. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. *Circulation* 2003;108:1316-1323.
356. **Mehran R**, Aymong ED, Ashby DT, Fischell T, Whitworth H Jr, Siegel R, Thomas W, Wong SC, Narasimaiah R, Lansky AJ, Leon MB. Safety of an aspirin-alone regimen after intracoronary stenting with a heparin-coated stent: final results of the HOPE (HEPACOAT and an Antithrombotic Regimen of Aspirin Alone) study. *Circulation* 2003;108:1078-1083.
357. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Reikhter MD, Bahr R, Grundy SM, **Mehran R**, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Parts I and II. *Circulation* 2003;108:1664-1778.
358. Iakovou I, Mintz GS, Dangas G, Abizaid A, **Mehran R**, Kobayashi Y, Lansky AJ, Aymong ED, Nikolsky E, Stone GW, Moses JW, Leon MB. Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study. *J Am Coll Cardiol* 2003;42:1900-1905.
359. Costantini CO, Lansky AJ, Mintz GS, Shirai K, Dangas G, **Mehran R**, Fahy M, Slack S, Coral M, Teirstein PS, Waksman R, Stone G, Moses J, Leon MB. Intravascular brachytherapy for native coronary ostial in-stent restenotic lesions. *J Am Coll Cardiol* 2003;41:1725-1731.
360. Cox DA, Stone GW, Grines CL, Stuckey T, Cohen DJ, Tchong JE, Garcia E, Guagliumi G, Iwaoka RS, Fahy M, Turco M, Lansky AJ, Griffin JJ, **Mehran R**, CADILLAC Investigators. Outcomes of optimal or "stent-like" balloon angioplasty in acute myocardial infarction: the CADILLAC trial. *J Am Coll Cardiol* 2003;42:971-977.
361. Ashby DT, Dangas G, Aymong E, Iakovou I, Keupper F, **Mehran R**, Stone GW, Leon MB, Moses JW. Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. *J Am Coll Cardiol* 2003;41:749-752.
362. Iakovou I, Dangas G, **Mehran R**, Lansky AJ, Ashby DT, Fahy M, Mintz GS, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB. Impact of gender on the incidence and outcome of contrast-induced nephropathy after percutaneous coronary intervention. *J Invasive Cardiol* 2003;15:18-22.
363. Nikolsky E, **Mehran R**. Understanding the consequences of contrast-induced nephropathy. *Rev Cardiovasc Med* 2003;4(Suppl 5):S10-S18.
364. Nikolsky E, Aymong E, Dangas G, **Mehran R**. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. *Rev Cardiovasc Med* 2003;4(Suppl 1):S7-S14.
365. Ashby DT, Dangas G, **Mehran R**, Lansky AJ, Narasimaiah R, Iakovou I, Polena S, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Comparison of clinical outcomes using stents versus no stents after percutaneous coronary intervention for proximal left anterior descending versus proximal right and left circumflex arteries. *Am J Cardiol* 2002;89:1162-1166.
366. Iakovou I, Dangas G, **Mehran R**, Lansky AJ, Stamou SC, Pfister AJ, Dullum MK, Leon MB, Corso PJ. Minimally invasive direct coronary artery bypass (MIDCAB) versus coronary artery stenting for elective revascularization of the left anterior descending artery. *Am J Cardiol* 2002;90:885-887.

367. Dangas G, **Mehran R**, Feldman D, Stoyioglou A, Pichard AD, Kent KM, Satler LF, Fahy M, Lansky AJ, Stone GW, Leon MB. Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention. *Am J Cardiol* 2002;89:586-589.
368. Iakovou I, Dangas G, **Mehran R**, Lansky AJ, Kobayashi Y, Adamian M, Polena S, Collins MB, Roubin GS, Stone GW, Leon MB, Moses JW. Gender differences in clinical outcomes after stenting with glycoprotein GPIIb/IIIa inhibitors. *Am J Cardiol* 2002; 89:976-979.
369. Ashby DT, Dangas G, **Mehran R**, Lansky AJ, Fahy MP, Iakovou I, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Comparison of one-year outcomes after percutaneous coronary intervention among current smokers, ex-smokers, and nonsmokers. *Am J Cardiol* 2002;89:221-224.
370. Ajani AE, Waksman R, Zimarino M, Kim HS, Pichard AD, Satler LF, Kent KM, White RL, Pinnow E, **Mehran R**, Lansky A, Lindsay J. Device selection in the treatment of in-stent restenosis with and without radiation (from the Gamma Radiation Trials). *Am J Cardiol* 2002;89:137-144.
371. Gruberg L, Dangas G, **Mehran R**, Mintz GS, Kent KM, Pichard AD, Satler LF, Lansky AJ, Stone GW, Leon MB. Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure. *Cathet Cardiovasc Interv* 2002;55:66-72.
372. New G, Moses JW, Roubin GS, Leon MB, Colombo A, Iyer S, Tio FO, **Mehran R**, Kipshidze N. Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in porcine coronary model. *Catheter Cardiovasc Interv* 2002;57:266-271.
373. Ashby DT, Dangas G, **Mehran R**, Leon MB. Coronary artery stenting. *Catheter Cardiovasc Interv* 2002;56:83-102.
374. Lansky AJ, **Mehran R**, Dangas G, Desai K, Constantini-Oritz C, Cristea E, New G, Negoita M, Stone GW, Leon MB. New-device angioplasty in women: clinical outcome and predictors in a 7,372-patient registry. *Epidemiology* 2002;13(3 Suppl):S46-S51.
375. Kipshidze N, Iverson P, Keane E, Stein D, Chawla P, Skriniska V, Shankar LR, **Mehran R**, Chekanov V, Dangas G, Komorowski R, Haudenschild C, Khanna A, Leon MB, Keelan MH, Moses JW. Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced C-Myc antisense at six months follow-up in a rabbit balloon injury model. *Cardiovasc Radiat Med* 2002;3:26-30.
376. Dangas G, **Mehran R**, Fahy M, Leon MB, Stone GW. Reply Letter. *J Am Coll Cardiol* 2002;39:1706-1708.
377. Kipshidze NN, Kim HS, Iversen P, Yazdi HA, Bhargava B, New G, **Mehran R**, Tio F, Haudenschild C, Dangas G, Stone GW, Iyer S, Roubin GS, Leon MB, Moses JW. Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. *J Am Coll Cardiol* 2002;39:1686-1691.
378. Stone GW, Peterson MA, Lansky AJ, Dangas G, **Mehran R**, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. *J Am Coll Cardiol* 2002;39:591-597.
379. Lansky AJ, Dangas G, **Mehran R**, Desai K, Mintz GS, Wu H, Fahy M, Stone GW, Waksman R, Leon MB. Quantitative angiographic methods for appropriate endpoint analysis, edge-effect evaluation, and prediction of recurrent restenosis after coronary brachytherapy with gamma irradiation. *J Am Coll Cardiol* 2002;39:274-280.
380. Kobayashi Y, Moussa I, Dangas G, **Mehran R**, Desai K, Adamian M, Collins M, Kreps E, Stone GW, Leon MB, Moses JW. Acute angiographic and clinical results of the NIR w/SOX stent. *J Invasive Cardiol* 2002;14:14-18.
381. Ahmed JM, Mintz GS, Waksman R, **Mehran R**, Leiboff B, Pichard AD, Satler LF, Kent KM, Weissman NJ. Serial intravascular ultrasound assessment of the efficacy of intracoronary gamma-radiation therapy for preventing recurrence in very long, diffuse, in-stent restenosis lesions. *Circulation* 2001;104:856-859.
382. Stone GW, **Mehran R**, Dangas G, Lansky AJ, Kornowski R, Leon MB. Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention. A device-specific analysis of 7147 patients. *Circulation* 2001;104:642-647.
383. Dangas G, **Mehran R**, Kokolis S, Feldman D, Satler LF, Pichard A, Kent KM, Lansky AJ, Stone GW, Leon MB. Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. *J Am Coll Cardiol* 2001;38:638-641.
384. Hong MK, **Mehran R**, Dangas G, Mintz GS, Lansky AJ, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB. Have we made progress with percutaneous saphenous vein graft treatment? Comparison of 1990-94 and 1995-98 results. *J Am Coll Cardiol* 2001;38:150-154.
385. Kim HS, Waksman R, Cottin Y, Kollm M, Bhargava B, **Mehran R**, Chan RC, Mintz GS. Edge stenosis and geographical miss following intracoronary gamma radiation therapy for in-stent restenosis. *J Am Coll Cardiol* 2001;37:1026-1030.
386. Ahmed JM, Ajani AE, Dangas G, Lansky AJ, **Mehran R**, Hong MK, Mintz GS, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Influence of gender on early and on-year clinical outcomes after saphenous vein graft stenting. *Am J Cardiol* 2001;87:401-405.
387. Ahmed JM, Mintz GS, Waksman R, Lansky AJ, **Mehran R**, Wu H, Weissman NJ, Pichard AD, Satler LF, Kent KM, Leon MB. Serial intravascular ultrasound analysis of edge recurrence after intracoronary gamma radiation treatment of native artery in-stent restenosis lesions. *Am J Cardiol* 2001;87:1145-1149.



388. Dangas G, **Mehran R**, Abizaid AS, Curry BH, Lansky AJ, Kent KM, Pichard AD, Satler LF, Paliou M, Stone GW, Leon MB. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. *Am J Cardiol* 2001;87:470-472.
389. Gruberg L, **Mehran R**, Waksman R, Dangas G, Fuchs S, Wu H, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB. Creatine kinase-MB fraction elevation after percutaneous coronary intervention in patients with chronic renal failure. *Am J Cardiol* 2001;87:1356-1360.
390. Waksman R, Ajani AE, White RL, Pinnpw E, **Mehran R**, Bui AB, Deible R, Gruberg L, Mintz GS, Satler LF, Pichard AD, Kent KM, Lindsay J. Two-year follow-up after beta and gamma intracoronary radiation therapy for patients with the diffuse in-stent restenosis. *Am J Cardiol* 2001;88:425-428.
391. Castagna MT, Mintz GS, Leiboff BO, Ahmed JM, **Mehran R**, Satler LF, Kent KM, Pichard AD, Weissman NJ. The contribution of "mechanical" problems to in-stent restenosis: an intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. *Am Heart J* 2001;142:970-974.
392. **Mehran R**, Dangas G, Abizaid A, Lansky AJ, Mintz GS, Pichard AD, Satler LF, Kent KM, Waksman R, Stone GW, Leon MB. Treatment of focal in-stent restenosis with balloon angioplasty alone versus stenting: short- and long-term results. *Am Heart J* 2001;141:610-614.
393. Kim H, Cottin Y, Kollum M, Lansky AJ, Chan RC, **Mehran R**, Bhargava B, Waksman R. The edge stenosis after intracoronary radiation therapy: is it all a "geographical miss"? *Cardiovasc Radiat Med* 2001;2:59.
394. Limpijankit T, Honda Y, **Mehran R**, Waksman R, Lansky AJ, Mintz GS, Yock PG, Fitzgerald PJ. The effect of intracoronary gamma-radiation therapy for in-stent restenosis: an intravascular ultrasound study. *Cardiovasc Radiat Med* 2001;2:54.
395. Zimarino M, Waksman R, **Mehran R**, Lansky AJ, Pichard AD, Bhargava B, Satler LF, Kent KM, White LR, Chan RC. Device influence on outcome in the treatment of in-stent restenosis. A subanalysis from the WRIST study. *Cardiovasc Radiat Med* 2001;2:59-60.
396. Bhargava B, Mintz GS, **Mehran R**, Lansky AJ, Weissman NJ, Walsh C, Chan RC, Waksman R. Serial volumetric intravascular ultrasound analysis of the efficacy of beta irradiation versus gamma irradiation in preventing recurrent in-stent restenosis. *Cardiovasc Radiat Med* 2001;2:60.
397. Bhargava B, Waksman R, Lansky AJ, Kornowski R, **Mehran R**, Leon MB. Clinical outcomes of compromised side branch (stent jail) after coronary stenting with the NIR stent. *Catheter Cardiovasc Interv* 2001;54:295-300.
398. Giri S, Ito S, Lansky AJ, **Mehran R**, Margolis J, Gilmore P, Garratt KN, Cummins F, Moses J, Rentrop P, Osterle S, Power J, Kent KM, Satler LF, Pichard AD, Wu H, Greenberg A, Bucher TA, Kerker W, Abizaid AS, Saucedo J, Leon MB, Popma JJ. Clinical and angiographic outcome in the laser angioplasty for restenotic stents (LARS) multicenter registry. *Catheter Cardiovasc Interv* 2001;52:24-34.
399. Gruberg I, **Mehran R**, Dangas G, Mintz GS, Waksman R, Kent KM, Pichard AD, Satler LF, WU H, Leon MB. Acute renal failure requiring dialysis after percutaneous coronary interventions. *Catheter Cardiovasc Interv* 2001;52:409-416.
400. El-Omar MM, Dangas G, Iakovou I, **Mehran R**. Update on in-stent restenosis. *Curr Interv Cardiol Rep* 2001;3: 296-305.
401. Abizaid A, Pichard AD, Mintz GS, Abizaid AS, **Mehran R**, Sousa A, Sousa E, Leon MB. Intravascular-ultrasound-guided percutaneous transluminal coronary angioplasty/provisional stent implantation strategy: impact on long-term clinical follow-up. *Int J Cardiovasc Intervent* 2001;4:107-114.
402. Dangas G, Laird JR Jr, **Mehran R**, Satler LF, Lansky AJ, Mintz G, Monsien LH, Laureno R, Leon MB. Carotid artery stenting in patients with high-risk anatomy for carotid endarterectomy. *J Endovasc Ther* 2001;8:39-43.
403. Dangas G, Laird JR, **Mehran R**, Lansky AJ, Mintz GS, Leon MB. Intravascular ultrasound-guided renal artery stenting. *J Endovasc Ther* 2001;8:238-247.
404. Dangas G, Monsein LH, Laureno R, Peterson MA, Laird JR Jr, Satler LF, **Mehran R**, Leon MB. Transient contrast encephalopathy after carotid artery stenting. *J Endovasc Ther* 2001;8:111-113.
405. Kobayashi Y, **Mehran R**, Moussa I, Reyes A, Moses JW. Negative remodeling at the ostium of the left circumflex artery. *J Invasive Cardiol* 2001;13:805-807.
406. **Mehran R**, Ashby DT. Radiocontrast-induced acute renal failure: allocations and outcomes. *Rev Cardiovasc Med* 2001;2 (Suppl 1):S9-S13.
407. Stone GW, Peterson MA, Lansky AJ, Dangas G, **Mehran R**, Leon MB. Impact of normalized myocardial perfusion after successful angioplasty in acute myocardial infarction. *J Am Coll Cardiol* 2001;39:591-597.
408. Ahmed JM, Hong MK, **Mehran R**, Dangas G, Mintz GS, Pichard AD, Satler LF, Kent KM, Wu H, Stone GW, Leon MB. Influence of diabetes mellitus on early and late clinical outcomes in saphenous vein graft stenting. *J Am Coll Cardiol* 2000;36:1186-1193.
409. Ahmed JM, Hong MK, **Mehran R**, Mintz GS, Lansky AJ, Pichard AD, Satler LF, Kent KM, Wu H, Stone GW, Leon MB. Comparison of debulking followed by stenting versus stenting alone for saphenous vein graft aorto-ostial lesions: immediate and one-year clinical outcomes. *J Am Coll Cardiol* 2000;35:1560-1568.

410. Gruberg L, Mintz GS, **Mehran R**, Dangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB. The prognostic implications of further renal function deterioration within 48 hours of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. *J Am Coll Cardiol* 2000;36:1542-1548.
411. Gruberg L, Dangas G, **Mehran R**, Hong MK, Mintz GS, Lansky AJ, Pichard AD, Kent KM, Satler LF, Stone GW, Leon MB. Percutaneous revascularization of internal mammary artery grafts. *J Am Coll Cardiol* 2000;35:944-948.
412. Bhargava B, Kornowski R, **Mehran R**, Kent KM, Hong MK, Lansky AJ, Waksman R, Pichard AD, Satler LF, Leon MB. Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting. *J Am Coll Cardiol* 2000;35:389-397.
413. Gruberg L, **Mehran R**, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Effect of plaque debulking and stenting on short- and long-term outcomes after revascularization of chronic total occlusions. *J Am Coll Cardiol* 2000;35:151-156.
414. Saucedo JF, **Mehran R**, Dangas G, Hong MK, Lansky AJ, Kent KM, Satler LF, Pichard AD, Stone GW, Leon MB. Long-term clinical events following creatine kinase-myocardial band isoenzyme elevation after successful coronary stenting. *J Am Coll Cardiol* 2000;35:1134-1141.
415. Kornowski R, Bhargava B, Fuch S, Lansky AJ, Satler LF, Pichard AD, Hong MK, Kent KM, **Mehran R**, Stone GW, Leon MB. Procedural results and late clinical outcomes after percutaneous interventions using long ( $\geq 25$  mm) vs. short ( $< 20$  mm) stents. *J Am Coll Cardiol* 2000;35:612-618.
416. Waksman R, Bhargava B, Mintz GS, **Mehran R**, Lansky AJ, Satler LF, Pichard AD, Kent KM, Leon MB. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. *J Am Coll Cardiol* 2000;36:65-68.
417. **Mehran R**, Dangas G, Stamou SC, Pfister AJ, Dullum MKC, Leon MB, Corso PJ. One-year clinical outcome after minimally invasive direct coronary artery bypass. *Circulation* 2000; 102:2799-2802.
418. **Mehran R**, Dangas G, Mintz GS, Waksman R, Abizaid A, Satler LF, Pichard AD, Kent KM, Lansky AJ, Stone GW, Leon MB. Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. *Circulation* 2000;101:2484-2489.
419. Waksman R, Bhargava B, White L, Chan RC, **Mehran R**, Lansky AJ, Mintz GS, Satler LF, Pichard AD, Leon MB, Kent KK. Intracoronary radiation therapy inhibits recurrence of in-stent restenosis. *Circulation* 2000;101:1895-1898.
420. Lansky AJ, Roubin GS, O'Shaughnessy CD, Moore PB, Dean LS, Raizner AE, Safian RD, Zidar JP, Kerr JL, Popma JJ, **Mehran R**, Kuntz RE, Leon MB, for the GR-II® Randomized Clinical Trial Investigators. A randomized comparison of the GR-II® stent and the Palmaz-Schatz stent for elective treatment of coronary stenoses. *Circulation* 2000;102:1364-1368.
421. **Mehran R**, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions. Intravascular ultrasound study of 2,256 patients. *Circulation* 2000;101:604-610.
422. Abizaid AD, Mintz GS, Abizaid A, Saucedo JF, **Mehran R**, Pichard AD, Kent KM, Satler LF, Leon MB. Influence of patient age on acute and late clinical outcomes following Palmaz-Schatz coronary stent implantation. *Am J Cardiol* 2000; 85:338-343.
423. Ahmed JM, Hong MK, **Mehran R**, Pichard AD, Satler LF, Kent KM, Mintz GS, Wu H, Leon MB. Assessing a strategy of initial stand-alone extractional atherectomy followed by staged stent placement in degenerated saphenous vein graft lesions. *Am J Cardiol* 2000;86:923-926.
424. Bhargava B, Mintz GS, **Mehran R**, Lansky AJ, Weissman NJ, Walsh C, Chan RC, Waksman R. Serial volumetric intravascular ultrasound analysis of the efficacy of beta irradiation in preventing recurrent in-stent restenosis. *Am J Cardiol* 2000;85:651-653.
425. Dangas G, **Mehran R**, Lansky AJ, Waksman R, Satler LF, Pichard AD, Kent KM, Mintz GS, Stone GW, Leon MB. Acute and long-term results of treatment of diffuse in-stent restenosis in aortocoronary saphenous vein grafts. *Am J Cardiol* 2000;86:777-779.
426. Dangas G, Mintz GS, **Mehran R**, Ahmed JM, Lansky AJ, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Stent implantation neutralizes the impact of preintervention arterial remodeling on subsequent target lesion revascularization. *Am J Cardiol* 2000;86:452-455.
427. Fuchs S, Kornowski R, **Mehran R**, Lansky AJ, Satler LF, Pichard AD, Kent KM, Clark CE, Stone GW, Leon MB. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. *Am J Cardiol* 2000;85:1077-1082.
428. Gruberg L, Hong MK, Mintz GS, **Mehran R**, Waksman R, Dangas G, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB. Optimally deployed stents in the treatment of restenotic versus de novo lesions. *Am J Cardiol* 2000;85:333-337.
429. Hong MK, **Mehran R**, Dangas G, Mintz GS, Lansky A, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB. Comparison of time course of target lesion revascularization following successful saphenous vein graft angioplasty versus successful native coronary angioplasty. *Am J Cardiol* 2000;85:256-258.
430. Rasuli P, **Mehran R**, French G, Turek M, Lalonde KA, Cardinal P. Percutaneous retrieval of vena cava filter from the right atrium: case report. *Can Assoc Radiol J* 2000;51:30-35.
431. Cottin Y, Lansky AJ, Kim HS, Kollum M, Abrahimi A, **Mehran R**, Bhargava B, Chan RC, Waksman R. Intracoronary brachytherapy not associated with changes in major side branches. *Catheter Cardiovasc Interv* 2000;51:154-158.

432. Goldberg SL, Berger P, Cohen DJ, Shawl F, Buchbinder M, Fortuna R, O'Neill W, Leon MB, Braden GA, Teirstein PS, Reisman M, Bailey SR, Dauerman HL, Bowers T, **Mehran R**, Colombo A. Rotational atherectomy or balloon angioplasty in treatment of intra-stent restenosis: BARASTER multicenter registry. *Catheter Cardiovasc Interv* 2000;51:407-413.
433. Kornowski R, Fuchs S, Hong MK, **Mehran R**, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Prognostic value of recurrent episodes of creatine kinase-MB elevation following repeated catheter-based coronary interventions. *Catheter Cardiovasc Interv* 2000;51:131-137.
434. Fuchs S, Kornowski R, **Mehran R**, Gruberg L, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Clinical outcomes following rescue administration of abciximab in patients undergoing percutaneous coronary angioplasty. *J Invasive Cardiol* 2000;12:497-501.
435. Dangas G, Laird JR, Satler LF, **Mehran R**, Mintz GS, Larrain G, Lansky AJ, Gruberg L, Parsons EM, Laureno R, Monsein LH, Leon MB. Postprocedural hypotension after carotid artery stent placement: predictors and short- and long-term clinical outcomes. *Radiology* 2000;215:677-683.
436. Dangas G, Gruberg L, **Mehran R**, Leon MB. Carotid artery stenting 1999. *ACC Current Journal Review* 2000;9:34-36.
437. Abizaid AS, Mintz GS, **Mehran R**, Abizaid A, Lansky AJ, Pichard AD, Satler LF, Wu H, Pappas C, Kent KM, Leon MB. Long-term follow-up after percutaneous transluminal coronary angioplasty was not performed based on intravascular ultrasound findings: importance of lumen dimensions. *Circulation* 1999;100:256-261.
438. Dangas G, Mintz GS, **Mehran R**, Lansky AJ, Kornowski R, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Preintervention arterial remodeling as an independent predictor of target lesion revascularization after non-stent coronary intervention. An analysis of 777 lesions with intravascular ultrasound imaging. *Circulation* 1999;99:3149-3154.
439. Hong MK, **Mehran R**, Dangas G, Mintz GS, Lansky AJ, Pichard AD, Kent KM, Satler LF, Stone GW, Leon MB. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. *Circulation* 1999;100:2400-2405.
440. **Mehran R**, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. *Circulation* 1999;100:1872-1878.
441. Peterson MA, Monsein LH, Dangas G, **Mehran R**, Leon MB. Percutaneous transcatheter management of giant coronary aneurysms. *Circulation* 1999;100:E8-E11.
442. Gruberg L, Hong MK, **Mehran R**, Mintz GS, Kornowski R, Lansky AJ, Kent KM, Pichard AD, Satler LF, Dangas G, Wu H, Stone GW, Leon MB. In-hospital and long-term results of stenting compared with balloon angioplasty for treatment of narrowing at the saphenous vein graft distal anastomosis site. *Am J Cardiol* 1999;84:1381-1384.
443. Abizaid A, Pichard AD, Mintz GS, Abizaid AS, Klutstein MW, Satler LF, **Mehran R**, Leiboff B, Kent KM, Leon MB. Acute and long-term results of an intravascular ultrasound-guided percutaneous transluminal coronary angioplasty/provisional stent implantation strategy. *Am J Cardiol* 1999;84:1298-1303.
444. Hoffmann R, Mintz GS, **Mehran R**, Kent KM, Pichard AD, Satler LF, Leon MB. Tissue proliferation within and surrounding Palmaz-Schatz stents is dependent on the aggressiveness of stent implantation technique. *Am J Cardiol* 1999;83:1170-1174.
445. Hong MK, Peterson MA, **Mehran R**, Dangas G, Mintz GS, Kent KM, Pichard AD, Satler LF, Leon MB. Atheroablation prior to stents. *Curr Interv Cardiol Rep* 1999;2:179-186.
446. Abizaid AS, Mintz GS, Abizaid A, **Mehran R**, Lansky AJ, Pichard AD, Satler LF, Wu H, Kent KM, Leon MB. One-year follow-up after intravascular ultrasound assessment of moderate left main coronary artery disease in patients with ambiguous angiograms. *J Am Coll Cardiol* 1999;34:3,707-715.
447. Fuchs S, Kornowski R, **Mehran R**, Satler LF, Pichard AD, Kent KM, Hong MK, Slack S, Stone GW, Leon MB. Cardiac troponin I levels and clinical outcomes in patients with acute coronary syndromes: the potential role of early percutaneous revascularization. *J Am Coll Cardiol* 1999;34:1704-1710.
448. Kornowski R, **Mehran R**, Satler LF, Pichard AD, Kent KM, Greenberg A, Mintz GS, Hong MK, Leon MB. Procedural results and late clinical outcomes following multivessel coronary stenting. *J Am Coll Cardiol* 1999;33:420-426.
449. Lansky AJ, Popma JJ, Massullo V, Jani S, Russo RJ, Schatz RA, Steuterman S, Guarneri EM, Wu H, **Mehran R**, Mintz GS, Leon MB, Teirstein PS. Quantitative angiographic analysis of stent restenosis in the Scripps Coronary Radiation to Inhibit Intimal Proliferation Post Stenting (SCRIPPS) Trial. *Am J Cardiol* 1999;84:410-414.
450. Waksman R, Bhargava B, White RL, Chan RC, Gierlach LM, **Mehran R**, Lansky A, Kent KM, Mintz GS, Satler LF, Pichard AD, Leon MB. Intracoronary radiation for patients with refractory in-stent restenosis: an analysis from the WRIST-Crossover Trial. Washington Radiation for In-Stent Restenosis Trial. *Cardiovasc Radiat Med* 1999;1:317-322.
451. Laird JR, Dangas G, Jaff M, Satler LF, **Mehran R**, Leon MB. Intra-arterial reteplase for the treatment of acute limb ischemia. *J Invas Cardiol* 1999;11:757-762.
452. Kornowski R, Klutstein M, Satler L, Pichard A, Kent K, Abizaid A, Mintz G, Hong MK, Popma JJ, **Mehran R**, Leon MB. Impact of stents on clinical outcomes in percutaneous left main coronary artery revascularization. *Am J Cardiol* 1998;82:32-37.

453. Mintz GS, Hoffmann R, **Mehran R**, Pichard AD, Kent KM, Satler LF, Popma JJ, Leon MB. In-stent restenosis: The Washington Hospital Center Experience. *Am J Cardiol* 1998;81:7E-13E.
454. Dangas G, **Mehran R**, Duvvuri S, Vidhun R, Ambrose JA, Sharma SK. Directional atherectomy in acute myocardial infarction. *Cardiology* 1998;90:63-66.
455. Kornowski R, **Mehran R**, Hong MK, Satler LF, Pichard AD, Kent KM, Mintz GS, Waksman R, Laird JR, Lansky AJ, Bucher TA, Popma JJ, Leon MB. Procedural results and late clinical outcomes after placement of three or more stents in single coronary lesions. *Circulation* 1998;97:1355-1361.
456. Shiran A, Mintz G, Waksman R, **Mehran R**, Abizaid A, Kent K, Pichard A, Satler L, Popma JJ, Leon MB. Early lumen loss after treatment of in-stent restenosis. An intravascular ultrasound study. *Circulation* 1998;98:200-203.
457. Lansky AJ, Mintz GS, **Mehran R**, Popma JJ, Pichard AD, Kent KM, Satler LF, Leon MB. Insights into the mechanism of restenosis after PTCA and stenting. *Indian Heart J* 1998;50(Suppl 1):104-108.
458. Dangas G, **Mehran R**, Harpel PC, Sharma SK, Marcovina SM, Dube G, Ambrose JA, Fallon JT. Lipoprotein(a) and inflammation in human coronary atheroma; association with the severity of clinical presentation. *J Am Coll Cardiol* 1998;32:2035-2042.
459. Hoffman R, Mintz GS, **Mehran R**, Pichard AD, Kent KM, Satler LF, Popma JJ, Hongshen W, Leon MB. Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. *J Am Coll Cardiol* 1998;31:43-49.
460. **Mehran R**, Mintz G, Hong MK, Tio F, Bramwell O, Brahim A, Kent K, Pichard A, Satler L, Popma JJ, Leon MB. Validation of the in vivo intravascular ultrasound measurement of in-stent neointimal hyperplasia volumes. *J Am Coll Cardiol* 1998;32:794-799.
461. Abizaid A, Kornowski R, Mintz G, Hong MK, Abizaid A, **Mehran R**, Pichard A, Kent K, Satler L, Wu H, Popma JJ, Leon MB. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. *J Am Coll Cardiol* 1998;32:584-589.
462. Mintz GS, **Mehran R**, Waksman R, Pichard AD, Kent KM, Satler LF, Leon MB. Treatment of in-stent restenosis. *Semin Intervent Cardiol* 1998;3:117-121.
463. Hong MK, Kent KM, **Mehran R**, Mintz GS, Tio FO, Foegh M, Wong SC, Cathapermal SS, Leon MB. Continuous subcutaneous angiopeptin treatment significantly reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model. *Circulation* 1997;95:449-454.
464. **Mehran R**, Mintz GS, Bucher TA, Pichard AD, Satler LF, Kent KM, Popma JJ, Leon MB. Treatment of in-stent restenosis with excimer laser angioplasty: mechanisms and results compared with PTCA alone. *Circulation* 1997;96:2183-2189.
465. Abizaid A, Mintz GS, Abizaid AS, Satler LF, Popma JJ, Pichard AD, **Mehran R**, Kent KM, Leon MB. Clinical application of intracoronary ultrasound. *Arq Bras Cardiol* 1997;69:263-265.
466. Sharma SK, Dangas G, **Mehran R**, Duvvuri S, Kini A, Marmur JD, Kakarala V, Cohen AM, Ambrose JA. Risk factors for the development of slow flow during rotational coronary atherectomy. *Am J Cardiol* 1997;80:219-222.
467. Hong MK, **Mehran R**, Mintz GS, Leon MB. Restenosis after coronary angioplasty. *Curr Probl Cardiol* 1997;22:1-36.
468. Dangas G, **Mehran R**, Wallenstein S, Courcoutsakis NA, Kakarala V, Hollywood J, Ambrose JA. Correlation of angiographic morphology and clinical presentation in unstable angina. *J Am Coll Cardiol* 1997;29:519-525.
469. **Mehran R**, Mintz GS, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB. Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. *Am J Cardiol* 1996;78:618-22.
470. Dangas G, **Mehran R**, Duvvuri S, Cocke TP, Ambrose JA, Sharma SK. Use of a pneumatic compression system as a treatment option for femoral artery pseudoaneurysms after percutaneous cardiac procedures. *Catheter Cardiovasc Diagnosis* 1996;39:138-142.
471. Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, **Mehran R**, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. *Circulation* 1996;94:3090-3097.
472. **Mehran R**, Ambrose JA, Bongu RM, Almeida OA, Israel DH, Torres S, Sharma SK, Ratner DE. Angioplasty of complex lesions in ischemic rest angina: results of the TAUSA trial. *J Am Coll Cardiol* 1995;26:864-869.

### **BOOK CHAPTERS**

1. Vranckx P, Cutlip D, **Mehran R**, Leon M, Serruys P. Consensus on definitions of clinical endpoints: percutaneous coronary and valvular intervention trials. In: *Percutaneous Interventional Cardiovascular Medicine The Pcr-Eapci Textbook*. In Press.
2. Nikolsky E, **Mehran R**. Bleeding complications in patients undergoing percutaneous coronary intervention: prognostic implications and prevention. In: *Mechanical Reperfusion for STEMI: From Randomized Trials to Clinical Practice*. DeLuca G, Lansky A (eds), Informa Healthcare USA (New York), 2010.
3. **Mehran R**, Nikolsky E. Postprocedural complications II: contrast-induced renal insufficiency. In: *Textbook of Coronary Stents*. Stone GW, Leon MB (eds). WB Saunders Co (Boston), 2010.

4. Kobayashi Y, **Mehran R**. Stenting in the elderly. In: *Textbook of Coronary Stenting*. Stone GW, Leon MB (eds). WB Saunders Co (Boston), 2010.
5. **Mehran R**, Nikolsky E. Classification of in-stent restenosis. In: *Textbook of Coronary Stenting*. Stone GW, Leon MB (eds). WB Saunders Co (Boston), 2010.
6. Turcot D, **Mehran R**, Moussa I, Dangas G. Treatment of in-stent restenosis with PTCA, laser, atherectomy, and repeat stenting. In: *Textbook of Coronary Stenting*. Stone GW, Leon MB (eds). WB Saunders Co (Boston), 2010.
7. Turcot D, Aymong E, **Mehran R**, Dangas G, Leon M. Heparin-coated stents III: Evidence of thromboresistance from registry studies. In: *Textbook of Coronary Stenting*. Stone GW, Leon MB (eds). WB Saunders Co (Boston), 2010.
8. Nikolsky E, **Mehran R**. Approach to patients with impaired renal function. In: *Problem-Oriented Approaches in Interventional Cardiology*. Colombo A, Stankovic G (eds), Informa Healthcare. (London), 2007
9. Kimura M, Nikolsky E, Balter S, **Mehran R**. Complications related to radiation and contrast media exposure. In: *Handbook of Chronic Total Occlusions*. Dangas G, Mehran R, Moses J (eds), Informa Healthcare. (London), 2007.
10. Nikolsky E, Abizaid A, **Mehran R**. The kidney and percutaneous coronary interventions. In: *Common Clinical Dilemmas in Percutaneous Coronary Interventions*. Martinez E, Lemos P, Ong A, Serruys P (eds), Informa Healthcare. (London), 2007.
11. Nikolsky E, Lasic Z, **Mehran R**. Coronary artery perforation. In: *Strategic Approaches in Coronary Intervention*. Ellis SG, Holmes DR Jr (eds). 2005.
12. Dangas G, Leon MB, **Mehran R**. Appendix 2A-2: Intracardiac devices and catheters: coronary stents in common use. In: *Cardiovascular Therapeutics; A Companion to Braunwald's Heart Disease* (2<sup>nd</sup> edition). Antman E (ed). WB Saunders Co (Boston), 2002.
13. **Mehran R**, Gorlin R. Management of patients with stable coronary disease. In: *Heart Disease Management, A Pharmacological Approach*. Coopersmith J, Deedwania P (eds), Baltimore, MD, Williams & Wilkins, 1995.
14. **Mehran R**, Hong MK, Mintz GS, Popma JJ, Satler LF, Pichard AD, Kent KM, Leon, MB. Coronary heart disease. In: *Principles and Practice of Interventional Cardiology*. Apple, Lindsay J (eds); Phila., PA, Lippincott-Raven Publishers, 1997.
15. **Mehran R**, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, Leon MB. Clinical application of intravascular ultrasound imaging in a center with high-volume preintervention ultrasound imaging. In: *Intravascular Ultrasound Imaging in Coronary Artery Disease*. Siegel RJ (ed), Marcel Dekker; NY, 1997.
16. **Mehran R**, Leon MB. Treatment of multi-vessel coronary artery disease. In: *Contemporary Concepts in Cardiology*, Kluwer Academic Publishers, Gorlin R, Dangas G, Toutouzas PK (eds), Boston, 1999.
17. Dangas G, **Mehran R**. Restenosis. In: *Contemporary Concepts in Cardiology*. Gorlin R, Dangas G, Toutouzas PK (eds): Kluwer Academic Publishers, Boston, 1999.
18. Dangas G, **Mehran R**, Colombo A. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary revascularization procedures. In: Marco J, Fajadet J (eds): *Tenth Endovascular Therapy Course Book*, Europa Organization (Paris), 1999.
19. Dangas G, Laird J, Satler LF, **Mehran R**, Mintz GS, Larrain G, Gruberg L, Abizaid A, Lansky AJ, Parsons EM, Laureno RB, Monsein LH, Leon MB. Percutaneous endovascular carotid stent supported angioplasty: the Washington Hospital Center experience. In: Henry M, Amor M (eds): *Tenth International Course Book of Peripheral Vascular Intervention*, Europa Organization (Paris), 1999.
20. **Mehran R**, Peterson MA, Leon MB. The coronary NIR stent. In: *Strategic Approaches in Coronary Intervention*. Ellis SG, Holmes DR Jr (eds): Lippincott Williams & Wilkins Publishers, New York, 2000.

## ABSTRACTS

1. Claessen BE, Godino C, Obunai K, Kanwal S, Carlino M, Kim YH, DiMario C, Henriques JP, Park SJ, Stone GW, Leon MB, Dangas GD, Colombo A, **Mehran R**. Long-Term Clinical Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions in Insulin and Non-Insulin Dependent Diabetes Mellitus: Five-Year Outcomes from a 1,791 Patient Multi-National Registry." *Journal of the American College of Cardiology*. 2011 November; 58(20, Supplement): B2.
2. Kanwal S, Weisz G, Balter S, Hassanin A, Singh VP, Barkama R, Privitera L, Collins MB, **Mehran R**, Stone GW, Leon MB, Moses JW,. Increased Radiation Exposure in Percutaneous Coronary Interventions for Chronic Total Occlusions. *Journal of the American College of Cardiology*. 2011 November; 58(20, Supplement): B2.
3. Tobbia P, Brodie B, Stuckey T, Witzendichler B, Metzger C, Guagliumi G, Kellett M, Fahy M, **Mehran R**, Stone GW. Are Adverse Events Following Primary PCI for STEMI More Frequent at US Sites than Sites Outside the US (OUS)? Three-Year Analysis from the HORIZONS-AMI Trial. *Journal of the American College of Cardiology*. 2011 November; 58(20, Supplement): B2.
4. McEntegart MB, Kirtane AJ, Cristea E, Brener S, **Mehran R**, Fahy M, Moses JW, Stone GW. Intra-Procedural Thrombotic Events During Percutaneous Coronary Intervention in Patients with Non ST. *Journal of the American College of Cardiology*. 2011 November; 58(20, Supplement): B2.
5. Elevation Acute Coronary Syndromes are Associated with Adverse Outcomes: Analysis From the ACUITY Trial

6. Palmerini T, Genereux P, Caixeta A, Cristea E, Lansky A, **Mehran R**, Dangas G, Fahy M, Xu K, Stone GW. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY trial. *European Heart Journal*. 2011 August;Vol.32(Abtract Supplement):1046.
7. Claessen BEPM, Dangas GD, **Mehran R**, Witzenbichler B, Gaugliumi G, Peruga J, Xu K, Stone GW. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital; results of the HORIZONS-AMI trial. *European Heart Journal*. August 2011;Vol.32(Abtract Supplement):655.
8. Dangas G, **Mehran R**, Feit F, Cox D, Brodie BR, Witzenbichler B, Deliargyris E, Gersh B, Stone GW. Impact of bivalirudin therapy on mortality in patients with high risk features undergoing PCI: a patient-level pooled analysis from the REPLACE-2, ACUITY and HORIZONS-AMI trials. *European Heart Journal*. 2011 August; Vol.32(Abtract Supplement):232.
9. Baber U, Bander J, Muntner P, Kovacic J, Karajgikar R, Badimon J, Dangas G, Kini A, **Mehran R**, Sharma S. Impact of hemoglobin on residual platelet reactivity in patients undergoing percutaneous coronary intervention. *European Heart Journal*. 2011 August;Vol.32(Abtract Supplement):171.
10. Baber U, Weinberg M, Kovacic J, Bander J, Dangas G, Kini A, Sweeny J, **Mehran R**, Sharma S. Impact of the everolimus eluting stent on stent thrombosis: a meta-analysis. *European Heart Journal*. 2011 August;Vol.32(Abtract Supplement):409.
11. Claessen BEPM, Weisz G, Dangas GD, Colombo A, Park SJ, Moses JW, Dimario C, Stone GW, Witzenbichler B, **Mehran R**. Impact of TIMI 0/1 flow in non-infarct related arteries in patients with ST-elevation myocardial infarction on myocardial blush and long-term mortality: three-year results from the HORIZONS-AMI trial. *European Heart Journal*. 2011 August;Vol.32(Abtract Supplement):413.
12. Claessen BEPM, Suh JW, Dangas GD, Obunai K, Godino C, Kim JH, Dimario C, Colombo A, Park SJ, **Mehran R**. Long-term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients: five-year outcomes from a 1,791 patient multi-national registry. *European Heart Journal*. 2011 August;Vol.32(Abtract Supplement):744.
13. Fiocca L, Rossini R, Parise H, Musumeci G, Vassileva A, Lortkipanidze N, Valsecchi O, **Mehran R**, Stone GW, Guagliumi G. Long-term outcomes of patients with acute myocardial infarction undergoing primary PCI excluded from the HORIZONS-AMI trial: results from a high volume recruiting center. *European Heart Journal*. 2011 August;Vol.32(Abtract Supplement):871.
14. Brener SJ, **Mehran R**, Brodie BR, Guagliumi G, Witzenbichler B, Cristea E, Xu K, Lanski AJ, Stone GW. Predictors and implications of infarct artery patency at initial angiography in patients with acute myocardial infarction: lessons from the CADILLAC and HORIZONS-AMI trials. *European Heart Journal*. 2011 August;Vol.32 (Abtract Supplement):233.
15. Narula A, Stone GW, Weisz G, Dangas G, Witzenbichler B, Guagliumi G, Dudek D, Kornowski R, Parise H, **Mehran R**. Does the choice of contrast media impact outcomes after primary PCI? Results from HORIZONS-AMI. *European Heart Journal*. 2011 August;Vol.32 (Abtract Supplement):243.
16. Narula A, Stone GW, Dangas GD, Witzenbichler B, Guagliumi G, Kornowski R, Dudek D, Nikolsky E, Fahy M, **Mehran R**. Impact of contrast nephropathy on long term outcomes after acute MI: three year results from HORIZONS-AMI study. *European Heart Journal*. 2011 August;Vol.32 (Abtract Supplement):234.
17. Narula A, Stone GW, Dangas GD, Weisz G, Witzenbichler B, Kornowski R, Nikolsky E, Parise H, Fahy M, **Mehran R**. Application of a prior contrast induced acute kidney injury score to patients with STEMI undergoing primary PCI: the HORIZONS-AMI trial. *European Heart Journal*. 2011 August;Vol.32(Abtract Supplement):240.
18. **Mehran R**, Claessen B, Godino C, Obunai K, Dangas G, Carlino M, Kim Y, DiMario C, Park S, Stone G, Colombo A, Moses J, Leon M. Long-Term Clinical Safety and Efficacy of Drug-Eluting Stents for the Treatment of Chronic Total Occlusions: Report from a Multi-National 763 Patient Registry. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-28.
19. Claessen B, **Mehran R**, Godino C, Obunai K, Dangas G, Carlino M, Kim Y, DiMario C, Park S, Stone G, Colombo A, Leon M, Moses J, On Behalf of The Multinational CTO Registry. Long-Term Clinical Outcomes after Percutaneous Coronary Intervention with Drug-eluting Stents versus Bare Metal Stents for Chronic Total Occlusions: Two-Year Outcomes from a 1,781 Patient Multi-National Registry. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-29.
20. Claessen B, **Mehran R**, Obunai K, Godino C, Dangas G, Carlino M, Kim Y, DiMario C, Park S, Stone G, Colombo A, Leon M, Moses J, On Behalf of The Multinational CTO Registry. Impact of Target Vessel on Long-Term Survival after Percutaneous Coronary Intervention for Chronic Total Occlusions: Two-Year Outcomes from a 1,781 Patient Multi-National Registry. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-32.
21. Claessen B, Mintz G, **Mehran R**, Maehara A, Weisz G, Sanidas E, Syros G, Franklin-Bond T, Apostolidou I, Henriques J, Stone G, Moses J, Leon M, Dangas G. Intravascular Ultrasound-Guided Drug-Eluting Stent Placement is Associated with Reduced Incidence of Recurrent Clinical Events (Death or MI). *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-41.

22. Singh S, **Mehran R**, Stone G, Dangas G. Two-Year Clinical Follow-up Comparing Eptifibatid and Abciximab in Patients Undergoing Primary Percutaneous Revascularization for ST-Elevation Myocardial Infarction Results from the HORIZONS-AMI Trial. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-83.
23. Cubeddu R, Blankenship J, Dangas G, Lansky A, Palacios I, Witzendichler B, Guagliumi G, Kornowski R, Dudek D, Stone G, **Mehran R**. STEMI Presentation During Off-Hours Does Not Compromise Response Times or Mortality: A HORIZONS-AMI Substudy. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-87.
24. Genereux P, Palmerini T, Caixeta A, Cristea E, **Mehran R**, Sanchez R, Lazar D, Jankovic I, Corral M, Dressler O, Fahy M, Lansky A, Stone G. SYNTAX Score Reproducibility and Agreement Between Interventional Cardiologists and Core Laboratory Technician Measurements. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-157.
25. Brar S, Hiremath S, **Mehran R**, Patel K, Shah A, Kangavari S, Aharonian V, Der D, Beckham G. A 2010 Updated Meta-Analysis for the Prevention of Contrast Induced Nephropathy with Sodium Bicarbonate: the Importance of the Small Study Effect. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-328.
26. Stone G, Parise H, Witzendichler B, Kirtane A, Guagliumi G, Peruga J, Brodie B, Dudek D, Mockel M, Lansky A, **Mehran R**. Selection Criteria for Drug-Eluting Versus Bare Metal Stents: The HORIZONS-AMI Trial. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-427.
27. Nikolsky E, **Mehran R**, D. Metzger C, Wöhrle J, Huber K, Suryapranata H, Guetta V, Witkowski A, Ruzyllo W, Reyes S, Stone G. Outcomes of Patients with ST-Segment Elevation Myocardial Infarction and Prior Coronary Artery Bypass Grafting: The HORIZONS-AMI Trial. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-429.
28. Dudek D, Rakowski T, Dziewierz A, Witzendichler B, Guagliumi G, Kornowski R, Hartmann F, Lansky A, **Mehran R**, Stone G. Impact of Infarct-related Artery Patency Before Primary PCI on Outcome in Patients with Acute Myocardial Infarction. The HORIZONS-AMI Trial. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-432.
29. Huber K, **Mehran R**, Stone G, Lansky A, Guagliumi G, Brodie B, Jarai R, Kornowski R, Dangas G. Impact of Baseline BNP Level On Early and Late Clinical Outcomes After Acute MI; 2-year Results of the HORIZONS-AMI Study. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-433.
30. Caixeta A, **Mehran R**, Dangas G, Witzendichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Claessen B, Leon S, Lansky A, Stone G. Clinical Outcomes in Patients with Right Coronary vs. Left Circumflex Artery Myocardial Infarction Treated With Primary PCI: Results of the HORIZONS-AMI Trial. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-435.
31. Kelly D, Gershlick T, Witzendichler B, Guagliumi G, **Mehran R**, Stone G. Incidence, Severity and Predictors of Congestive Heart Failure Following Primary PCI: The HORIZONS-AMI trial. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-436.
32. Dudek D, Dziewierz A, Rakowski T, Brzezinski M, Witzendichler B, Guagliumi G, Peruga J, Brodie B, **Mehran R**, Lansky A, Stone G. Impact of Bifurcation Target Lesion on Angiographic, Electrocardiographic and Clinical Outcomes of Patients Undergoing Primary PCI: A HORIZONS-AMI Substudy. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-439.
33. Palmerini T, **Mehran R**, Dangas G, Witzendichler B, Guagliumi G, Dudek D, Genereux P, Caixeta A, Rabbani L, Weisz G, Parise H, Brodie B, Lansky A, Stone G. Impact of White Blood Cell Counts on Mortality and Major Bleeding in Patients with STEMI Undergoing Primary PCI: 1 -year Results from HORIZONS-AMI. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-451.
34. Huber K, **Mehran R**, Stone G, Guagliumi G, Brodie B, Dudek D, Witzendichler B, Jarai R, Lansky A, Dangas G. Impact of Baseline hs-CRP level on Early and Late Stent Thrombosis After Acute MI; 2-year Results of the HORIZONS-AMI Study. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-456.
35. El Hakim D, Dangas, G, Caixeta A, Nikolsky E, Lansky A, Moses J, Palmerini T, Fahy M, White H, Ohman E, Manoukian S, **Mehran R**, Stone G. Impact of Baseline Thrombocytopenia on the Early and Late Outcomes After ST-Elevation Myocardial Infarction Treated With Primary Angioplasty: Analysis from the HORIZONS AMI Trial. *Journal of the American College of Cardiology*. 2010 September; 56(13, Supplement): TCT-461.
36. Lansky AJ, **Mehran R**, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW. *Am J Cardiol*. 2009 May 1;103(9):1196-203.PMID: 19406258 [PubMed - indexed for MEDLINE Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial)
37. Solinas E, Gobbi G, Dangas G. **Mehran R**, Fahy M, Ippolito L, Bolognesi MG, Ruenes R. Merlini PA, Ardissino D, Vitale M. Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes. *J Thromb Thrombolysis* 2007 Nov 30

38. Nikolsky E, **Mehran R**, Grines CL, Griffin JJ, Negoita M, Turco M, Lansky AJ, Mercado DJ, Cox DA, Stuckey T, Guagliumi G, Na Y, Stone GW, Moussa I. Blood Transfusion in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Analysis from the CADILLAC Trial. *J Am Coll Cardio* 2006;47(Supplement A)4
39. Stone GW, Popma JJ, Cox DA, Hermiller J, Cannon L, Mann JT, **Mehran R**, Koglin J, Ellis SG, Russell ME. Do the Traditional Risk Factors of Vessel Size, Lesion Length and Diabetes Mellitus Predict Restenosis With TAXUS Stents? Insights from a TAXUS Meta-Analysis. *J Am Coll Cardio* 2006;47(Supplement A)4
40. Kakadiaris I, O'Malley S, Hartley C, Metcalfe R, Carlier S, **Mehran R**, Naghavi M, Vavuranakis M. Intravascular Ultrasound-Based Imaging of Vasa Vasorum for the Detection of Vulnerable Atherosclerotic Plaque. *J Am Coll Cardio* 2006;47(Supplement A)4
41. Stone GW, Webb J, Qureshi M, Rutherford BD, Antoniucci D, Krucoff MW, Jones D, **Mehran R**, Dangas G, Lansky AJ, Cox DA, Kalynych A, Turco M, Lee EA, Nikolsky E, Brodie BR, Schultheiss HP, Dulas D, Gibbons RJ. Microvascular Flow and Myocardial Perfusion After Acute MI Angioplasty in Anterior Versus Non-Anterior Infarcts: Results From the EMERALD Trial. *J Am Coll Cardio* 2006;47(Supplement A)4
42. Kodali S, Liuzzo J, **Mehran R**, Dangas G, Moussa I, Weisz G, Sulaiman R, Negoita M, Moses JW, Stone GW, Leon MB, Krebs E, Lansky AJ, Collins M, Nikolsky E. Overlapping Sirolimus-Eluting Stents: Analysis From the Matrix Registry. *J Am Coll Cardio* 2006;47(Supplement A)4
43. Agahtehrani A, Nikolsky E, Weisz G, Kodali S, **Mehran R**, Rabbani L, Addo T, Na Y, Dangas G, Goyal N, Moses JW, Stone GW, Lansky AJ, Sherman W, Leon MB. Predictors of Target Lesion Revascularization and Target Vessel Revascularization After Implantation of Sirolimus- Eluting Stent: Pooled Analysis From 6 Randomized Trials and Registries. *J Am Coll Cardio* 2006;47(Supplement A)4
44. Leon MB, Nikolsky E, Moses JW, Pocock S, Stone GW, Fahy M, **Mehran R**, Lansky AJ, Popma JJ. Relationship between Late Loss, Diameter Stenosis and Target Lesion Revascularization After Stent Implantation: An Examination of Surrogate Endpoints From a Pooled Analysis of Eight Large Randomized DES Trials. *J Am Coll Cardio* 2006;47(Supplement A)4
45. **Mehran R**, Leon MB, Moses JW, Stone GW, Nikolsky E, Yingbo Na, Lincroft AM, Dangas G, Lansky AJ. Risk Score for Prediction of Major Bleeding After Percutaneous Coronary Intervention. *J Am Coll Cardio* 2006;47(Supplement A)4
46. Moses JW, Cohen SA, **Mehran R**, Cambier P, Bachinsky B, Leya F, Kuntz R, Popma JJ, Leon MB, On behalf of the Sirolimus-Eluting BX Velocity™ Stent Investigators.
47. Jensen LO, Mintz GS, Carlier SG, Fujii K, Moussa I, Dangas G, **Mehran R**, Stone GW, Leon MB, Moses JW. Intravascular Ultrasound Analysis of the Residual Fibrous Cap after Vulnerable Plaque Rupture. *Am J Cardiol.* 2005;96(suppl 7A):200H.
48. Fujii K, Carlier SG, Mintz GS, Costa JR, Kimura M, Sano K, Quin J, Lui J, Moussa I, Dangas G, **Mehran R**, Collins M, Kreps EM, Stone GW, Moses JW, Leon MB. A Pre-Rupture Intravascular Ultrasound Profile of Vulnerable Plaques. *Am J Cardiol.* 2005;96(suppl 7A):199H
49. Costa JR, Leon MB, Mintz GS, **Mehran R**, Teirstein P, Waksman R, Mauri L, Turco M, Lee D, Fujii K, Costa R, Sano K, Kimura M, Qian J, Tanaka K, Lui J, Na Y, Dangas G, Weinberger J, Moussa I, Kreps EM, Stone GW, Moses JW, Carlier SG. Results from the Intravascular Ultrasound Sub-Study from the AngioSculpt® Scoring BalloonCatheterMulticenter Clinical Trial. *Am J Cardiol.* 2005; 96(suppl 7A):195H.
50. Moses JW, Nikolsky E, Cambier P, Bachinsky B, O'Shaughnessy C, **Mehran R**, Leya F, Kuntz R, Cohen SA, Tierstein P, Wong SC, Leon MB. Impact of lesion length on angiographic outcomes in patients with small coronary arteries treated with the 2.25 Sirolimus-Eluting BX Velocity™ Stent. *Am J Cardiol.* 2005;96(suppl 7A):187H.
51. Moses JW, Nikolsky E, Mintz GS, Dangas G, Grube E, Lansky AJ, Weisz G, Addo T, Na Y, Stone GW, Leon MB, **Mehran R**. Drug Eluting Stents May Challenge the Treatment paradigm of patients with intermediate coronary lesions. *Am J Cardiol.* 2005;96(suppl 7A):183H.
52. Nikolsky E, Moses JW, Cambier P, Bachinsky B, O'Shaughnessy C, **Mehran R**, Leya F, Kuntz R, Cohen SA, Tierstein P, Wong SC, Leon MB, On Behalf of the SIRIUS 2.25 mm investigators. Results from the 2.25 mm Sirolimus Eluting BX Velocity™ Stent Registry in patients with Native Coronary Artery Lesions. *Am J Cardiol.* 2005;96(suppl 7A):179H
53. Qin JZ, LaMonica D, Cresenzo K, Mintz GS, Conway T, Fujii K, Qian J, Boland PJ, Kral MA, **Mehran R**, Moses JW, Leon MB. Safety and Efficacy of Repeat Drug Eluting Stent Implantation in Patients with Drug Eluting Stent Failure. *Am J Cardiol.* 2005;96(suppl 7A):173H.
54. Kimura M, Carlier SG, Mintz GS, Lui J, Costa JR, Sano K, Takebayashi H, Yasuda T, Fujii K, **Mehran R**, Dangas G, Stone GW, Moses JW, Leon MB. Serial Intravascular Ultrasound Analysis of Vascular Remodeling at Sites of Incomplete Stent Apposition after Sirolimus-Eluting Stent Implantation. *Am J Cardiol.* 2005 ;96(suppl 7A):171H.
55. Nikolsky E, Lincroft MA, **Mehran R**, Bittl JA, Harrington RA, Gurm H, Micsa L, Kesanakurthy V, Na Y, Addo T, Kodali S, Mercado DJ, Turcanu G, Stone GW. Lower Body Mass Index is a risk factor for hemorrhagic complications following Percutaneous coronary interventions: Analysis from the REPLACE-2 trial. *Am J Cardio.* 2005;96(suppl 7A):153H.



56. Carlier SG, Weissman NJ, Mintz G, Koglin J, Turco M, Greenberg J, Mann JT, Kutcher M, Caputo R, **Mehran R**, Russel ME, Ellis SG, Stone GW. Paclitaxel-Eluting Stents Reduce Neointimal Hyperplasia in Both Diabetic and Non-Diabetic Coronary Arteries: A volumetric Intravascular Ultrasound TAXUS-IV Study. *Am J Cardiol.* 2005;96(suppl 7A):138H.
57. Nikolsky E, Moses JW, Schampaert E, Morice MC, Schofer J, Sousa JE, **Mehran R**, Fahy M, Leon MB. Sirolimus-Eluting Stents in the treatment of intermediate lesions: pooled analysis from six randomized trials and registries. *Am J Cardiol.* 2005;96(suppl 7B):133J.
58. Nikolsky E, Stone GW, **Mehran R**, Mori K, Weinberger J, Dangas G, Bittl JA, Harrington RA, Kleiman NS, Feit F, Na Y, Addo T, Negoita M, Cohen Y, Lincoff AM. Impact of age and choice of procedural antithrombotic regimen on ischemic and hemorrhagic outcomes following Percutaneous coronary intervention: Analysis from the REPLACE-2 Trial. *Am J Cardiol.* 2005;96(suppl 7A):126H.
59. Mori K, Lansky AJ, Costa RA, Mintz GS, Nikolsky E, **Mehran R**, Dangas G, Fahy M, Bittl JA, Harrington RA, Kleiman NS, Feit F, Lincoff AM, Stone GW. Do Women undergoing elective Percutaneous intervention (PCI) have similar late outcomes compared to men at all age groups? A REPLACE-2 study. *Am J Cardiol.* 2005; 96(suppl 7A):113H
60. Costa RA, Carlier SG, Mintz GS, Fujii K, Costa JR, Kimura M, Sano K, Tanaka K, Cristea E, Na Y, Lansky AJ, Dangas GD, **Mehran R**, Collins M, Kreps EM, Stone GW. Incidence and implications of incomplete “crush” stent apposition after Sirolimus-eluting treatment of coronary bifurcation lesions – an intravascular ultrasound (IVUS) Analysis. *Am J Cardiol.* 2005;96(suppl 7A):81H
61. Costa RA, Abizaid A, Muller R, Lansky AJ, **Mehran R**, Mori K, Cristea E, Patel B, Pop R, Corral M, Trauthen B, Verheye S, Neumann FJ, Feres F, McLean D, Grube E. Bifurcation Coronary Lesions Treated with a Novel Biolimus A9-Eluting, Self Expanding, Bifurcating Stent – Angiographic Results from the Prospective, Non-Randomized, Multicenter AXCESS Plus trial. *Am J Cardiol.* 2005;96(suppl 7A): 79H.
62. Sorajja P, Stone GW, Miller TD, Dangas G, Dixon S, Gersh BJ, O’Neill W, **Mehran R**, Gibbons RJ. Rescue Percutaneous Coronary Angioplasty is an independent predictor of infarct size in patients with acute myocardial infarction. *Am J Cardiol.* 2005;96(suppl 7A): 66H
63. Addo TA, Kodali S, Weinberger J, **Mehran R**, Fahy M, Pop R, Dixon S, O’Neill W, Grines C, Gibbons R, Leon MB, Stone G. Multivessel disease does not affect infarct size but affects clinical outcomes following primary angioplasty for acute myocardial infarction. *Am J Cardiol.* 2005;96(suppl 7A):65H
64. Brodie BR, Webb J, Cox DA, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford B, Antonicci D, Stuckey T, Krucoff M, Gibbons R, Lansky AJ, Na Y, **Mehran R**, Stone GW. Impact of time to treatment with primary PCI on Infarct size and Myocardial Reperfusion: Results from the EMERALD trial. *Am J Cardiol.* 2005;96(suppl 7A):65H
65. Dangas GD, **Mehran R**, Moses JW, Collins MB, Nikolsky E, Lansky AJ, Weisz G, Puruhit A, Leon MB, Brodie BR, Krucoff M, Grines C, Dixon SR, Stone GW. Epicardial Vessel Patency, Myocardial Perfusion and Infarct size after Percutaneous revascularization in Acute anterior versus non-anterior infarcts: pooled analysis from 4 randomized trials. *Am J Cardiol* 2005;96(suppl 7A):61H.
66. Nikolsky E, **Mehran R**, Grines CL, Turco M, Cox DA, Stuckey T, Guagliumi G, Griffin JJ, Lansky AJ, Na Y, Turcanu G, Sulaiman R, Kodali S, Spatareanu C, Stone GW. Blood Transfusion in patients undergoing primary Percutaneous coronary intervention for acute myocardial infarction: Analysis from the CADILLAC study. *Am J Cardiol.* 2005;96(suppl 7A):59H
67. Lee E, Dangas GD, **Mehran R**, Nikolsky E, Lansky AJ, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antonucci D, Krucoff MW, Gibbons RJ, Jones D, Stone GW. Microvascular Function and Myocardial Perfusion after Acute MI Angioplasty in Anterior Versus Non-Anterior Infarcts: Results from the EMERALD trial. *Am J Cardiol.* 2005;96(suppl 7A):55H
68. Nikolsky E, **Mehran R**, Grines CL, Turco M, Cox DA, Tchong JE, Brodie BR, Guagliumi G, Griffen JJ, Lansky AJ, Negoita M, Mercado DJ, Addo T, Stone GW. Impact of Baseline Platelet Count on Outcome of Patients Undergoing Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Analysis of the CADILLAC trial. *Am J Cardiol.* 2005; 96 (suppl 7A):29H.
69. Lansky AJ, Costa RA, **Mehran R**, Mori K, Cristea E, Na Y, Sanchez R, Cassidy L, Brodie BR, Cox DA, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schultheiss HP, Turco M, Webb J, Gibbons R, Krucoff M, Stone GW. Association of Myocardial Blush Grade (MBG) and ST-Segment Resolution (STR) Predicts Late Major Eschismic Events after Mechanical Reperfusion in Acute Myocardial Infarction (AMI) Results from the EMERALD Trial. *Am J Cardiol.* 2005;96(suppl 7A):27H
70. Moussa I, **Mehran R**, Lansky A, Krucoff M, Gibbons R, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Stone GW. Does vessel size have an impact on the efficacy of distal protection in patients undergoing primary angioplasty? An EMERALD Trial Analysis. *Am J Cardiol.* 2005;96(suppl 7A):27H.
71. Stone GW, Goldberg S, **Mehran R**, O’Shaughnessy C, Midei M, Siegel R, George B, Satler L, Raizner A, Negoita M, Fahy M, Arjomand-Fard H, Lansky AJ. A prospective, randomized US trial of the PTFE covered JOSTENT for the treatment of diseased saphenous vein grafts: the BARRICADE trial. *J Am Coll Cardiol* 2005;45:Supplement A.

72. Fujii K, Carlier SG, Mintz GS, Wijns W, Colombo A, Costa RA, de Ribamar Costa J Jr, Takebayashi H, Yasuda T, Kimura M, Sano K, Moussa I, Dangas G, **Mehran R**, Stone GW, Moses JW, Leon MB. Association of arterial remodeling and plaque characterization by intravascular ultrasound virtual histology analysis. *J Am Coll Cardiol* 2005;45:Supplement A.
73. Dangas GD, **Mehran R**, Lasic Z, Cox D, Ghali MGH, Henry TD, Teirstein PS, Stella JF, Browne KF Jr, Lewis SA, Knopf W, Kreps E, Leon MB, Collins M, Moses JW, Stone GW. Clinical evaluation of the concomitant use of bivalirudin and drug-eluting stents: results of the prospective, multicenter ADEST study. *J Am Coll Cardiol* 2005;45:Supplement A.
74. Tsuchiya Y, Lansky AJ, **Mehran R**, Costa RA, Cristea E, Tarawali M, Corral M, Pietras C, Na Y, Siegel R, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Stone GW. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction. Results from the CADILLAC trial. *J Am Coll Cardiol* 2005;45:Supplement A.
75. Nikolsky E, Lincoff MA, **Mehran R**, Sarembock IJ, Cohen DJ, Spriggs D, Stone GW. Contemporary outcomes of coronary artery perforation during percutaneous coronary intervention: insights from the REPLACE-2 trial. *J Am Coll Cardiol* 2005;45:Supplement A.
76. Costa RA, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Yasuda T, Costa J Jr, Kimura M, Sano K, Tsuchiya Y, Lansky AJ, **Mehran R**, Dangas GD, Collins M, Kreps EM, Moussa I, Colombo A, Stone GW, Moses JW, Leon MB. Coronary bifurcation lesions treated with the crush technique: an intravascular ultrasound (IVUS) analysis. *J Am Coll Cardiol* 2005;45:Supplement A.
77. O'Neill WW, Grines CL, Dixon SR, Griffin JJ, Martin JL, Cox DA, Webb JG, Brodie BR, **Mehran R**, Gibbons RJ, Held J, Stone GW. Does a 90-minute door-to-balloon time matter? Observations from four current reperfusion trials. *J Am Coll Cardiol* 2005;45:Supplement A.
78. Sousa JE, Abizaid A, Guagliumi G, Lewis B, **Mehran R**, Lansky A, Cohen S, Fitzgerald PJ, Chaves A, Mattos LA, Sousa A, Leon M. Does the dose of sirolimus effect outcomes after drug-eluting stenting in diabetic patients? Final results of the Double Dose Diabetes (3D) study. *J Am Coll Cardiol* 2005;45:Supplement A.
79. Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Dulas D, Kalnych A, Turco M, Schultheiss HP, Rutherford B, Kruckoff MW, Gibbons R, Lansky AJ, Schwartz A, Pop R, Jones D, **Mehran R**. Effectiveness of distal embolic protection during primary angioplasty: final 6-month results from the prospective, randomized EMERALD trial. *J Am Coll Cardiol* 2005;45:Supplement A.
80. O'Neill WW, Dixon SR, Stone GW, Griffin JJ, Cox DA, Webb JG, **Mehran R**, Brodie BR, Martin JL, Gibbons RJ, Held J, Grines CL. Excellent clinical outcomes in high risk non-shock acute myocardial infarction patients treated in the contemporary mechanical reperfusion era: a pooled analysis of 4 clinical trials. *J Am Coll Cardiol* 2005;45:Supplement A.
81. Nikolsky E, Kosinski E, Mishkel GJ, McGarry TF, Kimmelstiel C, Na Y, Negoita M, **Mehran R**, Stone GW. Impact of body mass index on restenosis after bare-metal and drug-eluting stent implantation: analysis from the TAXUS-IV trial. *J Am Coll Cardiol* 2005;45:Supplement A.
82. Prasad A, Stone G, Stuckey T, Costantini C, Zimetbaum P, McLaughlin M, **Mehran R**, Garcia E, Tcheng J, Cox D, Grines C, Lansky A, Gersh B. Impact of diabetes mellitus on myocardial perfusion following primary angioplasty in patients with acute myocardial infarction. *J Am Coll Cardiol* 2005;45:Supplement A.
83. Costa RA, Mintz GS, Carlier SG, Fujii K, Takebayashi H, Yasuda T, Costa J Jr, Kimura M, Sano K, Tsuchiya Y, Lansky AJ, **Mehran R**, Dangas GD, Collins M, Kreps EM, Moussa I, Colombo A, Stone GW, Moses JW, Leon MB. Impact of final stent dimensions on restenosis after crush drug-eluting stent implantation for bifurcation lesions. *J Am Coll Cardiol* 2005;45:Supplement A.
84. Addo TA, Lincoff AM, **Mehran R**, Dangas G, Kleiman NS, Jackman DS, Feit F, Stone GW. Impact of vascular closure device on hemorrhagic complications after angioplasty with bivalirudin compared to heparin plus IIb/IIIa inhibitors: analysis from REPLACE-2. *J Am Coll Cardiol* 2005;45:Supplement A.
85. Fujii K, Carlier SG, Mintz GS, Yang Y, Moussa I, Costa RA, de Ribamar Costa J Jr, Kimura M, Sano K, Dangas G, **Mehran R**, Lansky AJ, Stone GW, Moses JW, Leon MB. Intravascular ultrasound assessment of stent thrombosis after successful implantation of sirolimus-eluting stents. *J Am Coll Cardiol* 2005;45:Supplement A.
86. Leon MB, **Mehran R**, Popma J, Siegel RM, Kuntz R, Abizaid A, Meier B, Morice M-C, Serruys P, Moses JW, Schaempert E, Schofer J, Sousa A, Sousa JE. Long-term results after sirolimus-eluting stent in small vessel lesions: an integrated analysis of six multicenter trials. *J Am Coll Cardiol* 2005;45:Supplement A.
87. Nikolsky E, Singh M, Grines CL, Tcheng JE, Garcia E, Cox DA, Turco M, Stuckey TD, Na Y, Lansky AJ, Bersh BJ, O'Neill WW, **Mehran R**, Stone GW. Prediction of mortality following primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. *J Am Coll Cardiol* 2005;45:Supplement A.
88. Stone GW, Lincoff AM, Weisz G, Ebrahimi R, Keren G, Carr J, Feit F, **Mehran R**, Moses JW, Leon MB, Schwartz A. Predictors and clinical impact of the procedural ACT level in patients receiving bivalirudin during PCI: a REPLACE II sub study. *J Am Coll Cardiol* 2005;45:Supplement A.

89. Stone GW, O'Neill WW, Dixon S, Cox DA, Webb JG, Brodie B, Griffin JJ, Martin J, Gibbons R, Fahy M, **Mehran R**, Grines C. Predictors of infarct size by technetium-99m sestamibi imaging after angioplasty in acute myocardial infarction: meta-analysis from four contemporary randomized trials. *J Am Coll Cardiol* 2005;45:Supplement A.
90. Weisz G, Lincoff M, Moussa I, Ebrahimi R, Keren G, Carr J, Feit F, **Mehran R**, Moses JW, Leon MB, Stone GW. Relationship between activated clotting times and procedural outcomes in patients undergoing coronary intervention with unfractionated heparin and glycoprotein IIb/IIIa inhibitors. *J Am Coll Cardiol* 2005;45:Supplement A.
91. Dangas GD, **Mehran R**, Webb J, Cox DA, Brodie BR, Qureshi M, Dulas D, Kalynych A, Turco M, Schultheiss HP, Rutherford B, Krucoff M, Gibbons R, Lansky A, Spatareanu C, Popp R, Jones J, Schwartz A, Stone GW. Reperfusion success and clinical outcomes after rescue compared to primary angioplasty: results from the EMERALD trial. *J Am Coll Cardiol* 2005;45:Supplement A.
92. Weisz G, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cox D, Cambier P, Caputo R, Turco M, **Mehran R**, Popma J, Stone GW. Severity of thrombus score predicts adverse events after stenting in saphenous vein grafts with distal embolic protection: the FIRE trial. *J Am Coll Cardiol* 2005;45:Supplement A.
93. Sousa JE, Abizaid AS, Abizaid A, Neumann F, Horstkotte E, Nien Shen C, Verheye S, Hayashi EB, **Mehran R**, Lansky A, Sousa A, Feres F, Mogg M, Sikand R, Fitzgerald P, Leon M. Sirolimus-eluting heparin-coated cobalt chromium stent in the treatment of patients with de novo native coronary artery lesions in small vessels: final results of the EVOLUTION study. *J Am Coll Cardiol* 2005;45:Supplement A.
94. Abizaid A, Abizaid AS, **Mehran R**, Dangas GD, Morice M-C, Schofer J, Schaempart E, Moses JW, Popma J, Kuntz R, Leon MB, Meier B, Siegel RM, Moussa I, Moses JW, Leon MB, Sousa JE. Sirolimus-eluting stents in diabetic patients: integrated analysis of six multicenter trials. *J Am Coll Cardiol* 2005;45:Supplement A.
95. Nikolsky E, Grines CL, Cox DA, Stuckey T, Garcia E, Guagliumi G, Tchong JE, **Mehran R**, Negoita M, Sikand R, Lansky AJ, Stone GW. Stroke after primary angioplasty in acute myocardial infarction: analysis from the CADILLAC trial. *J Am Coll Cardiol* 2005;45:Supplement A.
96. **Mehran R**, Dangas GD, Kesanakurthy S, Siegel RM, Abizaid A, Abizaid AS, Moussa I, Mintz GS, Lansky AJ, Collins MB, Kreps E, Nikolsky E, Schwartz A, Stone GW, Moses JW, Leon MB. The changing incidence and patterns of in-stent restenosis: impact of drug-eluting stents. *J Am Coll Cardiol* 2005;45:Supplement A.
97. Tsuchiya Y, Lansky AJ, Costa RA, Pietras C, **Mehran R**, Cristea E, Sanchez R, Sahid B, Negoita M, Gilutz Y, Fahy M, Dangas G, Carlier S, Moussa I, Stone GW, Moses JW, Leon MB, Muller R, Rink M, Storger H, Hauptmann KE, Grube E. The effect of everolimus-eluting stents in different vessel sizes: results from the FUTURE 1 and 2 trials. *J Am Coll Cardiol* 2005;45:Supplement A.
98. Moussa I, Ellis SG, Moses JW, Jones M, Kereiakes DJ, McMartin D, Rutherford B, **Mehran R**, Collins M, Leon MB, Popma JJ, Russel ME, Stone GW. The impact of culprit lesion calcification in patients undergoing paclitaxel-eluting stent implantation: a TAXUS-IV sub study. *J Am Coll Cardiol* 2005;45:Supplement A.
99. Stone GW, Brodie BR, Caputo R, Feldman R, Rogers C, Cox DA, Roberts DK, Masud AZ, Hermiller J, Cambier P, Kovach R, Negoita M, Schwartz A, Pop R, Fahy M, Sikand R, **Mehran R**. Thirty-day and six-month outcomes after saphenous vein graft stenting with distal protection in patients excluded from randomized trials: the FilterWire EX high risk registry. *J Am Coll Cardiol* 2005;45:Supplement A.
100. Krucoff MW, Johanson P, Baeza R, Brodie BR, Webb J, Cox DA, Qureshi M, Dulas D, Kalynych A, Turco M, Schultheiss HP, Rutherford B, Lansky AJ, Negoita M, Na Y, **Mehran R**, Stone GW, for the EMERALD Investigators. Continuous 12-lead ST-segment recovery predicts ejection fraction, clinical outcome and death after PCI for acute ST-elevation MI: results from the EMERALD study. *J Am Coll Cardiol* 2005;45:Supplement A.
101. Teirstein PS, Dangas GD, Negoita M, Moussa I, Price MJ, Moses JW, Bass T, **Mehran R**, Leon MB. Sirolimus-eluting stents for failed brachytherapy: updated results from the SECURE registry. *Circulation* 2004;110(Suppl 1): Abstract 1924.
102. Nikolsky E, Negoita M, Collins M, Kreps E, Addo T, Kesanakurthy S, Na Y, Vagaonescu T, Ilic V, Scott T, Spatareanu C, Sulaiman R, **Mehran R**. Lower hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. *Circulation* 2004;110(Suppl 1):Abstract 2865.
103. **Mehran R**, Lansky AJ, Sousa E, Abizaid A, Abizaid A, Costa R, Negoita M, Dunne-Tramis AM, Sikand R, Mogg M, Fahy M, Leon MB, Grube E. First in-man experience of the biolimus A9 drug-eluting stent (MATRIX-stent) in treatment of de novo coronary lesions. Results from the STEALTH-I trial. *Circulation* 2004;110(Suppl 1):Abstract 3494.
104. Pinto DS, Stone GW, **Mehran R**, Ly H, Hermiller J, O'Shaughnessy C, Turco M, Caputo R, Greenberg J, Cohen DJ; TAXUS-IV Investigators. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. *Circulation* 2004;110(Suppl 1):Abstract 2472.

105. Moses JW, Nikolsky E, Lasala JM, Albin G, Dorey W, Hirsch C, Dunne-Tramis AM, Fahy M, Pop R, **Mehran R**. Paclitaxel-eluting stents are safe and effective in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. *Circulation* 2004;110(Suppl 1):Abstract 3068.
106. Moussa I, Leon MB, Lansky A, Lasic Z, Stone GW, Trubelja N, Vakher K, Monsuru I, Nikolsky E, Yang YM, Coplan NL, **Mehran R**, Cristea E, Coral M, Weisz G, Dangas G, Collins M, Iyer S, Kreps E, Moses JW. A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique." *Circulation* 2004;110(Suppl 1):Abstract 3013.
107. Nikolsky E, **Mehran R**, Lasic Z, Weisz G, Negoita M, Na Y, Krieger CL, Dunne-Tramis AM, Sikand R, Gilutz Y, Kesanakurthy S, Mogg M, Raj N, Stone GW, Moses JW, Leon MB, Dangas GD. Anemia is a novel risk factor for contrast-induced nephropathy after percutaneous coronary intervention. *Am J Cardiol*2004;94(Suppl 6A):23E.
108. **Mehran R**, Kesanakurthy S, Dangas GD, Lasic Z, Iyer S, Yadegar D, Moussa I, Nikolsky E, Kreps E, Collins M, Weisz G, Sulaiman R, Scott T, Moses JW, Stone GW, Leon MB. The risk of stent thrombosis after drug-eluting stenting in an unselected population. *Am J Cardiol*2004;94(Suppl 6A):26E.
109. Turco MA, Virmani R, Stone GW, Webb J, Cox DA, Brodie BR, Rutherford B, Kruckoff M, Gibbons R, Jones D, Weber DK, **Mehran R**. Is debris retrieval from the patients with acute myocardial infarction undergoing primary angioplasty of prognostic importance? Results from the roll-in phase of the EMERALD trial. *Am J Cardiol*2004;94(Suppl 6A):35E.
110. Dangas G, Lasic Z, **Mehran R**, Moses JW, Cox D, Ghali MG, Henry TD, Teirstein PS, Stella JF, Browne KF Jr, Lewis SA, Gilutz Y, Knopf W, Ambrose JA, Leon MB, Stone GW. Bivalirudin is a safe replacement to heparin during percutaneous coronary intervention with drug-eluting stents: final results of the multicenter ADEST study. *Am J Cardiol*2004;94(Suppl 6A):37E.
111. Price MJ, Sawhney N, Madrid A, Lasic Z, **Mehran R**, Negoita M, Moses JW, Leon MB, Dangas G, Teirstein PS. Impact of preprocedure clopidogrel when bivalirudin is used during percutaneous intervention. *Am J Cardiol*2004;94(Suppl 6A):37E.
112. Moussa I, Jones M, Kereiakes DJ, McMartin D, Lasic Z, Collins M, Lee H, Cox D, Fahy M, Negoita M, Rutherford B, **Mehran R**, Stone G. Does culprit lesion calcification affect the performance of the paclitaxel-eluting stent? A TAXUS-IV substudy. *Am J Cardiol*2004;94(Suppl 6A):66E.
113. **Mehran R**, Lansky AJ, Sousa E, Abizaid A, AbizaidAS, Costa R, Fahy M, Negoita M, Leon MB, Grube E. Biolimus A9 drug-eluting stent (MATRIX stent) in treatment of de novo coronary lesions: first-in-man experience (the STEALTH-I trial). *Am J Cardiol*2004;94(Suppl 6A):69E.
114. Moses JW, **Mehran R**, Nikolsky E, Lasala JM, Corey W, Albin G, Hirsch C, Leon MB, Russell ME, Ellis SG, Na Y, Stone GW. Paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial. *Am J Cardiol*2004;94(Suppl 6A):72E.
115. Nikolsky E, Kosinski E, Mishkel GJ, Kimmelstiel C, McGarry TF Jr, **Mehran R**, Leon MB, Russell ME, Ellis SG, Negoita M, Pop R, Fahy M, Stone GW. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation: analysis from the TAXUS-IV trial. *Am J Cardiol*2004;94(Suppl 6A):73E.
116. Weisz G, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cox D, Cambier P, Caputo R, Turco M, **Mehran R**, Popma J, Stone GW. Thrombus score in saphenous vein grafts predicts adverse events after stenting with distal embolic protection. *Am J Cardiol*2004;94(Suppl 6A):104E.
117. Moussa I, Leon MB, Lansky A, Lasic Z, Trubelja N, Yang YM, Katherine V, Ibraheem M, **Mehran R**, Cristea E, Coral M, Weisz G, Nikolsky E, Coplan N, Iyer S, Kreps E, Collins M, Stone GW, Dangas G, Moses JW. Treatment of coronary bifurcation lesions with sirolimus-eluting stents using the "crush technique." *Am J Cardiol*2004;94(Suppl 6A):109E.
118. Weisz G, Moussa I, Kesanakurthy S, Halkin A, Yadegar D, **Mehran R**, Dangas D, Collins M, Kreps E, Stone GW, Moses JW. Early experience with sirolimus-eluting stents for unprotected left main coronary artery. *Am J Cardiol*2004;94(Suppl 6A):132E.
119. Halkin A, **Mehran R**, Casey CW, Gordon P, Matthews R, Wilson BH, Leon MB, Russell ME, Ellis SG, Stone GW. Impact of renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV trial. *Am J Cardiol*2004;94(Suppl 6A):156E.
120. Costa RA, Lansky AJ, Tsuchiya Y, **Mehran R**, Cristea E, Pop R, Sahid B, Chen Y, Brodie BR, Cox DA, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schultheiss H-P, Turco M, Webb J, Krucoff M, Gibbons R, Stone GW. Impact of staged nontarget vessel revascularization on clinical outcomes after primary stenting for acute myocardial infarction: results from the EMERALD trial. *Am J Cardiol*2004;94(Suppl 6A):172E.
121. Costa R, Mintz G, Carlier S, Moussa I, Fujii K, Takebayashi H, Takenori Y, Costa J Jr, Tsuchiya Y, Lasic Z, Halkin A, Lansky A, Dangas G, **Mehran R**, Collins M, Kreps E, Stone G, Colombo A, Leon M, Moses J. Coronary bifurcation lesions treated with the crush technique. An intravascular ultrasound analysis. *Am J Cardiol*2004;94(Suppl 6A):182E.
122. Nikolsky E, Grines CL, Cox DA, Garcia E, **Mehran R**, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Halkin A, Weisz G, Na Y, Slack S, Lansky AJ, Stone GW. Implications of stroke after primary angioplasty in acute myocardial infarction. *Am J Cardiol*2004;94(Suppl 6A):200E.

123. Lasic Z, **Mehran R**, Moussa I, Nikolsky E, Addo T, Kipshidze N, Collins M, Kreps E, Qin J, Plent S, Tsounias E, Sikand R, Trubelja N, Mohammad A, Kotsishevsky L, Moses J, Leon M, Stone G, Dangas G. Sirolimus-eluting stents plus bivalirudin and outcome of percutaneous coronary intervention in saphenous vein grafts: results of the ADEST study. *Am J Cardiol*2004;94(Suppl 6A):209S.
124. Lasic Z, **Mehran R**, Nikolsky E, Gilutz Y, Addo T, Mogg M, Negoita M, Dunne-Tramis AM, Sikand R, Plent S, Collins M, Kreps E, Moussa I, Trubelja N, Tsounias E, Kipshidze N, Moses J, Leon M, Stone G, Dangas G. Bivalirudin- and sirolimus-eluting stents in multilesion percutaneous coronary intervention: results of the ADEST study. *Am J Cardiol*2004;94(Suppl 6A):210S.
125. **Mehran R**, Kesanakurthy S, Dangas GD, Iyer S, Spatareanu C, Elliott N, Bajraktari F, Lander J, Nikitina A, Moussa I, Kreps E, Collins M, Moses JW, Stone GW, Leon MB. Drug-eluting stents and patterns of in-stent restenosis. *Am J Cardiol*2004;94(Suppl 6A):211E.
126. Kutcher MA, Applegate RJ, Hermiller J, Cox DA, O'Shaughnessy CD, Feldman R, Moak AS, Smalling R, **Mehran R**, Russell ME, Ellis SG, Stone GW. Optimal stent implantation pressure in the drug-eluting stent era: observations from the TAXUS-IV study. *Am J Cardiol*2004;94(Suppl 6A):213E.
127. Lasic A, **Mehran R**, Negoita M, Gilutz Y, Mogg M, Roopan S, Plent S, Nikolsky E, Addo T, Krieger C, Pop R, Na Y, Arif M, Kotsishevsky L, Tsounias E, Moussa I, Kreps E, Moses J, Leon M, Stone G, Dangas G. Outcome of percutaneous coronary intervention in diabetic patients treated with bivalirudin- and sirolimus-eluting stents: results of the ADEST study. *Am J Cardiol*2004;94(Suppl 6A):218E.
128. Kandzari DE, Cox DA, Stuckey T, Turco M, **Mehran R**, Gersh BJ, Garcia E, Zimmetbaum P, McGlaughlin M, Lansky AJ, Costantini CO, Grines CL, Tchong JE, Stone GW. Reperfusion success and prognosis in patients with anterior compared with nonanterior infarction: insights from the CADILLAC trial. *Am J Cardiol*2004;94(Suppl 6A):230E.
129. Halkin A, Turco M, Cox DA, Stuckey TD, Garcia E, Guagliumi G, **Mehran R**, Rutherford BD, Griffin JJ, Tchong JE, Grines CL, Stone GW. Outcomes of percutaneous coronary intervention in patients with acute myocardial infarction excluded from randomization: the CADILLAC trial. *Am J Cardiol*2004;94(Suppl 6A):234E.
130. Costa R, Lansky A, Tsuchiya Y, **Mehran R**, Cristea E, Tarawalli M, Corral M, Pop R, Cox DA, Kalynych A, Turco M, Schultheiss H-P, Krucoff M, Gibbons R, Brodie BR, Webb J, Qureshi M, Dulas D, Rutherford B, Stone GW. Correlation between myocardial blush grades with ST-segment resolution, infarct size, and clinical outcomes after primary coronary intervention: results from the EMERALD trial. *Am J Cardiol*2004;94(Suppl 6A):235E.
131. Costa R, Lansky A, Tsuchiya Y, **Mehran R**, Cristea E, Pop R, Sanchez R, Caluser C, Brodie BR, Cox DA, Dulas D, Kalynych A, Qureshi M, Rutherford B, Schultheiss H-P, Turco M, Webb J, Krucoff M, Gibbons R, Stone GW. Impact of female sex on reperfusion success and clinical outcomes in patients with acute myocardial infarction undergoing primary coronary stenting: results from the EMERALD trial. *Am J Cardiol*2004;94(Suppl 6A):237E.
132. Costa RA, Lansky AJ, **Mehran R**, Tsuchiya Y, Cristea E, Gilutz Y, Coral M, Negoita M, Pop R, Rink M, Muller R, Techen G, Grube E. The multicenter evaluation of the everolimus-eluting stent for inhibition of neointimal hyperplasia: results of the pooled FUTURE I and II trials. *J Am Coll Cardiol*2004;43(5):12A.
133. Mintz GM, Nikolsky E, Wijns W, Kobayashi Y, Erbel R, **Mehran R**, Pop R, Colombo A, Serruys PW, Carlier SG, Abizaid A, Vince EG, Moses JW, Stone GW, Leon MB. Virtual histology of intravascular ultrasound images: feasibility and clinical correlations in humans. *J Am Coll Cardiol* 2004;43(5):33A.
134. Nikolsky E, **Mehran R**, Dangas GD, Mintz GS, Lasic A, Vagaonescu T, Pop R, Lansky AJ, Moussa I, Glasser L, Ibrahim S, Iyer S, Leon MB. Impact of cerebrovascular and peripheral arterial diseases on outcomes after percutaneous coronary interventions. *J Am Coll Cardiol* 2004;43(5):43A.
135. Weisz G, Rogers C, Herrmiller J, Feldman R, Hall P, Haber R, Masud Z, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Cox DA, **Mehran R**, Stone GW. Predilatation before distal protection device placement is associated with increased procedure-related myocardial infarction: analysis from the FIRE trial. *J Am Coll Cardiol* 2004;43(5):52A.
136. Fujii K, Kobayashi Y, Mintz GS, Jacoboff D, Takebayashi T, Yasuda T, Moussa I, **Mehran R**, Dangas G, Lansky AJ, Kreps E, Collins M, Stone GW, Leon MB, Moses JW. Creatine kinase-MB elevation after coronary stenting in lesions with ruptured plaque. *J Am Coll Cardiol* 2004;43(5):54A.
137. Nikolsky E, Halkin A, **Mehran R**, Krieger SR, Aymong EA, Lasic Z, Negoita M, Sulaiman R, Costa RA, Moses JW, Stone GW, Leon MB, Dangas GD. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. *J Am Coll Cardiol*2004;43(5):62A.
138. Takebayashi H, Kobayashi Y, Mintz GS, Fujii K, Yasuda T, **Mehran R**, Jacoboff D, Dangas GD, Lansky AJ, Moussa I, Collins MB, Kreps E, Stone GW, Leon MB, Moses JW. Intravascular ultrasound assessment of lesions with sirolimus-eluting stent failure. *J Am Coll Cardiol* 2004;43(5):65A.
139. Fujii K, Kobayashi Y, Mintz GS, Takebayashi H, Yasuda T, Jacoboff D, Moussa I, **Mehran R**, Dangas G, Lansky A, Kreps E, Collins M, Stone GW, Leon MB, Moses JW. Contribution of stent underexpansion to target lesion revascularization after sirolimus-eluting stenting for in-stent restenosis. *J Am Coll Cardiol*2004;43(5):66A.

140. Teirstein PS, Bass TA, Costa MA, Yakubov S, Carter AJ, Moses JW, Leon MB, **Mehran R**, Price MJ, Fischell TA. Sirolimus-eluting stents for failed brachytherapy: results from the SECURE registry. *J Am Coll Cardiol* 2004;43 (5);70A.
141. Jonas M, Stone GW, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HW, Cox D, **Mehran R**, Rogers C. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. *J Am Coll Cardiol* 2004;43(5);71A.
142. Teirstein PS, Moses J, Leon M, Collins M, **Mehran R**, Montang E, Negoita M, Giap H, Lin R, Jani S, Balter S, Dalton J, Lipsztein R, Price MJ. Impact of radiation dose on outcomes in diabetic patients: results from the SCRIPPS IV trial. *J Am Coll Cardiol* 2004;43(5);71A.
143. Swaminathan A, Herrmann HC, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P, Caputo RP, Cox DA, Pop R, Fahy M, **Mehran R**, Stone GW. Impact of vessel size on outcomes of different distal protection devices during saphenous vein graft intervention: a FIRE trial substudy. *J Am Coll Cardiol* 2004;43(5); 72A.
144. Weisz G, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud Z, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Cox DA, **Mehran R**, Stone GW. Relationship between embolic material retrieval and adverse events with different distal protection devices during saphenous vein graft stenting. *J Am Coll Cardiol* 2004;43(5);72A.
145. Tsuchiya Y, Lansky AJ, Costa RA, **Mehran R**, Negoita M, Cristea E, Marginean H, Corral M, Tarawali M, Babb J, Cox DA, Stone GW. The impact of myocardial blush grade on clinical outcomes of patients treated with saphenous vein grafts and thrombotic native coronary arteries: analysis from the X-TRACT trial. *J Am Coll Cardiol* 2004;43 (5);72A.
146. Teirstein PS, Moses J, Leon M, Collins M, **Mehran R**, Aymong E, Negoita M, Giap H, Lin R, Jani S, Balter S, Dalton J, Lipsztein R, Sawhney N, Tripuraneni P. Increasing brachytherapy dose dramatically improves outcome in patients with long lesion. *J Am Coll Cardiol* 2004;43(5);79A.
147. Teirstein PS, Moses J, Leon M, Collins M, **Mehran R**, Aymong E, Negoita M, Giap H, Jani S, Balter S, Dalton J, Lipsztein R, Sawhney N, Tripuraneni P. A double-blind randomized dose finding study of gamma radiation for in-stent restenosis. *J Am Coll Cardiol* 2004;43(5);79A.
148. Grube E, Costa RA, **Mehran R**, Negoita M, Gilutz Y, Tsuchiya Y, Fahy M, Cristea E, Sahid B, Marginean H, Muller R, Techen G, Rinck M, Lansky AJ, Hauptmann KE, Storger H. Everolimus-eluting stents for the prevention of restenosis: results of the FUTURE II trial. *J Am Coll Cardiol* 2004;43(5);86A.
149. Lasic Z, **Mehran R**, Nikolsky E, Negoita M, Costa R, Cox DA, Babb J, Nukta D, Bilodeau L, Cannon L, Stuckey TD, Hermiller J, Lansky A, Leon MB, Stone GW. Implications and prevention of large periprocedural myocardial infarction after percutaneous intervention of diseased saphenous vein grafts and thrombotic native coronary lesions. *J Am Coll Cardiol* 2004;43(5);88A.
150. Nikolsky E, **Mehran R**, Lansky AJ, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Rutherford B, Stone GW. Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction: the obesity paradox. *J Am Coll Cardiol* 2004;43(5);244A.
151. Pellizzon GG, Marso SP, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Lansky AJ, **Mehran R**, Rutherford BD, Stone GW. Predictors of reinfarction after ST elevation myocardial infarction and glycoprotein receptor blockade: analysis from the CADILLAC trial. *J Am Coll Cardiol* 2004;43(5);266A.
152. Costa RA, Lansky AJ, Costantini CO, Tsuchiya Y, Caluser C, Sahid B, Fahy M, Nikolsky E, Aymong E, Negoita M, **Mehran R**, Cox DA, Grines CL, Stone GW. Predictors of survival after primary percutaneous coronary intervention: the impact of myocardial perfusion grade in female patients. *J Am Coll Cardiol* 2004;43(5);266A.
153. Nikolsky E, Halkin A, Aymong EA, **Mehran R**, Lansky A, Grines CL, Turco M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Cohen DA, Rutherford DA, Stone GW. Anemia worsens prognosis after primary angioplasty in acute myocardial infarction: analysis from the CADILLAC trial. *J Am Coll Cardiol* 2004;43 (5);267A.
154. Klima U, Martens S, Wimmer-Greinecker G, Gummert J, Wolf R, Falk V, Costa RA, Lansky AJ, Cristea E, **Mehran R**, Casselman F, van Praet F, Vanermen H. Late angiographic patency of the magnetic vascular port (MVP®) system for coronary artery anastomosis. *J Am Coll Cardiol* 2004;43(5);271A.
155. Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Dulas D, Kalynych A, Turco M, Schultheiss HP, Rutherford B, Kruckoff M, Gibbons R, Lansky AJ, Pop R, **Mehran R**, Jones D. Primary angioplasty in acute myocardial infarction with distal protection of the microcirculation: principal results from the prospective, randomized EMERALD trial. *J Am Coll Cardiol* 2004;43(5);285A.
156. Brodie BR, Costantini CO, Aymong E, Stuckey TD, Cox DA, Zimetbaum P, McLaughlin M, Garcia E, Turco MA, **Mehran R**, Grines CL, Lansky AJ, Stone GW. Relationship between time to reperfusion, ST-segment resolution, myocardial blush scores and mortality with primary percutaneous coronary intervention for acute myocardial infarction: results from the CADILLAC trial. *J Am Coll Cardiol* 2004;43(5);303A.

157. Halkin A, Grines CL, Cox DA, Garcia E, **Mehran R**, Tcheng JE, Griffin JJ, Guagliumi G, Brodie B, Turco M, Rutherford BD, Aymong EA, Lansky AJ, Stone GW. Impact of intravenous beta-blockade during primary percutaneous intervention on convalescent left ventricular function. *J Am Coll Cardiol*2004;43(5):303A.
158. Nikolsky E, **Mehran R**, Negoita M, Narasimaiah R, Kesanakurthy S, Vagonescu T, Lasic Z, Kreps E, Ibrahim S, Pop R, Leon MB. Anemia predicts adverse outcome in patients with coronary artery disease treated by percutaneous coronary interventions. American Heart Association Scientific Sessions 2003; November 9-12, 2003; Orlando (FL). Abstract No. 1671.
159. Stone GW, Cox DA, Brodie BR, Webb J, Qureshi M, Dulas D, Turco M, Rutherford B, Johanson P, Gibbons R, Lansky AJ, Pop R, Aymong E, Cristea E, **Mehran R**. Primary angioplasty in acute myocardial infarction with distal protection of the microcirculation: results from the roll-in phase of the EMERALD trial. American Heart Association Scientific Sessions 2003; November 9-12, 2003; Orlando (FL). Abstract No. 1913.
160. Costantini CO, Lansky A, **Mehran R**, Grines CL, Shirai K, Costa RA, Cristea E, Fahy M, Buga S, Marginean H, Griffin JJ, Stone GW. Impact of myocardial blush analysis methodologies in predicting short and long-term mortality after primary angioplasty. The CADILLAC trial. American Heart Association Scientific Sessions 2003; November 9-12, 2003; Orlando (FL). Abstract No. 1916.
161. Aymong ED, Fahy M, Limpijankit T, Farkouh ME, Kesanakurthy S, Turcot D, Vagonescu T, **Mehran R**, Mintz GS. Interaction of diabetes and acute coronary syndromes in predicting death, myocardial infarction, and non-target lesion revascularization at 1-year follow-up after percutaneous coronary intervention. American Heart Association Scientific Sessions 2003; November 9-12, 2003; Orlando (FL). Abstract No. 2448.
162. Prasad A, Stone G, Aymong E, Zimetbaum PJ, McLaughlin M, **Mehran R**, Garcia E, Tcheng JE, Cox DA, Grines C, Gersh BJ. Impact of ST-segment resolution following primary angioplasty on outcomes after myocardial infarction in the elderly: an analysis from the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial. American Heart Association Scientific Sessions 2003; November 9-12, 2003; Orlando (FL). Abstract No. 2450.
163. Costa RA, Lansky A, **Mehran R**, Tsuchiya Y, Cristea E, Negoita M, Nikolsky E, Fahy M, Pop R, Gilutz Y, Leon M, Grube E. Everolimus-eluting stent for the treatment of de novo coronary lesions: angiographic follow-up of the FUTURE trial. American Heart Association Scientific Sessions 2003; November 9-12, 2003; Orlando (FL). Abstract No. 3191.
164. Aymong E, Limpijankit T, Fahy M, Kesanakurthy S, **Mehran R**, Dangas G, Buga S, Pop R, Negoita M, Mintz GS. Target lesion and nontarget lesion events are associated with increased Q-wave and non-Q-wave myocardial infarction (but not mortality) 1 year after percutaneous coronary intervention. *Am J Cardiol*2003;92(Suppl 6A):5L.
165. Kesanakurthy S, Dangas GD, Lasic A, Vagonescu T, Halkin A, Qin Z, Stone G, Moses JW, Leon MB, **Mehran R**. Clinical outcomes with the use of bivalirudin versus unfractionated heparin in octogenarians undergoing percutaneous coronary interventions. *Am J Cardiol*2003;92(Suppl 6A):11L.
166. Nikolsky E, Halkin A, Krieger S, **Mehran R**, Aymong E, Mintz GS, Negoita M, Gilutz Y, Hjadi I, Narasimaiah R, Stone GW, Moses JW, Leon MB, Dangas GD. Arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. *Am J Cardiol*2003;92(Suppl 6A):17L.
167. **Mehran R**, Marx S, Kesanakurthy S, Adamian Y, Qin Z, Moussa I, Collins M, New G, Polena S, Cosico J, Negoita M, Lansky AJ, Moses JW, Stone GW, Leon MB, Marks AR, Dangas G. Oral rapamycin for prevention of in-stent restenosis: long-term clinical, angiographic, and intracoronary ultrasound results. *Am J Cardiol*2003;92(Suppl 6A): 26L.
168. Masud AZ, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Kovach R, Cambier P, Capuot R, Cox DA, Pop R, Fahy M, **Mehran R**, Stone GW. Results of intervention in ostial and nonostial saphenous vein graft lesions using different distal protection devices. The FIRE trial. *Am J Cardiol*2003;92(Suppl 6A):33L.
169. Hermiller JB, Masud A, Cox D, Feldman R, Hall P, Haber R, Cambier P, Caputo R, Turco M, Kovach R, Brodie BR, Hermmann HC, Popma J, **Mehran R**, Aymong E, Rogers C, Stone GW. Impact of transient flow reduction on the efficacy of embolic protection results from the FIRE trial. *Am J Cardiol*2003;92(Suppl 6A):34L.
170. Sadeghi HM, Grines CL, **Mehran R**, Lansky AJ, Fahy M, Cox DA, Tcheng JE, Dixon SR, Griffin JJ, Stuckey TD, Brodie BR, Turco M, Carroll JD, Stone GW. Incidence and implications of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. *Am J Cardiol*2003;92(Suppl 6A):40L.
171. Stuckey ED, Grines CL, Cox DA, Brodie BR, Turco M, Zimetbaum P, Tcheng JE, Garcia E, Griffin JJ, Guagliumi G, **Mehran R**, Aymong E, Stone GW. Does stenting and glycoprotein IIb/IIIa receptor blockade improve ST-segment recovery and outcome in patients undergoing primary angioplasty in acute myocardial infarction? The CADILLAC trial. *Am J Cardiol*2003;92(Suppl 6A):41L.
172. Costantini CO, Lansky AJ, Costa RA, **Mehran R**, Aymong E, Cox DA, Tcheng JE, Stuckey T, Carroll JD, Garcia E, Guagliumi G, Fahy M, Griffen JJ, Grines CL, Stone GW. Impact of myocardial blush analysis methodologies in predicting short and long-term mortality after primary angioplasty: the CADILLAC trial. *Am J Cardiol*2003;92(Suppl 6A):43L.

173. Turco MA, Zimetbaum P, McLaughlin M, Aymong E, **Mehran R**, Cox D, Grines C, Tcheng J, Garcia E, Griffin J, Guagliumi G, Stuckey T, Stone GW. Is ST-segment resolution predictive of mortality after primary PCI in both anterior and nonanterior infarction? Analysis from the CADILLAC trial. *Am J Cardiol* 2003;92(Suppl 6A):43L.
174. Costa RA, Lansky AJ, Leon MB, **Mehran R**, Tsuchiya Y, Cristea E, Midei M, Cox D, O'Shaughnessy C, Applegate R, Fink S, Knopf W, O'Neill W. Paclitaxel-coated stents for the treatment of de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. *Am J Cardiol* 2003;92(Suppl 6A):60L.
175. Costa RA, Lansky AJ, **Mehran R**, Tsuchiya Y, Cristea E, Negoita M, Aymong E, Pop R, Gilutz Y, Nikolsky E, Leon MB, Grube E. Everolimus-eluting stent for the treatment of de novo coronary lesions: B-angiographic follow-up of the FUTURE trial. *Am J Cardiol* 2003;92(Suppl 6A):61L.
176. Tsuchiya Y, Lansky A, **Mehran R**, Costa RA, Cristea E, Corral M, Pop R, Aymong E, Negoita M, Grube E. Effect of everolimus-eluting stents in different vessel sizes: results from the FUTURE trial. *Am J Cardiol* 2003;92(Suppl 6A): 61L.
177. Costa RA, Tsuchiya Y, Cox DA, Babb J, Nukta D, Bilodeau L, Cannon L, Stuckey TD, Hermiller J, Aymong E, Slack S, **Mehran R**, Lansky AJ, Stone GW. Late outcomes of patients treated with thrombectomy prior to stenting in saphenous vein grafts and thrombus containing native coronary arteries: results from the X-TRACT trial. *Am J Cardiol* 2003;92(Suppl 6A):73L.
178. Tsuchiya Y, Costa RA, Fahy M, Slack S, Aymong E, **Mehran R**, Lansky AJ, Stone GW, Cox DA, Babb J, Nukta D, Bilodeau L, Cannon L, Stuckey T. Impact of gender on outcomes of thrombectomy in patients undergoing stenting of diseased saphenous vein grafts or thrombotic native coronary arteries: results from the X-TRACT trial. *Am J Cardiol* 2003;92(Suppl 6A):74L.
179. Tsuchiya Y, Costa RA, Fahy M, Slack S, Aymong E, **Mehran R**, Lansky AJ, Stone GW, Cox DA, Babb J, Nukta D, Bilodeau L, Cannon L, Stuckey T. Utility of thrombectomy in women undergoing stenting of diseased saphenous vein grafts and thrombus containing native coronary arteries: results from the X-TRACT trial. *Am J Cardiol* 2003;92(Suppl 6A):74L.
180. Nikolsky E, **Mehran R**, Aymong E, Mintz GS, Dangas G, Lansky AJ, Negoita M, Fahy M, Pop R, Roubin GS, Moses JW, Stone GW, Leon MB. The impact of symptomatic peripheral artery disease on 1-year mortality in patients undergoing percutaneous coronary interventions. *Am J Cardiol* 2003;92(Suppl 6A):77L.
181. Turcot D, Aymong E, **Mehran R**, Mintz G, Negoita M, Farkouh M, Dangas G. Detrimental impact of chronic renal failure and diabetes mellitus on prognosis after percutaneous coronary interventions. *Am J Cardiol* 2003;92(Suppl 6A):79L.
182. Aymong E, Limpijankit T, Fahy M, **Mehran R**, Leon M, Moses J, Stone G, Mintz GS. Interaction of diabetes and acute coronary syndromes in predicting death, myocardial infarction, and non-target lesion revascularization at 1-year follow-up after percutaneous coronary intervention. *Am J Cardiol* 2003;92(Suppl 6A):80L.
183. Moussa I, Jaff M, Iyer S, **Mehran R**, Klein H, Dangas G, Stone GW, Lansky A, Leon MB. Detection of peripheral arterial disease in patients presenting for coronary angiography or intervention for coronary artery disease: the peripheral arterial disease in interventional patients study (PIPS). *Am J Cardiol* 2003;92(Suppl 6A):83L.
184. Moussa I, Leon MB, **Mehran R**, Dangas G, Weiss G, Lansky A, Stone GW, Moses JW. The impact of platelet glycoprotein IIb/IIIb receptor inhibitors on outcome of diabetic patients undergoing sirolimus-eluting versus bare metal stent implantation: results from the SIRIUS trial. *Am J Cardiol* 2003;92(Suppl 6A):91L.
185. Dangas G, **Mehran R**, Farkouh M, Aymong E, Lansky A, Leon MB, Moses JW, Teirstein P. Sirolimus drug-eluting stents for diabetic patients who are poor candidates for other revascularization options: results of the secure compassionate use registry. *Am J Cardiol* 2003;92(Suppl 6A):92L.
186. Halkin A, Aymong E, Nikolsky E, Lansky A, **Mehran R**, Cox CA, Grines CL, Griffin JJ, Stone GW. Prediction of survival by index left ventricular ejection fraction measured during primary percutaneous intervention in patients with acute myocardial infarction. *Am J Cardiol* 2003;92(Suppl 6A):112L.
187. Halkin A, Aymong E, Lansky A, **Mehran R**, Cox DA, Grines CL, Garcia E, Guagliumi G, Stone GW. Determinants of convalescent left ventricular function after acute myocardial infarction treated by primary percutaneous intervention. *Am J Cardiol* 2003;92(Suppl 6A):113L.
188. Costa RA, Tsuchiya Y, Tarawali M, Marginean H, Sanchez R, Cristea E, **Mehran R**, Stuckey T, Guagliumi G, Cox DA, Tcheng JE, Carroll JD, Griffen JJ, Grines CL, Lansky AJ, Stone GW. Impact of age on the outcomes of women with acute myocardial infarction undergoing primary coronary stenting. *Am J Cardiol* 2003;92(Suppl 6A):115L.
189. **Mehran R**, Aymong E, Moses J, Lansky A, Stone G, Leon M, Moussa I, Dangas G. Early clinical benefit with bivalirudin compared to unfractionated heparin during percutaneous coronary intervention. *Am J Cardiol* 2003;92(Suppl 6A):134L.
190. **Mehran R**, Aymong E, Stone G, Moses J, Leon M, Dangas G. Very high activated clotting time values with bivalirudin therapy during percutaneous coronary intervention do not confer high bleeding risk. *Am J Cardiol* 2003;92(Suppl 6A):134L.
191. Nikolsky E, **Mehran R**, Aymong E, Mintz GS, Dangas G, Lansky AJ, Negoita M, Pop R, Moses JW, Stone GW, Leon MB. The impact of anemia on outcome after percutaneous coronary intervention. *Am J Cardiol* 2003;92(Suppl 6A): 138L.



192. Aymong E, Fahy M, Lansky A, **Mehran R**, Grines CL, Cox DA, Garcia CE, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Stone GW. Can stents and glycoprotein IIb/IIIa inhibitors improve the prognosis of young patients with acute myocardial infarction? A report from the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) study. *Am J Cardiol* 2003;92(Suppl 6A):142L.
193. Kesanakurthy S, **Mehran R**, Tchelebi A, Stone G, Lasic A, Qin Z, Vagaonescu T, Coplan N, Balter S, Moses JW, Dangas GD. Superior clinical outcomes with bivalirudin during intracoronary brachytherapy. *Am J Cardiol* 2003;92(Suppl 6A):172L.
194. Vagaonescu TD, Grines CL, Cox CA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Fahy M, Costantini C, **Mehran R**, Stone GW. Does treatment with abciximab influence survival in patients with acute myocardial infarction and elevated baseline white blood cell count undergoing primary angioplasty? The CADILLAC trial. *Am J Cardiol* 2003;92(Suppl 6A):228L.
195. Halkin A, Nikolsky E, Aymong E, **Mehran R**, Tcheng JE, Cox DA, Stuckey T, Lansky AJ, Stone GW. The survival benefit of periprocedural  $\beta$ -blockers in patients with acute myocardial infarction undergoing primary angioplasty is determined by use of these drugs before admission. *Am J Cardiol* 2003;92(Suppl 6A):228L.
196. Weisz G, **Mehran R**, Nikolsky E, Aymong ED, Polena S, Hjazi I, Moussa I, Kreps E, Stone GW, Moses JW, Leon MB, Dangas G. Does genetic polymorphism for platelet glycoprotein IIIA impact early and long-term outcomes after elective percutaneous coronary interventions? *J Am Coll Cardiol* 2003;41(6):12A.
197. Abizaid AS, **Mehran R**, Mintz GS, Abizaid AA, Dangas G, Lansky AJ, Farkouh M, Adamian MG, Aymong ED, Negoita M, Hjazi I, Costantini C, Kobayashi Y, Moses JW, Stone GW, Leon MB. Impact of diabetes on coronary remodeling in patients with acute coronary syndromes: an intravascular ultrasound study. *J Am Coll Cardiol* 2003; 41(6):8A.
198. Iakovou I, Dangas G, **Mehran R**, Mintz GS, Lansky AJ, Adamian MG, Hirose M, Kobayashi Y, Moussa I, Stone GW, Moses JW, Leon MB. Intravascular ultrasound predictors of late recurrence after stent implantation in small coronary arteries. *J Am Coll Cardiol* 2003;41(6):35A.
199. **Mehran R**, Aymong ED, Dangas G, Abizaid AS, Abizaid AA, Mintz GS, Adamian MG, Moussa I, Lansky AJ, Stone GW, Moses JW, Leon MB. A risk score prediction of contrast-induced nephropathy after percutaneous coronary intervention. *J Am Coll Cardiol* 2003;41(6):37A.
200. New G, Roubin GS, Iyer SS, **Mehran R**, Adamya YG, Brennan C, Dangas G, Losquadro M, Guiry M, Kumar P, Vitek JJ. Low stroke rates during carotid artery stenting with neuroprotection. *J Am Coll Cardiol* 2003;41(6):50A.
201. Kokolis S, Dangas G, **Mehran R**, Kokolis R, Lasic Z, Hanna R, Collins M, Iyer S, Hirose M, Kobayashi Y, Kreps E, Stone GW, Leon MB, Moses JW. Human immunodeficiency virus infection and high C-reactive protein correlated with increased in-stent restenosis rate. *J Am Coll Cardiol* 2003;41(6):66A.
202. Costantini CO, Lansky AJ, **Mehran R**, Shirai K, Corral M, Tarawali M, Conway R, Proctor B, Cristea E, Dangas G, Stone GW, Leon MB. Angiographic in-stent restenosis pattern predicts outcome after gamma vascular brachytherapy. *J Am Coll Cardiol* 2003;41(6):69A.
203. Costantini CO, Lansky AJ, Shirai K, Cristea E, Marginean H, Ispas C, Proctor B, Tarawali M, Midei MG, Buchbinder M, **Mehran R**, Dangas G, Moses JW, Leon MB, Stone GW. The Radiance P-32 RDX balloon in saphenous vein grafts: a comparison of de novo and in-stent restenotic lesions in the SVG BRITETrial. *J Am Coll Cardiol* 2003;41(6):70A.
204. **Mehran R**, Marx S, Kesanakurthy S, Adamian Y, Aboufares A, Moussa I, Kokolis S, Collins M, New G, Polena S, Cosisco J, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. Oral rapamycin for the prevention of in-stent restenosis. *J Am Coll Cardiol* 2003;41(6):74A.
205. Iakovou I, Dangas G, **Mehran R**, Mintz GS, Lansky AJ, Kreps EM, Collins MB, Moussa I, Glasser LA, Stone GW, Leon MB, Moses JW. Percutaneous coronary interventions in octogenarians with use of glycoprotein GP IIb/IIIa inhibitors: similar major adverse cardiac events but higher hemorrhagic stroke rate than younger patients. *J Am Coll Cardiol* 2003;41(6):78A.
206. New G, Roubin GS, Iyer SS, Dangas G, **Mehran R**, Adamyan YG, Limpijankit T, Brennan C, Kumat P, Vitek JJ. Outcomes from carotid artery stenting in over 1,000 cases from a single group of operators. *J Am Coll Cardiol* 2003;41 (6):79A.
207. Kobayashi Y, **Mehran R**, Hirose M, Dangas G, Lansky AJ, Stone GW, Moussa I, Mintz GS, Collins MB, Kreps E, Moses JW, Leon MB. Acute and long-term outcomes of multivessel stenting in patients aged 80 years. *J Am Coll Cardiol* 2003;41(6):180A.
208. Kipshidze NN, Tchekanov G, Dangas G, **Mehran R**, Tio F, Roubin GS, Adamina MG, Leon MB, Colombo A, Edelman E, Moses JW, Akhtar M, Chekanov V. Transplantation of autologous endothelial cells induces angiogenesis in a sheep model of chronic ischemia. *J Am Coll Cardiol* 2003;41(6):308A.
209. Feldman DN, Farkouh M, **Mehran R**, Aymong ED, Fahy M, Nikolsky E, Abizaid AS, Abizaid AA, Dangas G. Prognostic role of troponin T and troponin I in patients with acute coronary syndromes: meta analysis of 20 studies. *J Am Coll Cardiol* 2003;41(6):353A.

210. Sadeghi HM, Grines CL, **Mehran R**, Chandra HR, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Turco M, Carroll JD, Rutherford BD, Stone GW. Magnitude and impact of after hours treatment delay in patients undergoing primary angioplasty for acute myocardial infarction: the CADILLAC trial. *J Am Coll Cardiol* 2003; 41(6):1A.
211. Madrid AP, Grise MA, Reilly JP, Moses JW, Leon MB, Tcelibi A, Ciora C, Giap H, Jani S, Balter S, Tripuraneni P, Lansky AJ, Negoita M, **Mehran R**, Teirstein PS. Coronary brachytherapy is an effective treatment for chronic in-stent total occlusions. *J Am Coll Cardiol* 2003;41(6):48A.
212. Grise MA, Madrid AP, Moses JW, Leon MB, Casterella PJ, Thcelibi A, Ciora C, Giap H, Jani S, Balter S, Reilly JP, Tripuraneni P, Lansky AJ, Negoita M, **Mehran R**, Teirstein PS. Intracoronary gamma radiation for elderly patients. *J Am Coll Cardiol* 2003;41(6):48A.
213. Adamyan YG, New G, Iyer S, Limpijankit T, Brennan C, Adamian MG, **Mehran R**, Hجازي I, Lasic Z, Ibrahim S, Vitek JJ, Roubin GS. Is bivalirudin a safe alternative to heparin during carotid stenting? A case matched study. *J Am Coll Cardiol* 2003;41(6):52A.
214. Abizaid AA, New G, Abizaid AS, Costa M, Vaz V, Kipshidze N, Staico R, Feres F, **Mehran R**, Pinto I, Roubin G, Iyer S, Moses JW, Leon MB, Sousa A, Sousa JEM. First clinical experience with 17-estradiol-eluting BiodivYsio matrix LO stent to prevent restenosis in de novo native coronary arteries: six-month clinical outcomes and angiographic follow-up from the EASTER trial. *J Am Coll Cardiol* 2003;41(6):56A.
215. Moussa I, **Mehran R**, Roubin GS, Iyer S, Limpijankit T, Losquadro M, Glasser L, Klein H, Slack S, Leon MB, Moses JW. Detection of peripheral arterial disease in patients presenting for coronary angiography and/or intervention patients study (PIPS). *J Am Coll Cardiol* 2003;41(6):253A.
216. Aymong ED, McLaughlin MG, Zimetbaum P, Grines CL, Tcheng JE, Cox DA, Stuckey TD, Turco M, Garcia E, Griffin JJ, **Mehran R**, Stone GW. Prognostic value of the absolute degree of ST-segment elevation of the ECG at baseline and after primary angioplasty: analysis from the CADILLAC trial. *J Am Coll Cardiol* 2003;41(6):323A.
217. Ashby DT, Tcheng JE, Grines CL, Cox DA, **Mehran R**, Fahy MP, Garcia E, Griffin JJ, Guagliumi G, Stuckey TD, Turco M, Lansky AJ, Stone GW. Outcomes in patients requiring bail-out abciximab during primary intervention in acute myocardial infarction: analysis from the CADILLAC trial. *J Am Coll Cardiol* 2003;41(6):333A.
218. Brodie BR, Gersh B, Stuckey TD, Zimetbaum P, McLaughlin MG, Aymong ED, **Mehran R**, O'Neill B, Tcheng JE, Turco M, Cox DA, Grines CL, Stone GW. Relationship between time to treatment, electrocardiographic ST-segment resolution, and outcomes with primary percutaneous coronary intervention for acute myocardial infarction: results from the CADILLAC trial. *J Am Coll Cardiol* 2003;41(6):342A.
219. Kandzari DE, Tcheng JE, Grines CL, Effron M, Cox DA, Garcia E, Griffin JJ, Guagliumi G, Stuckey TD, Turco M, Lansky AJ, **Mehran R**, Stone GW. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the CADILLAC trial. *J Am Coll Cardiol* 2003;41(6):357A.
220. Brodie BR, Cox DA, Stuckey TD, Turco M, Garcia E, Griffin JJ, Fahy M, Tcheng JE, Grines CJ, **Mehran R**, Stone GW. How important is time to treatment with primary percutaneous coronary intervention for acute myocardial infarction? Results from the CADILLAC trial. *J Am Coll Cardiol* 2003;41(6):368A.
221. Turco MA, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Carroll JD, Grines CL, Rutherford BD, Slack S, Fahy M, **Mehran R**, Lansky AJ, Stone GW. Baseline features and clinical results in patients excluded from randomization from a large international trial of reperfusion strategies in acute myocardial infarction: the CADILLAC registry. *J Am Coll Cardiol* 2003;41(6):368A.
222. Turco MA, Fahy M, **Mehran R**, Lansky AJ, Grines CL, Tcheng JE, Garcia E, Guagliumi G, Cox DA, Stuckey TD, Shadlinger DE, Stone GW. Predictors of treatment delay in patients with acute myocardial infarction undergoing primary angioplasty: an analysis from the CADILLAC trial. *J Am Coll Cardiol* 2003;41(6):376A.
223. Sadeghi HM, Grines CL, **Mehran R**, Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey TD, Turco M, Carroll JD, Rutherford BD, Stone GW. Marked mortality risk of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. *J Am Coll Cardiol* 2003;41 (6):384A.
224. McLaughlin MG, Gardner G, Aymong ED, **Mehran R**, Lansky AJ, Grines CL, Tcheng JE, Cox DA, Stuckey TD, Garcia E, Guagliumi G, Turco M, Zimetbaum P, Stone GW. ST-segment elevation resolution as a predictor of mortality in patients with thrombolysis in myocardial infarction III flow in the infarct artery after primary angioplasty: the CADILLAC trial. *J Am Coll Cardiol* 2003;41(6):392A.
225. Aymong ED, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumu G, Stuckey TD, Turco M, Carroll JD, Rutherford BD, Lansky AJ, **Mehran R**, Stone GW. Predictors and sequelae of subacute thrombosis after percutaneous intervention in acute myocardial infarction: the CADILLAC trial. *J Am Coll Cardiol* 2003;41(6):393A.
226. Kandzari DE, Tcheng JE, Grines CL, Cohen DJ, Bekhai A, Cox DA, Stuckey TD, Effron M, Griffin JJ, Turco M, Carroll JD, Fahy M, **Mehran R**, Stone GW. Safety of an early discharge strategy following primary intervention with adjunctive glycoprotein IIb/IIIa inhibition: the CADILLAC trial. *J Am Coll Cardiol* 2003;41(6):538A.

227. Stone GW, **Mehran R**, Midei M, Waksman R, Schaer G, Lansky AJ, Buchbinder M. Beta radiation for de novo and in-stent restenotic lesions in saphenous vein grafts: the SVG BRITE trial. *Circulation* 2002;106(19):II-335.
228. Limpijankit T, **Mehran R**, Dangas G, Lansky A, Costantini C, Moussa I, Glasser L, Adamian M, Ciora C, Collins M, Leon MB. The fate of patients after GAMMA vascular brachytherapy failure: long-term follow-up from GAMMA I, II and SCRIPPS III. *Circulation* 2002;106(19):II-335.
229. Costantini CO, Lansky A, Shira K, Desai K, Corral M, Roca R, Margienan H, Goldberg A, Patel P, Limpijankit T, Leon MB, **Mehran R**. Clinical and angiographic discordance in GAMMA VBT trials: pooled results from the GAMMA I, GAMMA II, WRIST, and Long WRIST trials. *Circulation* 2002;106(19):II-336.
230. Kokolis S, Moses JW, **Mehran R**, Moussa I, Hanna R, Feldman D, Kokolis R, Polena S, Glasser LA, Iyer S, Coplan N, Dangas G. Human immunodeficiency virus infection correlates with a very high in stent restenosis rate. *Circulation* 2002;106(19):II-392.
231. Sousa JE, Abizaid A, Abizaid AS, New G, Costa MA, Staico R, Feres F, Sousa AGMR, **Mehran R**, Kipshidze N, Goodhand M, Kreimer S, Moses J, Leon M. First clinical experience with 17- $\beta$  estradiol-eluting Biodivysiomatrix LO stent to prevent restenosis in de novo native coronary arteries. Early clinical outcomes and angiographic follow-up from the EASTER trial. *Circulation* 2002;106(19):II-393.
232. Kokolis S, **Mehran R**, Moses JW, Andrieni J, Moussa I, Polena S, Felman D, Coplan N, Collins M, Glasses LA, Leon MB, Dangas G. Systemic administration of chemotherapy decreases in-stent restenosis. *Circulation* 2002;106(19):II-592.
233. Kokolis S, Dangas G, **Mehran R**, Kokolis R, Andrieni J, Leon MB, Moses J. Use of systemic chemotherapy decreases the rate of in-stent restenosis. *Am J Cardiol* 2002;90(Suppl 6A):10H.
234. Weisz G, Dangas G, Colombo C, Moussa I, Collins M, Adamian M, Adamyan J, Ashby D, LaRoche V, Lansky A, **Mehran R**, Teirstein P, Stone GW, Moses JW, Leon MB. T-stenting technique with sirolimus-eluting stents for bifurcation lesions. *Am J Cardiol* 2002;90(Suppl 6A):5H.
235. Kokolis S, **Mehran R**, Andreieni J, Hanna R, Polena S, Kokolis R, Amheriene M, Moses J, Leon MB, Kipshidze N, Dangas G. Human immunodeficiency virus infection increases in-stent restenosis rate. *Am J Cardiol* 2002;90 (Suppl 6A):86H.
236. Costantini CO, Dangas G, Shirai K, Kobayashi Y, Hirose M, Tarawali M, Corral M, Desai K, Ashby D, **Mehran R**, Lansky A, Leon MB. Plaque morphology diversity in aorto-ostial lesions does not affect clinical outcome. *Am J Cardiol* 2002;90(Suppl 6A):91H.
237. Iakovou I, Dangas G, **Mehran R**, Mintz G, Abizaid A, Kuepper F, Kobayashi Y, Ashby D, Hirose M, Stone GW, Leon MB. Neutral impact of preintervention remodeling of saphenous vein grafts on subsequent target lesion revascularization. *Am J Cardiol* 2002;90(Suppl 6A):132H.
238. Adamian M, **Mehran R**, Moussa I, Dangas G, Mintz GS, Lansky AJ, Adamyan Y, Ibrahim S, Fahy M, Ciora C, Losquadro M, Reyes A, Stone GW, Moses JW, Leon MB. Mucomyst administration in percutaneous coronary interventions in patients with impaired renal function: a matched comparison. *Am J Cardiol* 2002;90(Suppl 6A):144H.
239. Costantini CO, Dangas G, Lansky AJ, Shirai K, Tarawali M, Corral M, Ashby D, Hirsose M, Kobayashi Y, **Mehran R**, Leon MB. Clinical outcomes after elective multivessel stenting in patients with severe left ventricular dysfunction: prophylactic intra-aortic balloon pump (IABP) versus non-IABP support. *Am J Cardiol* 2002;90 (Suppl 6A):149H.
240. Weisz G, **Mehran R**, Polena S, Ashby D, Moussa I, Stone G, Roubin GS, Moses JW, Leon MB, Dangas G. In patients receiving oral antiplatelet agents, platelet glycoprotein IIIa heterozygous polymorphism does not increase risk of percutaneous coronary interventions. *Am J Cardiol* 2002;90(Suppl 6A):161H.
241. Adamian M, Farkouh M, **Mehran R**, Moussa I, Weisz G, HJazi I, Pop R, Limpjankit T, Adamyan Y, Collins M, Losquadro M, Dangas G, Stone GW, Moses JW, Leon MB. A matched comparison of safety and feasibility of bivalirudin in patients with diabetes mellitus during percutaneous coronary interventions. *Am J Cardiol* 2002;90 (Suppl 6A):161H.
242. Adamian M, **Mehran R**, Mintz GS, Dangas G, Moussa I, Ashby DT, Ibrahim S, Adamyan Y, Negoita M, Reyes A, Narasimaiah R, Kreps EM, Stone GW, Moses JW, Leon MB. Safety and feasibility of direct thrombin inhibitor bivalirudin during percutaneous coronary interventions in patients with chronic renal failure. Results of the pilot study. *Am J Cardiol* 2002;90(Suppl 6A):162H.
243. Kuepper F, Lansky AJ, Dangas G, Iakovou I, Ashby DT, Costantini CO, Farkouh M, Stone GW, Leon MB, **Mehran R**. Patients with diabetes after percutaneous interventions in saphenous vein grafts: sex-based differences in clinical outcomes at 1-year follow-up. *Am J Cardiol* 2002;90(Suppl 6A):178H.
244. Adamian MG, **Mehran R**, Dangas G, Farkhouh M, Abizaid A, Reyes A, HJazi I, Negoita M, Mohamed M, Cioata C, Pop R, Lansky AJ, Stone GW, Moses JW, Leon MB. Stenting in acute myocardial infarction in patients with chronic renal failure: predictors of in-hospital and long-term outcome. *J Am Coll Cardiol* 2002;39(Suppl A):309A.
245. Adamaian MG, Stone GW, **Mehran R**, Dangas G, Abizaid AS, Abizaid A, Mohamed M, Adamyan Y, Reyes A, HJazi I, Iakovou I, Hirose M, Lansky AJ, Moses JW, Leon MB. Have the outcomes of rescue angioplasty after failed thrombolytic therapy in acute myocardial infarction improved in the stent era? *J Am Coll Cardiol* 2002;39 (Suppl A):309A.

246. **Mehran R**, Lotan C, Kranjec I, Holmer Em Haase K, Camenzind E, Zelizko M, Maillard L, Seabra-Gomes R, Vandormael MG, Lansky AJ, Dangas G, Stone GW, Ashby D, Leon MB. The [HEP@NET](#) study: an internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation. *J Am Coll Cardiol* 2002;39(Suppl A):75A.
247. Iakovou I, Dangas G, Abizaid A, Mintz G, **Mehran R**, Kobayashi Y, Ashby D, Hirose M, Iyer S, Stone GW, Collins M, Roubin G, Astatkie M, Moses JW, Leon MB. In saphenous vein grafts bigger is not significantly better: an intravascular ultrasound study. *J Am Coll Cardiol* 2002;39(Suppl A):74A.
248. Brennan C, Roubin GS, Iyer SS, Mgaieith S, Kumar P, Al-Mubarak N, **Mehran R**, Dangas G, Leon MB, Vitel JJ, New G. Neuroprotection reduces the risk of periprocedural major strokes and death in octogenarians. *J Am Coll Cardiol* 2002;39(Suppl A):66A.
249. Costantini C, Lansky AJ, **Mehran R**, Fahy M, Shirai K, Dave N, Stone GW, Dangas G, Leon MB. Efficacy of gamma vascular brachytherapy for ostial versus nonostial in stent restenotic lesions. *J Am Coll Cardiol* 2002;39 (Suppl A):66A.
250. Hirose M, Kobayashi Y, **Mehran R**, Moussa I, Dangas G, Pop R, Adamian M, Collins M, Grise MA, Lansky AJ, Mintz GS, Stone GW, Moses JW, Leon MB, Teirstein PS. Retreatment immediately after gamma radiation for in-stent restenosis results in need for target vessel revascularization beyond target lesion. *J Am Coll Cardiol* 2002;39 (Suppl A):65A.
251. Adamian M, **Mehran R**, Dangas G, New G, Abizaid A, Lansky AJ, Weisz G, Grise MA, Collins MB, Kreps EM, Stone GW, Moussa I, Moses JW, Leon MB, Teirstein PS. Does vessel size have an impact on recurrence rates following gamma vascular brachytherapy: acute and nine-month results from SCRIPPS III registry? *J Am Coll Cardiol* 2002;39(Suppl A):64A.
252. Adamian M, Moussa I, **Mehran R**, Dangas G, Lansky AJ, Mintz GS, Moussavian M, Abizaid A, Adamyan Y, Mohamed M, Kuntz R, Stone GW, Moses JW, Leon MB, Teirstein PS. Gamma vascular brachytherapy neutralizes the negative impact of diabetes mellitus on clinical outcomes after PCI for in-stent restenosis: pooled data from Gamma I, Gamma II, and SCRIPPS III Trials. *J Am Coll Cardiol* 2002;39(Suppl A):64A.
253. Ashby D, Dangas G, Farkouh M, Iakovou I, Weisz G, Hجازي I, Adamian M, Aymong E, Mohamed M, **Mehran R**, Stone GW, Lansky AJ, Collins M, Moses J, Leon MB. Impact of smoking habit on clinical outcomes after percutaneous coronary intervention. *J Am Coll Cardiol* 2002;39(Suppl A):63A.
254. Ashby D, Dangas G, **Mehran R**, Lansky AJ, Adamian M, Collins M, Krepps E, New G, Moussa I, Stone GW, Roubin GS, Iyer S, Moses JW, Leon MB, Teirstein PS. Do multiple prior interventions for in-stent restenosis impact the success of gamma brachytherapy? *J Am Coll Cardiol* 2002;39(Suppl A):58A.
255. Baungart D, Limpijankit T, Serruys P, Colombo A, Silber S, Eeckhout E, Urban P, Bonan R, Zeiher A, Gershlick AH, Dangas G, Lansky AJ, **Mehran R**, Stone GW, Leon MB. Efficacy of long radiation treatment in native in-stent restenosis: a subanalysis from the RENO registry. *J Am Coll Cardiol* 2002;39(Suppl A):57A.
256. Iakovou I, Dangas G, Lansky AJ, Negoita M, Hجازي I, Ashby D, Forman J, Guiry M, Brandweun R, Losquadro M, Limpijankit T, Stone GW, Moses JW, Leon MB, **Mehran R**. Predictors of contrast-induced nephropathy after percutaneous coronary intervention in patients with and without chronic renal failure. *J Am Coll Cardiol* 2002;39 (Suppl A):56A.
257. Abizaid AS, **Mehran R**, Lansky AJ, Dangas G, Abizaid A, Mohamed M, Hجازي I, Stone GW, Leon MB. Intravascular ultrasound guidance decreases target lesion revascularization in long-diffuse coronary lesions. *J Am Coll Cardiol* 2002;39(Suppl A):55A.
258. Costantino C, Lansky AJ, **Mehran R**, Mintz GS, Desai K, Shirai K, Marginean H, Stone GW, Dangas G, Leon MB. Vascular brachytherapy for ostial in-stent restenosis lesions. *J Am Coll Cardiol* 2002;39(Suppl A):46A.
259. Limpijankit T, Abizaid A, **Mehran R**, Lansky AJ, Dangas G, Kipshidze N, Stone GW, CollinsMB, Moses JW, Leon MB, Teirstein PS. Predictors of radiation failure after treatment of in-stent restenosis with gamma vascular brachytherapy: pooled analysis from GAMMA I, II, and SCRIPPS III Studies. *J Am Coll Cardiol* 2002;39 (Suppl A):46A.
260. Hirose M, Kobayashi Y, Arif F, Balan O, Reyes A, Iakovou I, Costantini C, Moussa I, Dangas G, **Mehran R**, Lansky AJ, Stone GW, Mintz GS, Leon MB, Moses JW. Different mechanism of lumen enlargement during balloon angioplasty between focal and diffuse in-stent restenosis. *J Am Coll Cardiol* 2002;39(Suppl A):37A.
261. Arif F, Kobayashi Y, Hirose M, Balan O, Reyes A, Iakovou I, Adamian M, **Mehran R**, Dangas G, Lansky AJ, Moussa I, Stone GW, Leon MB, Moses JW, Mintz GS. Different mechanism of lumen enlargement in lesions with stent underexpansion after balloon angioplasty for in-stent restenosis compared to those with optimal stent expansion: an intravascular ultrasound study. *J Am Coll Cardiol* 2002;39(Suppl A):36.
262. Abizaid AS, **Mehran R**, Mintz GS, Lansky AJ, Stone GW, Abizaid A, Dangas G, Limpijankit T, Iakovou Y, Moses J, Leon MB. Direct stenting improves target lesion revascularization in saphenous vein grafting lesions: an intravascular ultrasound-guided study. *J Am Coll Cardiol* 2002;39(Suppl A):35A.
263. Iakovou I, **Mehran R**, Mintz G, Dangas G, Koboyashi Y, Abizaid A, Ashby D, Limpijankit T, Narasimaiah R, Hجازي I, Kipshidze N, Lansky AJ, Stone GW, Moses JW, Leon MB. Increased CKMB release is a trade-off for optimal stent implementation: an intravascular ultrasound study. *J Am Coll Cardiol* 2002;39(Suppl A):28A.

264. Ashby D, Dangas G, **Mehran R**, Limpijankit T, Weisz G, Stone GW, Constantini C, Lansky AJ, Leon MB, New G, Iyer S, Kreps E, Roubin G, Collins M, Moses J. Relationship of the degree of procedural anticoagulation to outcomes after stent implementation. *J Am Coll Cardiol* 2002;39(Suppl A):27A.
265. Limpijankit T, Dangas G, **Mehran R**, Lansky AJ, Stone GW, Kipshidze N, Astatkie M, Hawkey M, Ashby D, Mohamed M, Moussa I, Collins MB, Moses JW, Leon MB. Predictors and prognostic values of CK-MB cardiac enzyme elevation after coronary intervention with radiation treatment in in-stent restenosis. *J Am Coll Cardiol* 2002; 39(Suppl A):23A.
266. Shirai K, Lansky AJ, **Mehran R**, Desai K, Costantini C, Proctor B, Conway T, Fahy M, Dave N, HJazi I, Dangas G, Stone GW, Teirstein P, Moses J, Leon MB. Beta versus gamma radiation for treatment of in-stent restenosis: angiographic predictors and outcomes in 630 patients. *J Am Coll Cardiol* 2002;39(Suppl A):21A.
267. Costantini CO, Lansky AJ, **Mehran R**, Desai K, Proctor B, Shirai K, Dave N, Cristea E, Fahy M, Dangas G, Stone GW, Waksman R, Moses J, Leon MB. Is bigger better with vascular brachytherapy (VBT) for in-stent restenosis? Impact of optimal final angiographic results and predictors of restenosis in 990 VBT patients. *J Am Coll Cardiol* 2002;39(Suppl A):20A.
268. Costantini CO, Lansky AJ, **Mehran R**, Desai K, Proctor B, Shirai K, Marginean H, Conway T, Fahy M, Dangas G, Stone GW, Waksman R, Moses J, Leon MB. Impact of vessel size after coronary vascular brachytherapy: a report of 990 patients. *J Am Coll Cardiol* 2002;39(Suppl A):14A.
269. Costantini CO, Lansky AJ, Desai K, **Mehran R**, Kazuyuki S, Cristea E, Marginean H, Dangas G, Stone GW, Leon MB. Geographic miss is not associated with restenosis or the edge phenomenon in the INHIBIT trial. *J Am Coll Cardiol* 2002;39(Suppl A):13A.
270. Shirai K, Lansky AJ, **Mehran R**, Desai K, Costantini CO, Proctor B, Conway T, Fahy M, Corral M, Brestowski C, Dangas G, Stone GW, Teirstein P, Moses J, Leon MB. Impact of lesion length on vascular brachytherapy failure: a comparison of beta (b) versus gamma (g) irradiation in 990 patients. *J Am Coll Cardiol* 2002;39(Suppl A):13A.
271. Kobayashi Y, Moussa I, Hirose M, Arif F, Balan O, Reyes A, Mohamed M, Adamian M, **Mehran R**, Dangas G, Lansky AJ, Stone GW, Leon MB, Moses JW, Mintz GS. Small proximal vessels are not always small: an intravascular ultrasound study. *J Am Coll Cardiol* 2002;39(Suppl A):5A.
272. Iakovou I, Dangas G, Lansky AJ, Mintz G, Ashby D, Losquadro, Guiry M, Kipshidze N, Brandwein R, Limpijankit T, Forman J, HJazi I, Stone GW, Leon MB, **Mehran R**. Incidence, predictors, and economic impact of contrast-induced nephropathy: results in 8,628 patients treated with percutaneous coronary interventions. *J Am Coll Cardiol* 2002;39(Suppl A):2A.
273. Ashby D, **Mehran R**, Lansky AJ, Iakovou I, Weisz G, Costantini C, Shirai K, HJazi I, Farkouh M, Dangas G, Stone GW, New G, Moses J, Leon MB. Gender differences in clinical outcomes after percutaneous coronary intervention in small coronary arteries. *J Am Coll Cardiol* 2002;39(Suppl A):2A.
274. Iakovou I, Dangas G, Lansky AJ, Negoita M, HJazi I, Ashby D, Constantini C, Guiry M, Brandwein R, Losquadro M, Forman J, Moses JW, Stone GW, Leon MB, **Mehran R**. Impact of gender on the incidence and outcomes of contrast-induced nephropathy after percutaneous coronary intervention. *J Am Coll Cardiol* 2002;39(Suppl A):2A.
275. Adamian MG, Moussa I, Dangas G, **Mehran R**, Farkhouh M, Adamyan Y, Mohamed M, Negoita A, Reyes A, Losquadro M, Collins M, Kreps EM, Moses JW, Stone GW, Leon MB. The role of mucomyst administration prior to percutaneous interventions on renal function in patients with chronic renal failure. *J Am Coll Cardiol* 2002;39 (Suppl A):1A.
276. Abizaid AS, Abizaid A, Mattos I, Mintz GS, Staico R, Costa M, Seixas AC, de Paula E, Chaves A, Centemero M, Tanajura LF, **Mehran R**, Sousa A, Sousa EJ. Gold-coated versus uncoated stents: an intravascular ultrasound volumetric analysis showing an increase in intimal hyperplasia in gold-coated stents. *J Am Coll Cardiol* 2002;39 (Suppl A):60A.
277. Moussavian M, Negoita M, Moses JW, Leon MB, **Mehran R**, Reilly JP, Grise MA, Teirstein PS. Catheter-based brachytherapy for aorto-ostial in in-stent restenosis. *J Am Coll Cardiol* 2002;39(Suppl A):47A.
278. Lotan C, Kdranjec I, Holmer E, Haase K, Camenzind E, Zelizko M, Maillard L, Seabra-Gomes R, Vandormael MG, **Mehran R**, Leon MB. Use of heparin-coated stents to reduce subacute stent thrombosis in complex lesions: results from the multicenter internet-based HEPANET registry. *Am J Cardiol* 2001;88(Suppl 5A):13G.
279. Feldman DN, Dangas G, **Mehran R**, Aymong E, Grayver E, Kobayashi Y, Gruberg L, Kent KM, Pichard AD, Satler LF, Lansky AJ, Stone GW. Impact of dialysis and chronic renal failure in nondiabetic patients on 1-year clinical outcome after percutaneous coronary intervention. *Am J Cardiol*;2001;88(Suppl 5A):40G.
280. Ashby DT, El-Omar M, Iakovou Y, Aymong E, Negoita M, HJazi I, **Mehran R**, Dangas G, Moses J, Stone GW, Leon MB. Effect of body mass index on in-hospital outcomes after percutaneous coronary interventions. *Am J Cardiol*2001;88(Suppl 5A):41G.
281. Ashby DT, Iakovou Y, El-Omar M, Aymong E, Narasimaiah R, Faraj H, **Mehran R**, Dangas G, Moses J, Leon MB. Clinical outcomes after percutaneous coronary intervention for proximal left anterior descending stenoses compared with proximal RCA and circumflex stenoses: nonstenting versus stenting strategies. *Am J Cardiol* 2001;88(Suppl 5A):45G.
282. Costantini CO, Shirai K, Desai K, Lansky AJ, Dave N, **Mehran R**, Dangas G, Negoita M, Iakovou, Ashby DT, El-Omar M, Hirose M, Stone GW, Waksman R, Leon MB. Debulking versus no debulking beforey-vascular brachytherapy. *Am J Cardiol* 2001;88(Supl 5A):58G.

283. Adamian M, Farkouh M, **Mehran R**, Dangas G, Moussa I, Feldman D, Ashby D, Reyes A, Iakovou I, Adamian Y, Mohamed M, Lansky AJ, Stone GW, Moses JW, Leon MB. Effect of diabetes mellitus on immediate and 1-year outcomes after stenting in acute myocardial infarction. *Am J Cardiol*;2001;88(Suppl 5A):70G.
284. Lasic Z, Ilic V, Dangas G, Koklis S, **Mehran R**, Stogioglou A, Karatepe M, Knezevic D, Mani A, Bolon D, Aboufares A, Coplan N, Moussa I, Moses JW. Clopidogrel and glycoprotein IIb/IIIa inhibitors: effect on adenosine diphosphate-induced platelet aggregation during coronary interventions. *Am J Cardiol* 2001;88(Suppl 5A).
285. Iakovou Y, **Mehran R**, Ashby DT, El-Omar M, Dangas G, Hirose M, Kobayashi Y, Izat H, Lansky AJ, Stone GW, Moses J, Leon MB. Similar intergender incidence and outcome of contrast-induced nephropathy among patients with chronic renal failure. *Am J Cardiol* 2001;88(Suppl A):117G.
286. Kobayashi Y, **Mehran R**, Dangas G, Moussa I, Abizaid AS, Abizaid A, Adamian M, New G, Lansky AJ, Roubin GS, Iyer S, Stone GW, Moses JW, Leon MB. Effect of coronary plaque calcification on the final lumen dimensions after stenting without rotational atherectomy: an intravascular ultrasound study. *J Am Coll Cardiol* 2001;37:11A.
287. Waksman R, Ajani AE, Kin HS, **Mehran R**, Lansky AJ, Deible R, Taaffe M, Mintz GS, Satler LF, Kent KM, Pichard AD. Is 6 months of Plavix enough to prevent late total occlusion after gamma radiation for in-stent restenosis? *J Am Coll Cardiol* 2001;37:14A.
288. Dangas G, **Mehran R**, Lansky AJ, Feldman D, D'Agate DJ, Satler LF, Kent KM, Pichard AD, Gruberg L, Ahmed JM, Stone GW, Leon MB. Gender and racial differences in clinical outcome after percutaneous coronary interventions. *J Am Coll Cardiol* 2001;37:15A.
289. Ahmed JM, Dangas G, **Mehran R**, Pichard AD, Satler LF, Kent KM, Hong, MK, Stone GW, Leon MB. Clinical, angiographic, and intravascular ultrasound predictors of target lesion revascularization and late cardiac events after stent implantation in saphenous vein grafts. *J Am Coll Cardiol* 2001;37:20A.
290. Gruberg L, **Mehran R**, Dangas G, Satler LF, Wu H, Gevorkian N, Gruberg RE, Purser A, Pichard AD, Kent KM, Waksman R. Evaluation of paradoxical beneficial effect of obesity in patients undergoing percutaneous coronary intervention: the obesity paradox? *J Am Coll Cardiol* 2001;37:22A.
291. Abizaid AS, **Mehran R**, Dangas G, Fuchs S, Abizaid A, Lansky AJ, Kornowski R, Waksman R, Pichard AD, Satler LF, Stone GW, Leon MB. Positive troponin-I predicts early and late mortality after percutaneous coronary intervention. *J Am Coll Cardiol* 2001;37:23A.
292. **Mehran R**, Subramanian V, Mack M, Pfister A, Corso P, Gill IS, Douville EC, Brunsting T, Magovern J, Matheny R, Moses JW, Leon MB. Angiographic patency of LIMA-LAD anastomosis after MIDCB compared to conventional CABG: results from the POEM trial. *J Am Coll Cardiol* 2001;37:23A.
293. Abizaid A, Pichard AD, **Mehran R**, Mintz GS, Gruberg L, Ahmed J, Stone GW, Abizaid AS, Satler LF, Kent KM, Dangas G, Leon MB. Intravascular ultrasound-guided provisional stenting in small coronary stenosis. *J Am Coll Cardiol* 2001;37:26A.
294. Abizaid A, Dangas G, Abizaid AS, **Mehran R**, Negoita M, Cioara C, Narasimaiah R, Pichard AD, Lansky AJ, Stone GW, Mintz GS, Leon MB. Intravascular ultrasound versus angiography-guided stent implantation: acute and long-term outcome in 2,883 patients. *J Am Coll Cardiol* 2001;37:27A.
295. Lansky AJ, **Mehran R**, Desai K, Costantini C, Proctor B, Conway T, Fahy M, Dangas G, Stone GW, Waksman R, Moses JW, Leon MB. Impact of gamma and beta radiation vs. placebo on the changing pattern of in-stent restenosis: a matched angiographic analysis. *J Am Coll Cardiol* 2001;37:29A.
296. Abizaid AS, **Mehran R**, Abizaid A, Dangas G, Gruberg L, Pichard AD, Waksman R, Satler LF, Kent KM, Lansky AJ, Stone GW, Leon MB. Staged versus nonstaged approach for multivessel percutaneous coronary interventions. *J Am Coll Cardiol* 2001;37:33A.
297. Roubin GS, **Mehran R**, Diethrich E, Satler LF, Whitlow P, Ohki T, Guterman L, Subbarao M, Faraj H, New G, Iyer S, Leon MB. Carotid stent-supported angioplasty with distal neuro-protection using the Guardwire™: 30-day results from the Carotid Angioplasty Free of Emboli (CAFÉ-USA) trial. *J Am Coll Cardiol* 2001;37:38A.
298. Adamian M, **Mehran R**, Kobayashi Y, Dangas G, Moussa I, Collins MB, Glasser L, New G, Lansky AJ, Stone GW, Leon MB, Colombo A, Moses JW. Recurrence after treatment of in-stent restenosis: does diabetes impact outcomes in large vessels? *J Am Coll Cardiol* 2001;37:40A.
299. Castagna M, Mintz GS, Weissman NJ, **Mehran R**, Pichard AD, Gebreyesus AG, Satler LF, Kent KM. The contribution of mechanical problems to in-stent restenosis: an intravascular ultrasound analysis of 1090 consecutive in-stent restenosis lesions. *J Am Coll Cardiol* 2001;37:42A.
300. Abizaid A, Mintz GS, Abizaid AS, **Mehran R**, Dangas G, Pichard A, Satler LF, Hijazi I, Narasimaiah R, Lansky AJ, Stone GW, Leon, MB. Intravascular ultrasound predictors of late recurrence after stent implantation in small coronary disease. *J Am Coll Cardiol* 2001;37:42A.
301. Kim HS, Yazdi HA, Dangas G, **Mehran R**, Fournadjiev J, Seaborn R, Iversen PL, Leon M, Moses J, Kipshidze N. Local delivery of third-generation antisense drug inhibits neointimal formation after stent implantation in the porcine coronary artery. *J Am Coll Cardiol* 2001;37:44A.

302. Al-Mubarak N, Roubin GS, Iyer SS, Vitek JJ, New G, Dangas G, **Mehran R**, Leon MB. Predictors of microembolization during carotid stenting. *J Am Coll Cardiol* 2001;37:50A.
303. Kobayashi Y, Dangas G, **Mehran R**, Moussa I, New G, Balan O, Roubin GS, Iyer S, Al-Mubarak N, Cohen N, Stone GW, Leon MB. Stenting elderly patients in the new millennium: results in the year 2000. *J Am Coll Cardiol* 2001;37:52A.
304. Gruberg L, Waksman R, **Mehran R**, Kim HS, Ajani AE, Satler LF, Pichard AD, Kent KM, Lansky AJ. Intracoronary radiation therapy for patients with in-stent restenosis and chronic renal insufficiency. *J Am Coll Cardiol* 2001;37:54A.
305. Teirstein PS, Moses JW, Casterella PJ, Leon MB, Giap H, Koka A, Huppe G, Sirkin K, Jani S, Grise M, Balter S, Tripuraneni P, Lansky AJ, **Mehran R**. Late thrombosis after coronary radiation may be eliminated by longer antiplatelet therapy and reduced stenting: the Scripps III results. *J Am Coll Cardiol* 2001;37:60A.
306. Waksman R, Ajani AE, Zimmarino M, **Mehran R**, Kent KM, Kim HS, Satler LF, Pichard AD. Influence of device selection for the treatment of in-stent restenosis with and without radiation. A subanalysis from the gamma radiation trials. *J Am Coll Cardiol* 2001;37:60A.
307. Ajani AE, Waksman R, **Mehran R**, Lansky AJ, Satler LF, Pichard AD, Kent KM. The influence of reference vessel diameter on angiographic restenosis and target vessel revascularization in gamma radiation versus placebo for in-stent restenosis. *J Am Coll Cardiol* 2001;37:61A.
308. Kobayashi Y, Moussa I, **Mehran R**, Dangas G, Lansky AJ, New G, Adamian M, Abizaid A, Roubin G, Stone GW, Leon MB, Moses JW. Stenting without rotational atherectomy in lesions with at least moderate calcification by IVUS but insignificant calcification angiographically. *J Am Coll Cardiol* 2001;37:63A.
309. Moussa I, Colombo A, Di Mario C, Kobayashi Y, Adamian M, **Mehran R**, Kreps EM, Faraj H, Lansky AJ, Collins MB, Dangas G, Moses JW. Long-term outcome of patients with versus without diabetes mellitus in the DESTINI trial. *J Am Coll Cardiol* 2001;37:65A.
310. Abizaid A, Dangas G, **Mehran R**, Kobayashi Y, Abizaid AS, Mintz GS, Adamian MG, Narasimaiah R, Cioaro C, Pichard AD, Stone GW, Leon MB. One-year results after multivessel stenting in diabetic vs. nondiabetic patients. *J Am Coll Cardiol* 2001;37:68A.
311. Kim HS, Ajani AE, Satler LF, **Mehran R**, Lansky AJ, Mintz GS, Kent KM, Pichard AD, Gruberg L, Chan RC, Waksman R. Intracoronary gamma radiation for patients with totally occluded in-stent restenotic lesions: 6 months clinical and angiographic follow-up. *J Am Coll Cardiol* 2001;37:72A.
312. Gruberg L, Fuchs S, **Mehran R**, Satler LF, Pichard AD, Kent KM, Einav-Gruberg R, Gevorkian N, Wu H, Waksman R. Troponin I predicts adverse outcome after percutaneous coronary intervention in patients with chronic renal failure. *J Am Coll Cardiol* 2001;37:76A.
313. New G, Moussa I, Veeramachaneni V, **Mehran R**, Dangas G, Lansky AJ, Adamian M, Roubin GS, Collins MB, Kreps E, Iyer SS, Leon MB, Subramanian V, Connelly M, Moses JW. Is the need for re-intervention higher with percutaneous coronary interventions or with coronary artery bypass surgery? *J Am Coll Cardiol* 2001;37:82A.
314. Roubin GS, **Mehran R**, Iyer SS, Satler LF, Whitlow PL, Gutterman L, New GS, Leon MB. Carotid stent-supported angioplasty with distal neuro-protection using the Guardwire™: initial results from the carotid angioplasty free of Emboli (CAFÉ-USA) trial. *Circulation* 2000;102 (Suppl):18 II-475.
315. Waksman R, Bhargava B, Taaffe M, White RL, Salter LF, **Mehran R**, Kent KM, Pichard AD, Elsayyad S, Okubagzi P, Lansky AJ, Negoita M. Prolonged antiplatelet therapy to reduce late thrombosis after intracoronary gamma radiation in patients with in-stent restenosis: "Plavix Wrist." *Circulation* 2000;102(Suppl):18 II-570.
316. **Mehran R**, Subramanian V, Mack M, Pfister AJ, Corso PH, Gill IS, Douville EC, Brunsting T, Magovern JA, Matheny R, Moses JW, Leon MB. Is the angiographic patency of Lima-LAD anastomosis after midcab equivalent to conventional CABG? Final results from the POEM Trial. *Circulation* 2000;102(Suppl):18 II-581.
317. Waksman R, Elsayyad S, **Mehran R**, White RL, Chan RC, Rosales O, Bhargava B, Deible R, Purser A, Rosales O, Okubagzi P, Lansky AJ. High dose intracoronary gamma radiation for patients with diffuse in-stent restenosis. *Circulation* 2000;102 (Suppl):18 II-667.
318. Waksman R, Buchbinder M, Reisman M, Lansky AJ, Trauthen B, Okubagzi P, **Mehran R**. The BRITE trial: a feasibility study of a novel <sup>32</sup>p deployable balloon system for the treatment of in-stent restenosis. *Circulation* 2000;102 (Suppl):18 II-669.
319. Ahmed JM, Pichard AD, Hong MK, Abizaid A, Dangas G, Stone GW, Lansky AJ, **Mehran R**, Leon MB. Direct stenting in saphenous vein grafts: immediate and late clinical outcome. *Am J Cardiol* 2000;86(Suppl 8A):3i.
320. Leon MB, New G, Buchbinder M, Lansky AJ, Abizaid A, Abizaid AS, Dangas G, **Mehran R**. Preliminary findings using a PTFE-coated stent in patients with saphenous vein graft disease. *Am J Cardiol* 2000;86(Suppl 8A):19i.
321. Adamian M, Dangas G, **Mehran R**, Abizaid A, Abizaid AS, Gruberg L, Lansky AJ, Stone GW, Moses JW, Leon MB. One-year clinical outcome in diabetic patients with single-vessel versus multivessel native coronary stenting. *Am J Cardiol* 2000;86(Suppl 8A):89i.

322. Adamian M, Abizaid A, Abizaid AS, **Mehran R**, Dangas G, Lansky AJ, Stone GW, Moses JW, Leon MB. Acute and long-term outcome of stenting multiple saphenous vein graft lesions in diabetics versus nondiabetics. *Am J Cardiol* 2000;86(Suppl 8A):90i.
323. Adamian M, Lansky AJ, **Mehran R**, Abizaid AS, Abizaid A, Dangas G, Stone GW, Moses JW, Leon MB. "Rescue" administration of platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: are there any gender differences in outcome? *Am J Cardiol* 2000;86(Suppl 8A):90i.
324. Adamian M, **Mehran R**, Kobayashi Y, Dangas G, Collins MB, Stone GW, Leon MB, Colombo A, Moses JW. Recurrence after treatment of in-stent restenosis in large vessels: impact of diabetes mellitus. *Am J Cardiol* 2000; 86(Suppl 8A):125i.
325. Lasic Z, Kokolis S, Stogioglou A, Ilic V, Knezevic D, Mani A, Karatepe M, Aboufares A, Coplan N, **Mehran R**, Dangas G. Effect of clopidogrel and GPIIb/IIIa inhibitors on ADP-induced platelet aggregation during percutaneous interventional procedures. *Am J Cardiol* 2000;86(Suppl 8A):78i.
326. Dangas G, D'Agate DJ, **Mehran R**, Feldman D, Lansky AJ, Kent KM, Pichard AD, Satler LF, Wu H, Stone GW, Leon MB. Racial differences in clinical outcome after percutaneous coronary interventional procedures. *Am J Cardiol* 2000;86(Suppl 8A):49i.
327. Kobayashi Y, Moussa I, **Mehran R**, Abizaid A, Adamian M, Mintz GS, **Dangas G**, Stone GW, Leon MB, Moses JW. Are all "small" vessels really small? Implications for stent implantation. *Am J Cardiol* 2000;86(Suppl 8A):23i.
328. Kobayashi Y, Dangas G, Abizaid A, Abizaid AS, Lansky AJ, **Mehran R**, Moses JW, Leon MB. In-hospital and 1-year clinical outcome after stenting of ostial LAD lesions: results from 2 tertiary referral centers. *Am J Cardiol* 2000;86(Suppl 8A):90i.
329. Kobayashi Y, **Mehran R**, Dangas G, Moussa I, Abizaid A, Adamian M, Stone GW, Leon MB, Moses JW. Stent implantation compared to balloon angioplasty in small vessels. *Am J Cardiol* 2000;86(Suppl 8A):91i.
330. Ahmed J, Dangas G, **Mehran R**, Hong MK, Mintz GS, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Clinical, procedural, angiographic and intravascular ultrasound predictors of late cardiac events in patients with unstable angina undergoing percutaneous interventions. *Eur Heart J* 2000;21(Suppl):168.
331. Moussa I, New G, Al-Moubarak N, Iyer S, Vitek G, Dangas G, Gray W, **Mehran R**, Moses JW, Roubin GS. Clopidogrel may enhance the clinical efficacy of carotid artery stent implantation: the EMILY registry. *Eur Heart J* 2000;21(Suppl):320.
332. Cohen DJ, Seto TB, Neil N, **Mehran R**, Kuntz RE. Cost-effectiveness of vascular brachytherapy for treatment of in-stent restenosis: influence of angiographic restenosis pattern. *Eur Heart J* 2000;21 (Suppl):400.
333. Ahmed J, Dangas G, **Mehran R**, Hong MK, Satler LF, Pichard AD, Kent KM, Mintz GS, Stone GW, Leon MB. Predictive factors of target lesion revascularization and late cardiac events after stent implantation in saphenous veins grafts. *Eur Heart J* 2000;21(Suppl):637.
334. Mintz GS, Weissman NJ, Barghava B, Waksman R, Teirstein PS, **Mehran R**, Lansky AJ, Satler L, Leon MB. Are the intravascular ultrasound findings after brachytherapy treatment of in-stent restenosis reproducible? *J Am Coll Cardiol* 2000;35:6-7A.
335. Waksman R, White LR, **Mehran R**, Lansky AJ, Greenberg A, Bhargava B, Satler L, Kent K, Murphy M, Leon MB. Two year follow-up after intracoronary gamma radiation therapy for in-stent restenosis: results from a randomized clinical trial. *J Am Coll Cardiol* 2000;35:10A.
336. Mintz GS, **Mehran R**, Jackson M, Lansky AJ, Kent KM, Leon MB. Diabetes and ostial lesion location have an additive effect on target lesion revascularization after stent implantation. *J Am Coll Cardiol* 2000;35:17A.
337. Ahmed JM, **Mehran R**, Dangas G, Hong MK, Negoita M, Lansky AJ, Faraj H, Hashmi N, Okubagzi P, Modi N, Astatkie M, Kent KM, Weissman NJ, Curry B, Kupper F, Satler LF, Pichard AD, Stone GW, Leon MB. Predictors of late clinical outcomes in patients with unstable angina undergoing percutaneous coronary interventions. *J Am Coll Cardiol* 2000;35:18A.
338. Waksman R, Zimarino M, **Mehran R**, Lansky AJ, Pichard AD, Bhargava B, Satler L, Kent K, White LR, Leon MB. Device influence on outcome in the treatment of in-stent restenosis with and without radiation: a subanalysis from the WRIST study. *J Am Coll Cardiol* 2000;35:21A
339. Waksman R, Bhargava B, Chan RC, **Mehran R**, Lansky AJ, White LR, Satler L, Kent K, Leon MB. Safety and efficacy of manual stepping and overlapping of a B-Emitter for diffuse in-stent restenosis lesions. *J Am Coll Cardiol* 2000;35:21A
340. **Mehran R**, Dangas G, Hong MK, Deible R, Faraj H, Sayyad SE, Negoita M, Okubagzi P, Astatkie M, Pichard AD, Stone GW, Leon MB. Femoral vascular access complications following arteriotomy closure devices: a comparison with manual compression after percutaneous coronary interventions. *J Am Coll Cardiol* 2000;35:33A.
341. Gruberg L, **Mehran R**, Dangas G, Stone GW, Hong MK, Mintz GS, Waksman R, Kornowski R, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB. Acute renal failure requiring hemodialysis after percutaneous coronary intervention: in-hospital and one-year outcomes. *J Am Coll Cardiol* 2000;35:53A.
342. Gruberg L, **Mehran R**, Dangas G, Hong MK, Lansky AJ, Mintz GS, Waksman R, Kornowski R, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB. Revascularization of the internal mammary artery graft: in-hospital and one-year outcomes. *J Am Coll Cardiol* 2000; 35:54A.



343. Dangas G, Weissman NJ, Tinana A, Goyal N, Mintz GS, **Mehran R**, Ahmed JM, Lansky AJ, Laird JR, Jaff MR, Greenberg A, Pichard AD, Leon MB. Negative remodeling is an important determinant of lumen compromise in the aorto-ostial location: intravascular ultrasound analysis of coronary and renal artery atherosclerosis. *J Am Coll Cardiol* 2000;35:59A.
344. Dangas G, Laird JR, **Mehran R**, Gruberg L, Ahmed JM, Purush A, Pappas CK, Okubagzi P, Astatkie M, Bui A, Curry B, McCarthy N, Leon MB. Late clinical outcomes after renal artery stenting in patients with renal insufficiency and uncontrolled hypertension. *J Am Coll Cardiol* 2000;35:68A.
345. **Mehran R**, Dangas G, Gruberg L, Lansky AJ, Okubagzi P, Astatkie M, Purush A, Desai K, Kupper F, Faraj H, Kent KM, Stone GW, Leon MB. The detrimental impact of chronic renal insufficiency and diabetes mellitus on late prognosis after percutaneous coronary interventions. *J Am Coll Cardiol* 2000;35:73A.
346. Fuchs S, Kornowski R, **Mehran R**, Satler LF, Hong MK, Slack S, Stone GW, Leon MB. The deleterious prognostic impact of cardiac troponin I re-elevation following percutaneous coronary intervention in patients with acute coronary syndromes. *J Am Coll Cardiol* 2000;35:75A.
347. Kornowski R, Fuchs S, **Mehran R**, Satler LF, Pichard AD, Kent KM, Slack S, Hong MK, Stone GW, Leon MB. Prognostic value of recurrent episodes of CK-MB elevation following repeated catheter-based coronary interventions. *J Am Coll Cardiol* 2000;35:75A.
348. **Mehran R**, Lansky AJ, Waksman R. Gamma radiation vs. placebo in focal vs. diffuse in-stent restenosis: the length makes the difference. *J Am Coll Cardiol* 2000;35:82A.
349. Waksman R, Bhargava B, McCarthy N, White L, Satler LF, **Mehran R**, Kent KM, Pichard AD, Leon MB. Compassionate use of intracoronary gamma radiation therapy for patients with refractory in-stent restenosis. *J Am Coll Cardiol* 2000;35:82A.
350. Mintz GS, Bhargava B, **Mehran R**, Waksman R, Folescu M, Lansky AJ, Pichard AD, Leon MB. Does "stent-on-stent" for in-stent restenosis exaggerate intimal hyperplasia? A volumetric intravascular ultrasound analysis. *J Am Coll Cardiol* 2000;35:84A.
351. Dangas G, Laird JR, **Mehran R**, Weissman NJ, Satler LF, Lansky AJ, Parsons EM, Monsein LH, Mintz GS, Leon MB. Carotid stenting in symptomatic versus asymptomatic patients. Acute and long-term clinical outcomes. *J Am Coll Cardiol* 2000;35:86A.
352. Mintz GS, **Mehran R**, Lansky AJ, Harrington D, Leiboff B, Kent KM, Leon MB. Increased in-stent restenosis in diabetes is the combination of small vessel size and exaggerated intimal hyperplasia. *J Am Coll Cardiol* 2000; 35:95A.
353. Waksman R, Bhargava B, Taffle M, White RL, Satler LF, **Mehran R**, Kent KM, Pichard AD, Leon MB. Prolonged antiplatelet therapy prevents late thrombosis after radiation therapy in patients with in-stent restenosis. *J Am Coll Cardiol* 2000;35:243A.
354. **Mehran R**, Subramanian V, Mack M, Corso PJ, Pfister A, Dullum MKC, Gill IS, Douville EC, Brunsting T, Matheny R, Magovern, Lansky AJ, Leon MB. Preliminary results from the patency outcomes and economics of MIDCAB (POEM) trial: minimally invasive direct coronary revascularization versus conventional bypass surgery. *J Am Coll Cardiol* 2000;35:340A.
355. **Mehran R**, Pfister A, Dangas G, Dullum MKC, Peterson MA, Hashmi N, Stamou SC, Deible R, Purush A, Stone GW, Leon MB, Corso PJ. Acute and long-term outcomes of minimally invasive direct coronary artery bypass (MIDCAB) surgery. A comparison to single-vessel stenting of the left anterior descending artery. *J Am Coll Cardiol* 2000;35:354A.
356. Stone GW, Lansky AJ, **Mehran R**, Peterson MA, Gruberg L, Dangas G, Desai K, Slack S, Reed R, Proctor B, Leon MB. Beyond TIMI-3 flow: the importance of restored myocardial perfusion for survival in high risk patients undergoing primary or rescue PTCA. *J Am Coll Cardiol* 2000;35:403A.
357. Dangas G, Laird JR, **Mehran R**, Ahmed JM, Lansky AJ, Mintz GS, Pichard AD, Satler LF, Kent KM, Leon MB. Renal artery stenting with intravascular ultrasound guidance: results on 136 consecutive procedures. *Cathet Cardiovasc Interv* 1999;47:120.
358. Dangas G, Laird JR, Gruberg L, Satler LF, Monsein L, **Mehran R**, Mintz GS, Abizaid A, Parsons EM, Lansky AJ, Leon MB. Neurogenic hypotension after carotid stent-supported angioplasty. *Am J Cardiol* 1999;84(Suppl 6A): 18P.
359. Dangas G, Laird JR, Gruberg L, Satler LF, Monsein L, **Mehran R**, Mintz GS, Abizaid A, Parsons EM, Lansky AJ, Leon MB. Carotid stenting in patients with high-risk surgical anatomy. *Am J Cardiol* 1999;84(Suppl 6A):46P.
360. Gruberg L, Dangas G, **Mehran R**, Stone GW, Hong MK, Mintz GS, Waksman R, Kornowski R, Lansky AJ, Ahmed J, Kent KM, Pichard AD, Satler LF, Leon MB. Stenting of the left internal mammary artery graft: angiographic characteristics, in-hospital and long-term outcomes. *Am J Cardiol* 1999;84(Suppl 6A):48P.
361. Fuchs S, Kornowski R, **Mehran R**, Dangas G, Satler LF, Pichard AD, Slack ST, Kent KM, Leon MB. One-year clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary interventions. *Am J Cardiol* 1999;84(Suppl 6A):66P.
362. Gruberg L, Dangas G, **Mehran R**, Van Vorhees LB, Clark C, Stone GW, Hong MK, Mintz GS, Kornowski R, Lansky AJ, Kent KM, Waksman R, Pichard AD, Satler LF, Leon MB. Outcome of critically ill patients with acute renal failure requiring hemodialysis after percutaneous coronary interventions. *Am J Cardiol* 1999;84(Suppl 6A): 71P.
363. Dangas G, Laird J, **Mehran R**, Satler LF, Mintz G, Leon M. Carotid stent supported angioplasty and high risk carotid endarterectomy cases. *Int J Cardiovasc Interv* 1999;2(Suppl 2):30.

364. Laird J, Dangas G, **Mehran R**, Ahmed J, Mintz G, Lansky AJ, Satler LF, Leon M. IVUS guided renal artery stenting. *Int J Cardiovasc Interv* 1999;2(Suppl 2):29.
365. Dangas G, Laird JR, **Mehran R**, Ahmed JM, Mintz GS, Lansky AJ, Pichard AD, Satler LF, Kent KM, Leon MB. Renal artery stenting with intravascular ultrasound guidance. *Eur Heart J* 1999;20(Suppl):364.
366. Ahmed JM, Dangas G, Mintz GS, **Mehran R**, Hong MK, Peterson MA, Laird JR, Satler LF, Kent KM, Leon MB. Baseline remodeling of native de novo coronary lesions is predictive of target lesion revascularization after stent implantation. *Eur Heart J* 1999;20:368.
367. Ahmed JM, Hong MK, **Mehran R**, Larrain G, Kent K, Pichard AD, Satler LF, Mintz GS, Stone GW, Leon MB. Comparison of debulking plus stenting versus stenting alone for aorto-ostial saphenous vein graft lesions: immediate and late clinical outcome. *Eur Heart J* 1999;20(Suppl):387.
368. **Mehran R**, Dangas G, Peterson MA, Ahmed JM, Hong MK, Satler LF, Kent KM, Stone GW, Leon MB. Stenting of territories with prior coronary bypass grafts: should the target be the vein graft or the native vessel? *Eur Heart J* 1999;20(Suppl):388.
369. **Mehran R**, Dangas G, Mintz GS, Peterson MA, Ahmed JM, Pichard AD, Satler LF, Kent KM, Leon MB. Treatment of diffuse in-stent restenosis: short and long-term results of excimer laser angioplasty versus rotational coronary atherectomy. *Eur Heart J* 1999;20 (Suppl):509.
370. Ahmed JM, Hong MK, **Mehran R**, Peterson MA, Dangas G, Kent KM, Pichard AD, Mintz GS, Stone GW, Leon MB. Influence of diabetes in saphenous vein graft stenting: immediate and late outcomes. *Eur Heart J* 1999;20 (Suppl):607.
371. Lansky AJ, Stone GW, **Mehran R**, Hanzel G, Summers N, Bui AB, Morice MC, Mattos L, Cox D, Leon MB, Grines CL. Impact of vessel size and lesion length on outcomes after primary stenting versus angioplasty in acute myocardial infarction: results from Stent PAMI. *Eur Heart J* 1999;20(Suppl):615.
372. Waksman R, White LR, Chan RC, **Mehran R**, Bhargava B, Lansky AJ, Pichard AD, Stone GW, Leon MB. Intracoronary beta radiation therapy for patients with in-stent restenosis: the 6 month clinical and angiographic results. *Circulation* 1999;100 (Suppl I): I-75.
373. **Mehran R**, Waksman R, Chan RC, Gruberg L, Bhargava B, Murphy M, Kent KM, White LR. Diabetic patients with in-stent restenosis respond favorably to gamma radiation therapy: results from a randomized clinical trial. *Circulation* 1999;100(Suppl I):I-138-39.
374. Waksman R, **Mehran R**, Chan RC, Murphy M, Stone GW, Duncan CC, Satler LF, Kent KM, Geirlach LM, White LR. One year follow-up after intracoronary gamma radiation therapy for in-stent restenosis: results from a randomized clinical trial. *Circulation* 1999;100(Suppl I):I-154.
375. Waksman R, **Mehran R**, Bhargava B, Chan RC, Lansky AJ, Geirlach LM, Stone GW, Leon MB. Recurrent restenosis after "failed" intra-coronary radiation therapy: angiographic patterns and predictors. *Circulation* 1999; 100(Suppl I):I-222.
376. Waksman R, Bhargava B, Chan RC, **Mehran R**, Geirlach LM, Gruberg L, Stone GW, Leon MB. Late total occlusions following intracoronary radiation therapy for patients with in-stent restenosis. *Circulation* 1999;100 (Suppl I):I-222.
377. **Mehran R**, Gruberg L, Negoita M, Faraj H, El Sayyad SM, Curry B, Hong MK, Kent KM. Repeat stenting for treatment of in-stent restenosis: selective therapy vs. complete lesion coverage? *Circulation* 1999;100 (Suppl I): I-307.
378. Dangas G, **Mehran R**, Peterson MA, Duncan CC, Paliou MN, Purush A, Hong MK, Stone GW. Combination antiplatelet therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention subacute thrombosis after native coronary stent implantation. *Circulation* 1999;100(Suppl I):I-379.
379. Mahoney EM, Thompson TD, Veledar E, Chu H, Satler LF, **Mehran R**. In-hospital mortality in 11,029 stable patients undergoing PTCA in 1998: results from the National Cardiovascular Network (NCN). *Circulation* 1999; 100 (Suppl I): I-393-94.
380. Limpijankit T, **Mehran R**, Waksman R, Lee DP, Lansky AJ, Mintz GS, Yock PG, Fitzgerald PJ. The effect of <sup>192</sup>Ir-radiation on in-stent restenosis: an intravascular ultrasound volumetric analysis. *Circulation* 1999;100 (Suppl I):I-413.
381. Dangas G, **Mehran R**, Peterson MA, Modi N, Bui H, Brahimi A, Wu H, Laird JR, Pichard AD. Post-procedure CKMB enzyme elevation and baseline left ventricular dysfunction are additive predictors of late mortality after percutaneous coronary intervention. *Circulation* 1999;100(Suppl I):I-779-80.
382. Ahmed JM, Hong MK, **Mehran R**, Kent KM, Pichard AD, Satler LF, Greenberg A, Deforty D, Slack S, Wu H, Stone GW, Leon MB. Rescue reopro (abciximab) does not improve periprocedural outcomes in patients undergoing high risk angioplasty of degenerated saphenous vein grafts. *J Am Coll Cardiol* 1999;33:11-12A.
383. Laird JR, Satler LF, Monsein L, Dangas G, **Mehran R**, Lansky AJ, Parsons E, Deible R, Greenberg A, Leon MB. Comparison of results with the Palmaz Stent and wall stent for carotid stent supported angioplasty. *J Am Coll Cardiol* 1999;33(Suppl A):15A.
384. Dangas G, Laird JR, Satler LF, Monsein L, **Mehran R**, Lansky AJ, Peterson M, Slack S, Deible R, Greenberg A, Parsons E, Leon MB. Postprocedural hypotension after carotid stent implantation: incidence and clinical sequelae. *J Am Coll Cardiol* 1999;33 (Suppl A):16A.

385. Laird JR, Satler LF, Monsein L, Dangas G, **Mehran R**, Parsons E, Lansky AJ, Bui AB, Greenberg A, Leon MB. One year outcome following carotid stent supported angioplasty (CSSA). *J Am Coll Cardiol* 1999;33 (Suppl A):21-22A.
386. **Mehran R**, Dangas G, Mintz GS, Hong MK, Lansky AJ, Peterson M, Hanzel G, Laroche A, Slack S, Laird JR, Pichard AD, Kent KM, Satler LF, Stone GW, Leon MB. PTCA alone versus stent alone therapy for focal in-stent restenosis: acute and long-term results. *J Am Coll Cardiol* 1999;33 (Suppl A): 26-27A.
387. Gruberg L, **Mehran R**, Hong MK, Lansky AJ, Pichard AD, Peterson M, Walters CT, Murphy M, Laird JR, Satler LF, Kent KM, Stone GW, Leon MB. Stents do not improve acute and long-term clinical outcomes in patients with chronic renal failure and coronary disease. *J Am Coll Cardiol* 1999;33:28A.
388. Peterson M, Carter A, **Mehran R**, Kornowski R, Golden B, Negoita MA, Pichard AD, Satler LF, Kent KM, Mintz GS, Lansky AJ, Stone GW, Leon MB. Can debulking prior to stenting be justified as standard treatment for right coronary artery ostial lesions? *J Am Coll Cardiol* 1999;33:27-28A.
389. Hong MK, **Mehran R**, Kent KM, Pichard AD, Satler LF, Mintz GS, Wu H, Greenberg A, Slack S, Leon MB. Are we making progress with percutaneous saphenous vein graft treatment? Comparison of 1990-94 and 1995-98 results. *J Am Coll Cardiol* 1999;33 (Suppl A):36A.
390. Bhargava B, Kornowski R, Hong M, Kent KM, Pichard AD, Satler LF, Duncan C, **Mehran R**, Leon MB. Procedural results and late clinical outcomes following multiple saphenous vein graft stenting. *J Am Coll Cardiol* 1999;33 (Suppl A):50A.
391. **Mehran R**, Kornowski R, Dangas G, Lansky AJ, Hong MK, Pichard AD, Laird JR, Satler LF, Kent KM, Stone GW, Leon MB. Multivessel stenting reduces in-hospital complication compared with repeat aortocoronary bypass surgery. *J Am Coll Cardiol* 1999;33(Suppl A):51A.
392. **Mehran R**, Lansky AJ, Hong MK, Dangas G, Kornowski R, Peterson M, Laird JR, Waksman R, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Percutaneous revascularization of patients with prior coronary bypass surgery: saphenous vein graft or native coronary stenting? *J Am Coll Cardiol* 1999;33 (Suppl A):51A.
393. Gruberg L, **Mehran R**, Hong MK, Dangas G, Kornowski R, Laird JR, Peterson M, Satler LF, Pichard AD, Kent KM, Stone GW, Leon MB. Percutaneous revascularization of the internal mammary artery graft: in-hospital and long-term outcome. *J Am Coll Cardiol* 1999;33:51-52A.
394. Waksman R, White RL, Chan RC, Bhargava B, Mintz GS, Gierlach LM, Lansky AJ, Satler LF, **Mehran R**, Kent KM, Pichard AD, Leon MB. Clinical and angiographic outcomes of patients with in-stent restenosis crossing over from placebo to radiation therapy. *J Am Coll Cardiol* 1999;33 (Suppl A):57A.
395. Lansky AJ, Popma JJ, **Mehran R**, Hanzel G, Cutlip D, Ho KK, Proctor B, Happi JA, Kuntz RE, Baim DS, Heuser R, Midei M, O'Shaughnessy C, Leon MB. Tubular slotted stents: a "breakthrough therapy" for women undergoing coronary interventions. Pooled results from the STARS, ACSENT, SMART, and NIRVANA randomized clinical trials. *J Am Coll Cardiol* 1999;33(Suppl A):58A.
396. Hanzel G, Lansky AJ, Popma JJ, **Mehran R**, Curran MJ, George B, Hermiller J, Roubin G, Desai K, Tarawali M, Negoia C, Kerr J, Dean L, Cox D, O'Shaughnessy CD, Leon MB. Patterns of in-stent hyperplasia in the Gianturco-Roubin II compared to the Palmaz-Schatz stents. Results from the GRII randomized clinical trial. *J Am Coll Cardiol* 1999;33(Suppl A):61A.
397. **Mehran R**, Dangas G, Mintz GS, Hong MK, Lansky AJ, Peterson M, Abizaid AS, Ahmed JM, Kornowski R, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Excimer laser vs. rotational atherectomy or the treatment of diffuse in-stent restenosis: acute and long-term results. *J Am Coll Cardiol* 1999;(Suppl A):62A.
398. **Mehran R**, Dangas G, Mintz GS, Waksman R, Hong MK, Abizaid A, Abizaid AS, Kornowski R, Lansky AJ, Laird JR, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB. In-stent restenosis: "The Great Equalizer." Disappointing clinical outcomes with ALL interventional strategies. *J Am Coll Cardiol* 1999;33 (Suppl A):63A.
399. Waksman R, White RL, Chan RC, Bhargava B, Mintz GS, Gierlach LM, Lansky AJ, Satler LF, **Mehran R**, Kent KM, Leon MB. Angiographic patterns of in-stent restenosis lesions that failed radiation therapy. *J Am Coll Cardiol* 1999;33 (Suppl A):63A.
400. Kornowski R, **Mehran R**, Lansky AJ, Fuchs S, Satler LF, Curry B, Pichard AD, Kent KM, Greenberg A, Leon MB. Procedural results and late clinical outcomes following percutaneous interventions using long ( $\geq 25$ mm) stents. *J Am Coll Cardiol* 1999;33 (Suppl A):69A.
401. **Mehran R**, Mintz GS, Dangas G, Hong MK, Peterson M, Kornowski R, Lansky AJ, Kent KM, Pichard AD, Satler LF, Stone GW, Leon MB. One year follow-up after intravascular ultrasound guided coronary stenting of 2075 lesions. *J Am Coll Cardiol* 1999;33 (Suppl A):74A.
402. Stone GW, **Mehran R**, Lansky AJ, Mintz GS, Greenberg A, Slack S, Kornowski R, Hong MK, Laird JR, Satler LF, Kent KM, Pichard AD, Leon MB. Long-term influence of CPK-MB elevation on mortality after percutaneous intervention: analysis of 7359 patients. *J Am Coll Cardiol* 1999;33 (Suppl A):80A.

403. Stone GW, **Mehran R**, Lansky AJ, Slack S, Greenberg A, Mintz GS, Kornowski R, Hong MK, Laird JR, Satler LF, Kent KM, Pichard AD, Leon MB. What is the clinical significance of an elevated CPK-MB band fraction after percutaneous intervention if the total CPK is normal? *J Am Coll Cardiol* 1999;33 (Suppl A):80A.
404. Dangas G, Mintz GS, **Mehran R**, Kornowski R, Lansky AJ, Hong MK, Peterson M, Keers B, Pichard AD, Laird JR, Satler LF, Kent KM, Leon MB. Pre-intervention arterial remodeling: a new risk factor for restenosis after non-stent coronary interventions. *J Am Coll Cardiol* 1999;33 (Suppl A):86A.
405. Lansky AJ, **Mehran R**, Popma JJ, Hanzel G, Kent KM, Stone GW, Breedy F, Teperdei G, Burwell N, Pichard AD, Satler LF, Leon MB. Insulin treatment of diabetic women predicts a worse outcome after intracoronary stenting. clinical results of 564 consecutive patients. *J Am Coll Cardiol* 1999;33 (Suppl A):97A.
406. **Mehran R**, Lansky AJ, Dangas G, Hanzel G, Ahmed JM, Byrne M, Peterson M, Stone GW, Kent KM, Pichard AD, Satler LF, Leon MB. The impact of diabetes on the outcomes after treatment of in-stent restenosis. *J Am Coll Cardiol* 1999;33(Suppl A):98A.
407. Abizaid AS, Mintz GS, **Mehran R**, Satler LF, Pichard AD, Walsh CL, Greenberg A, Abizaid A, Slack S, Laroche V, Kent KM, Leon MB. One year follow-up of 300 patients after coronary intervention was deferred based on intravascular ultrasound findings. *J Am Coll Cardiol* 1999;33(Suppl A):100A.
408. Brodie BR, Stone GW, Morice MC, Cox DA, Garcia E, Mattos L, Boura J, O'Neill W, Stuckey TD, Milks S, **Mehran R**, Leon MB, Grines CL. Importance of time to reperfusion on outcomes after primary PTCA for acute myocardial infarction: results from stent PAMI. *J Am Coll Cardiol* 1999;33(Suppl A):353A.
409. Stone GW, Marcovitz P, Lansky AJ, Griffin J, **Mehran R**, Morice MC, Cox D, Garcia E, Brodie B, Mattos L, Leon MB, Boura J, O'Neill W, Grines CL. Differential effects of stenting and angioplasty in women versus men undergoing a primary mechanical reperfusion strategy in acute myocardial infarction-the PAMI stent randomized trial. *J Am Coll Cardiol* 1999;33(Suppl A):357A.
410. Stone GW, Morice MC, Cox D, Garcia E, Brodie B, Mattos L, St. Goar FG, Griffin J, **Mehran R**, Leon MB, Boura J, O'Neill W, Grines CL. Outcomes of bail-out stenting after failed primary angioplasty in acute myocardial infarction-analysis from the PAMI stent trial. *J Am Coll Cardiol* 1999;33 (Suppl A):361A.
411. Stone GW, Morice MC, Lansky AJ, Cox DA, Garcia E, Brodie Bruce, Mattos L, Griffin J, Leon MB, **Mehran R**, Boura J, O'Neill W, Grines CL. Routine stent implantation reduces restenosis after primary angioplasty in acute myocardial infarction: results from the PAMI stent randomized trial. *J Am Coll Cardiol* 1999;33 (Suppl A):361A.
412. Lansky AJ, Stone GW, **Mehran R**, Pompa JJ, Hanzel G, Summers N, Bui AB, Satler LF, Mattos L, Morice MC, Cox DA, Leon MB, Grines CL. Impact of baseline TIMI flow on outcomes after primary stenting versus primary PTCA in acute myocardial infarction. Results from PAMI stent. *J Am Coll Cardiol* 1999;33 (Suppl A):368A.
413. Stone GW, Morice MC, Cox DA, Garcia E, Brodie B, Mattos L, Griffin J, **Mehran R**, Leon MB, Boura J, O'Neill W, Grines CL. Predictors of six month event-free survival after mechanical reperfusion in acute myocardial infarction: the PAMI stent randomized trial. *J Am Coll Cardiol* 1999;33 (Suppl A):379A.
414. Cox DA, Stone GW, Niess GS, Brodie B, Garcia E, Mattos L, Lansky AJ, **Mehran R**, O'Neill W, Leon MB, Morice MC, Grines CL. Does "stent-like" primary PTCA in acute myocardial infarction confer long-term freedom from restenosis similar to primary stenting? Analysis from the PAMI stent randomized trial. *J Am Coll Cardiol* 1999;33(Suppl A):382A.
415. **Mehran R**, Pfister A, Corso P, Dullum, Dangas G, Lansky AJ, Hong MK, Greenberg A, Deible R, Pichard AD, Satler LF, Kent KM, Stone GW, Leon MB. Minimally invasive direct coronary artery bypass (MIDCAB): have we reached the plateau of the learning curve? *J Am Coll Cardiol* 1999;33 (Suppl A):551A.
416. Abizaid A, Mintz GS, **Mehran R**, Abizaid AS, Lansky AJ, Leiboff B, Weinberg NM, Morgan K, Satler LF, Leon MB. Stent design determines final ultrasound results: a matched comparison of 769 native lesions. *Circulation* 1998;98 (Suppl I): I-229.
417. Abizaid A, **Mehran R**, Abizaid AS, Leiboff B, Pappas C, Walsh CL, Ezibe M, Kent KM. Clinical, angiographic, and intravascular ultrasound predictors of target lesion revascularization in >1000 consecutive patients with native vessel lesions treated with Palmaz-Schatz stents. *Circulation* 1998;98 (Suppl I): I-229-30.
418. Hong MK, **Mehran R**, Satler LF, Wu H, Slack S, Greenberg A, Abizaid AS, Kent KM, Leon MB. Long-term clinical results and predictors after successful stent implantation in saphenous vein grafts. *Circulation* 1998;98 (Suppl I):I-286.
419. Tanguay JF, Wilensky RL, Weismann NJ, Bartorelli AL, **Mehran R**, Williams DO, Bucher TA, Wu H, Popma JJ, Kaplan AV. Clinical and intravascular ultrasound predictors of intimal hyperplasia after stenting in the HIPS trial. *Circulation* 1998;98(Suppl I):I-435.
420. **Mehran R**, Mintz GS, Hong MK, Abizaid AS, Lansky AJ, Parker M, Prunka N, Kent KM, Leon MB. Clinical, procedural, angiographic, and intravascular ultrasound predictors (and sequelae) of CK-MB rise (>5x normal) following catheter-based interventions. *Circulation* 1998;98 (Suppl I): I-496.
421. Waksman R, White LR, Chan RC, Porrado MS, Bass BG, Satler LF, Kent KM, Geirlach LM, **Mehran R**, Murphy M, Mintz GS, Leon MB. Intracoronary radiation therapy for patients with in-stent restenosis: 6 month follow-up of a randomized clinical study. *Circulation* 1998;98(Suppl I):I-651.

422. **Mehran R**, Mintz GS, Laird JR, Kent KM, Pichard AD, Satler LF, Popma JJ, Walsh CL, Ezibe M, Leon MB. The “pathology” of renal artery stenosis: an intravascular ultrasound study. *J Am Coll Cardiol* 1998;31:2(Suppl):1024-1072.
423. Laird JR, **Mehran R**, Satler LF, Popma JJ, Greenberg A, Bucher T, Altmeyer C, Mastoor M, Leon MB. Primary stent deployment for obstructive lesions of the subclavian or innominate artery. *J Am Coll Cardiol* 1998;31:2, Suppl:1024-75.
424. Abizaid AS, Popma JJ, Lansky AJ, **Mehran R**, Saucedo J, Ho K, Kuntz RE, Leon MB. The clinical impact of side branch occlusion and side branch narrowing after elective coronary stent placement in STARS. *J Am Coll Cardiol* 1998;31(2 Suppl):1005-84.
425. **Mehran R**, Mintz GS, Abizaid A, Kent KM, Pichard AD, Satler LF, Walsh CL, Popma JJ, Leon MB. Mechanistic comparison of rotational atherectomy and excimer laser angioplasty in the treatment of in-stent restenosis: a volumetric intravascular ultrasound study. *J Am Coll Cardiol* 1998;31(2 Suppl):1035-61.
426. Tebeica M, Mastoor M, Plude R, **Mehran R**, Pinnow E, Slack S, Bucher T, Popma JJ, Pichard AD, Lindsay J. Stent use in internal mammary graft angioplasty: a 4-year experience. *J Am Coll Cardiol* 1998;31(2 Suppl):1032-1081.
427. Mastoor M, **Mehran R**, Laird JR, Popma JJ, Lansky AJ, Pfister A, Corso P, Pichard AD, Satler LF, Hong KM, Kent KM, Leon MB. Angiographic findings after minimally invasive coronary bypass operation: an angiographic study. *J Am Coll Cardiol* 1998;31(2Suppl):813-4.
428. **Mehran R**, Ito S, Abizaid A, Abizaid AS, Lansky AJ, Popma JJ, Pichard AD, Satler LF, Kent KM, Leon MB. Does lesion length affect late outcome of patients with in-stent restenosis? Results of the multicenter laser angioplasty for stent restenosis (LARS) registry. *J Am Coll Cardiol* 1998;31:2, Suppl(1061-62).
429. **Mehran R**, AbizaidAS, Mintz GS, Kent KM, Pichard AD, Satler LF, Popma JJ, Leon MB. Patterns of in-stent restenosis: classification and impact on subsequent target lesion revascularization. *J Am Coll Cardiol* 1998;31:2, Suppl. (1060-85).
430. **Mehran R**, Popma JJ, Baim DS, Lansky AJ, Abizaid AS, Saucedo JF, Kent KM, Satler LF, Pichard AD, Kuntz RE, Ho K, Leon MB. Routine high pressure post-stent dilatation did not influence clinical restenosis in STARS. *J Am Coll Cardiol* 1998;31:2, Suppl.(821-1).
431. Lansky AJ, Popma JJ, **Mehran R**, Saucedo JF, Abizaid AS, O’Shaughnessy CO, Hermiller JB, Cutlip D, Kuntz RE, Baim DS, Leon MB. Late quantitative angiographic results after NIR stent use: results from the NIRVANA randomized trial and registries. *J Am Coll Cardiol* 1998; 31:2, Suppl (821-5).
432. Lansky AJ, Peterson Ed, Popma JJ, Anstrom KJ, Chonos N, **Mehran R**, Satler LF, Leon MB. Gender differences in device selection and procedural outcome: a national cardiovascular network (NCN) report. *J Am Coll Cardiol* 1998; 31:2, Suppl. (1086-82).
433. AbizaidAS, Popma JJ, **Mehran R**, Abizaid A, Clark CE, Pichard AD, Kent KM, Satler LF, Leon MB. Coronary stenting in the elderly: early in-hospital and long-term clinical outcomes. *J Am Coll Cardiol* 1998; 31:2, Suppl. (1086-84).
434. Saucedo JF, Popma JJ, **Mehran R**, Bucher T, Abizaid AS, Mastoor M, Mintz G, Kent KM, Pichard AD, Satler LF, Wu HS, Leon MB. Clinical outcomes of patients with low left ventricular ejection fraction undergoing intracoronary stenting. *J Am Coll Cardiol* 1998; 31:2, Suppl. (1086-88).
435. Tebeica M, Mastoor M, **Mehran R**, Plude G, Pinnow E, Slack S, Bucher T, Popma JJ, Pichard AD, Lindsay J. Internal mammary artery graft angioplasty: a single center experience. *J Am Coll Cardiol* 1998; 31:2, Suppl. (1112-78).
436. Hong MK, **Mehran R**, Kent KM, Pichard AD, Satler LF, Popma JJ, Mintz GS, Wu H, Bucher T, Greenberg A, Morgan K, Weaver T, Leon MB. Delayed time course of target lesion revascularization following saphenous vein graft angioplasty. *J Am Coll Cardiol* 1998; 31:2, Suppl. (1112-83).
437. Waksman R, **Mehran R**, Saucedo JF, Pichard AD, Satler LF, Kent KM, Popma JJ, Leon MB. Balloon PTCA is equivalent to stents in patients with small coronaries: a comparative retrospective matching study. *J Am Coll Cardiol* 1998; 31:2, Suppl. (1112-86).
438. Abizaid AS, Popma JJ, Abizaid A, **Mehran R**, Saucedo JF, Lansky AJ, Pichard AD, Satler LF, Kent KM, Leon MB. Comparison of early and late clinical events in coiled vs. tubular slotted stents. *J Am Coll Cardiol* 1998; 31:2, Suppl.(1137-80).
439. Saucedo JF, Popma JJ, **Mehran R**, Bucher T, Abizaid AS, Curran M, Mastoor M, Kent KM, Pichard AD, Satler LF, Leon MB. Lack of association of intermediate CPK-MB elevation and late mortality in patients treated with intracoronary stents. *J Am Coll Cardiol* 1998; 31:2, Suppl. (860-1).
440. Waksman R, White RL, Chan RC, Gierlach LM, Bass BG, Satler LF, **Mehran R**, Porrizzo M, Kent KM, Pichard AD, Popma JJ, Mintz GS, Leon MB. Intracoronary radiation therapy for patients with in-stent restenosis. Interim report from a randomized clinical study. *J Am Coll Cardiol* 1998; 31:2, Suppl. (865-1).
441. Hoffman R, Mintz GS, **Mehran R**, Kent KM, Pichard AD, Satler LF, Walsh CL, Popma JJ, Leon MB. Intimal hyperplasia thickness is independent of stent size: a serial intravascular ultrasound study. *J Am Coll Cardiol* 1998;31:2, Suppl. (881-5).
442. Abizaid A, Mintz GS, Oljaca B, Kent KM, Satler LF, Pichard AD, Wu H, **Mehran R**, Popma JJ, Leon MB. Predictors of target lesion revascularization in diabetic patients treated with Palmaz-Schatz stents. *J Am Coll Cardiol* 1998;31:2, Suppl. (1188-85).
443. **Mehran R**, Abizaid AS, Mintz GS, Abizaid A, Lansky AJ, Kent KM, Satler LF, Pichard AD, Bucher T, Popma JJ, Leon MB. Mechanisms and results of additional stent implantation to treat focal in-stent restenosis. *J Am Coll Cardiol* 1998;31:2, Suppl. (1188-88).

444. Hoffman R, Mintz GS, **Mehran R**, Kent KM, Pichard AD, Satler LF, Oljaca B, Ezibe M, Popma JJ, Leon MB. Predictors of intimal hyperplasia accumulation within Palmaz-Schatz stents: a serial quantitative angiographic and intravascular ultrasound study. *J Am Coll Cardiol* 1998;31:2, Suppl. (896-4).
445. Thompson C, **Mehran R**, Lansky AJ, Popma JJ, Kent KM, Satler LF, Pichard AD, Leon MB. The effect of height on vascular events after percutaneous intervention. *J Am Coll Cardiol* 1998;31:2, Suppl. (1234-51).
446. Waksman R, **Mehran R**, Saucedo JF, Abizaid A, Wu H, Mastoor M, Pichard AD, Satler LF, Kent KM, Leon MB. Does the RCA differ from the LAD after coronary stenting? *J Am Coll Cardiol* 1998; 31:2, Suppl. (1215-100).
447. Abizaid A, Lefevre T, Lansky AJ, Mintz GS, Oljaca B, Simon M, Dumas P, Pichard AD, **Mehran R**, Popma JJ, Morice MC. Is the response to high pressure adjunct PTCA stent design specific? A sequential intravascular ultrasound study. *J Am Coll Cardiol* 1998;31:2, Suppl. (1215-104).
448. Dangas G, **Mehran R**, Sharma SK, Ambrose JA, Meraj P, Harpel PC, Fallon JT. Association between lipoprotein Lp(a), macrophages, and vascular smooth muscle cells in human coronary atheroma. *J Am Coll Cardiol* 1998;31:5, Suppl. C (24C).
449. **Mehran R**, Abizaid A, Abizaid AS, Saucedo JF, Popma JJ, Mintz G, Kent KM, Satler LF, Pichard AD, Leon MB. Patterns of in-stent restenosis: classification and incidence. *J Am Coll Cardiol* 1998;31:5, Suppl C (309C).
450. Abizaid AS, Popma JJ, Saucedo JF, Lansky AJ, **Mehran R**, Abizaid A, Ito S, Ho K, Kuntz RE, Leon MB. Acute and late clinical outcome of bifurcation lesions treated with elective coronary stents: results from the STARS trial. *J Am Coll Cardiol* 1998;31:5, Suppl C (310C).
451. Abizaid AS, Clark CE, Popma JJ, Abizaid A, **Mehran R**, Saucedo JF, Kent KM, Pichard AD, Satler LF, Leon MB. Unstable angina continues to be an important predictor of early and late outcome after coronary intervention in the new device angioplasty era. *J Am Coll Cardiol* 1998;31:5, Suppl C (310C).
452. Abizaid AS, Clark CE, **Mehran R**, Lansky AJ, Popma JJ, Satler LF, Pichard AD, Kent KM, Leon MB. Intracoronary stents equalize the clinical restenosis rates in patients with chronic renal insufficiency. *J Am Coll Cardiol* 1998;31:5, Suppl C (310C).
453. Abizaid A, Waksman R, **Mehran R**, Oljaca B, Mintz G, Abizaid AS, Kent KM, Satler LF, Pichard AD, Leon MB. An ultrasound-dosimetry analysis for prescription of intracoronary radiation therapy. *J Am Coll Cardiol* 1998;31:5, Suppl C (310C-311C).
454. Lansky AJ, Popma JJ, Abizaid AS, **Mehran R**, Ito S, Kent KM, Cutlip D, Senercia C, Kuntz R, Leon MB. Procedural and late outcome of stenting in women. Results of the STARS randomized trial and registry. *J Am Coll Cardiol* 1998;1:5, Suppl C (311C).
455. Lansky AJ, Popma, **Mehran R**, Saucedo JF, Abizaid AS, Satler LF, Pichard AD, Hong M, Kent KM, Leon MB. Impact of atheroablation prior to stenting in native coronary arteries: clinical and angiographic outcomes in 1354 consecutive patients. *J Am Coll Cardiol* 1998;31:5, Suppl C (311C-312C).
456. **Mehran R**, Hong MK, Calaburg JN, Esfandiari NH, Keers B, Kent KM. Long-term clinical follow-up after successful recanalization of chronic total occlusions. *Circulation* 1997; 96:8, Suppl I:1491.
457. **Mehran R**, Hong MK, Lansky AJ, Brennan J, Morgan K, Weaver T, Wu H, Pichard AD. Vessel size and lesion length influence late clinical outcomes after native coronary artery stent placement. *Circulation* 1997;96(8),Suppl I:1520.
458. **Mehran R**, Abizaid AS, Hoffman RH, Bucher TA, Proctor B, Conway TY, Satler LF. Clinical and angiographic predictors of target lesion revascularization after stent placement in native coronary lesions. *Circulation* 1997; 96:8(Suppl I):2637.
459. Baim DS, Cutlip DE, Zhang Y, **Mehran R**, Abizaid AS, Fitzpatrick M. Characteristics and predictors of stent thrombosis from the stent anticoagulation regimen study (STARS). *Circulation* 1997;96:8(Suppl I):3655.
460. **Mehran R**, Hong MK, Mintz GS, Abizaid A, Dinger ML, Walsh CL, Hoeg JM. Impaired adaptive arterial remodeling and reduced coronary flow reserve in familial hypercholesterolemia: a combined intravascular ultrasound and physiologic assessment study. *Circulation* 1997;96:8(Suppl I):4057.
461. Abizaid AS, **Mehran R**, Saucedo J, Popma JJ, Abizaid A, Lansky A, Pichard AD, Kent KM, Satler LF, Mastoor M, Hashmi N, Duncan C, Leon MB. Small vessel stenting is associated with high event rate at late follow-up. *Am J Cardiol* 1997;80:7A.
462. Lansky AJ, **Mehran R**, Popma JJ, Abizaid AS, Mintz, Satler LF, Pichard AD, Kent KM, Bucher TA, Greenbert A, Leon MB. Predictors of procedural and late outcome after new device angioplasty in women. *Am J Cardiol* 1997; 80:7A.
463. Abizaid A, Mintz GS, Abizaid AS, **Mehran R**, Marconi J, Pichard AD, Kent KM, Satler LF, Popma JJ, Leon MB. Anatomic determinants of the coronary flow reserve: a correlation of Doppler velocimetric, intravascular ultrasound and quantitative angiographic measurements. *Am J Cardiol* 1997;80:7A.
464. **Mehran R**, Abizaid AS, Abizaid A, Mastoor M, Lansky AJ, Popma JJ, Mintz GS, Hong MK, Satler LF, Pichard AD, Kent KM, Laird JR, Waksman R, Bucher T, Greenberg, Hashmi N, Duncan C, Leon MB. Rotational atherectomy for the treatment of in-stent restenosis: long-term outcome compared to balloon angioplasty alone. *Am J Cardiol* 1997;80:7A.
465. Abizaid AS, Popma JJ, Clark C, **Mehran R**, Abizaid AS, Pichard AD, Satler LF, Kent KM, Greenberg A, Bucher T, Leon MB. Prophylactic versus rescue ReoPro in patients with complex or complicated coronary intervention. *Am J Cardiol* 1997;80:7A.
466. Ito S, Popma JJ, Lansky AJ, Laird JR, Abizaid AS, **Mehran R**, Saucedo JF, Pichard AD, Kent KM, Satler LF, Thompson C, Leon MB. Angiographic results with pullback atherectomy catheter: results of two multicenter registries. *Am J Cardiol* 1997;80:7A.

467. Abizaid A, **Mehran R**, Abizaid AS, Mintz GS, Popma JJ, Hong MK, Laird JR, Waksman R, Satler LF, Pichard AD, Kent KM, Bucher T. Adjunct stent therapy improves procedural results and late clinical outcomes in patients after rotational atherectomy. *Am J Cardiol* 1997;80:7A.
468. Thompson C, Ito S, Popma JJ, Lansky AJ, **Mehran R**, Abizaid AS, Saucedo J, Mooney MR, Hartman C, Jakubov SJ, Cannon LA, Baim DS, Leon MB. High pressure post-stent dilation with the 15mm NC bandit balloon catheter: results of the bandit registry. *Am J Cardiol* 1997;80:7A.
469. Laird JR, Satler LF, Pompa JJ, Mintz GS, Lansky AJ, Horton K, Cabellon S, Deible R, **Mehran R**, Prunka N, Leon MB. Procedural results and early clinical outcomes after carotid stent-supported angioplasty in high-risk patients. *Eur Heart J* 1997;18(Suppl):11.
470. Abizaid A, **Mehran R**, Mintz GS, Popma JJ, Hariri M, Ito S, Hong MK, Satler LF, Kent KM, Pichard AD, Leon MB. Adjunct stent therapy improves procedural results and late clinical outcomes in patients after rotational atherectomy. *Eur Heart J* 1997;18(Suppl):120.
471. Dangas G, **Mehran R**, Sharma SK, Harpel PC, Ambrose JA, Fallon JT. Macrophage infiltration in human coronary atheroma is predominantly detected in lipoprotein Lp(a) areas. Histopathologic analysis of atherectomy specimens. *Eur Heart J* 1997;18:487.
472. **Mehran R**, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, Bucher T, Leon MB. Morphologic and procedural predictors of diffuse in-stent restenosis. *J Am Coll Cardiol* 1997;29(2):76A.
473. **Mehran R**, Mintz GS, Popma MK, Hong MK, Laird JR, Satler LF, Kent KM, Pichard AD, Abizaid RA, DeForty DD, Donovan KM, Greenberg A, Leon MB. Treatment of in-stent restenosis: an intravascular ultrasound study of results in 159 stented lesions. *J Am Coll Cardiol* 1997;29(Suppl A):77A.
474. Abizaid A, **Mehran R**, Bucher TA, Greenberg A, Popma JJ, Mintz GS, Hong MK, Pichard AD, Kent KM, Satler LF, Leon MB. Does diabetes influence clinical recurrence after coronary stent implantation? *J Am Coll Cardiol* 1997;29:77A.
475. Kornowski R, Mintz GS, **Mehran R**, Pichard AD, Kent KM, Satler LF, Popma JJ, Hong MK, Laird JR, Bucher TA, Purkayastha, Leon MB. The "full-metal jacket" procedural results and late clinical outcomes after placement of three or more coronary stents. *J Am Coll Cardiol* 1997;29:188A.
476. Abizaid A, **Mehran R**, Pichard AD, Mintz GS, Popma JJ, Satler LF, Kent DM, MacKenzie J, Brennan JJ. Results of high pressure ultrasound-guided "over-sized" balloon PTCA to achieve "stent-like" results. *J Am Coll Cardiol* 1997;29:280A.
477. Laird JR, Satler LF, Popma JJ, Mintz GS, Lansky AJ, Horton K, Cabellon S, Deible R, **Mehran R**, Prunka N, Leon MB. Procedural results and early clinical outcomes after carotid stent-supported angioplasty in high-risk patients. *J Am Coll Cardiol* 1997;29(2):362A.
478. Hoffmann R, Mintz GS, **Mehran R**, Kent KM, Pichard AD, Satler LF, Popma JJ, Laird JR, Bucher TA, Bucher G, Leon MB. Late tissue proliferation both within and surrounding Palmaz-Schatz stents is associated with procedural vessel wall injury. *J Am Coll Cardiol* 1997;29(2):397A.
479. **Mehran R**, Bucher TA, Lansky AJ, Popma JJ, Mintz GS, Hong MK, Laird JR, Satler LF, Kent KM, Pichard AD, Summers NV, Wang B, Leon MB. Coronary stenting in women: early in-hospital and long-term clinical outcomes. *J Am Coll Cardiol* 1997;29(2):454A.
480. **Mehran R**, Popma JJ, Mintz GS, Hong MK, Laird LR, Satler LF, Kent KM, Pichard AD, Bucher TA, Kleiber B, Yeung S, Leon MB. A comparative analysis of clinical outcomes in 2268 patients undergoing "optimal" directional atherectomy or "optimal" stenting. *J Am Coll Cardiol* 1997;29(2):457A.
481. Lansky AJ, Kennard E, Yeung SE, **Mehran R**, Popma JJ, Harvey G, Summers NV, Conway T, Russo S, Leon MB, Robertson T, Detre K. Does gender affect outcome in the new approaches to coronary intervention (NACI) registry. *J Am Coll Cardiol* 1997;29(2):458A.
482. **Mehran R**, Mintz GS, Popma JJ, Laird JR, Satler LF, Kent KM, Pichard AD, Leon MB. Mechanisms of lumen enlargement during atheroablation of in-stent restenosis: a volumetric ultrasound analysis. *J Am Coll Cardiol* 1997;29:497A.
483. Sharma SK, Dangas G, **Mehran R**, Duvvuri S, Ambrose JA. Rest angina and use of  $\beta$ -blockers prior to rotational atherectomy are strong predictors of slow flow. *Eur Heart J* 1996;17(Suppl)195:174.
484. **Mehran R**, Dangas G, Sharma SK, Dube G, Harpel PC, Ambrose JA, Fallon JT. Quantitation of lipoprotein(a) in atherosclerotic plaques. A histologic study of atherectomy. *Eur Heart J* 1996;17 (Suppl)195:193.
485. Sharma-SK, Duvvuri S, **Mehran R**, Dangas G, Lotvin A, Kuthuru M, Cohen AM, Marmur JD, Cocke T, Ambrose JA. What are the best predictors of slow flow after rotational atherectomy? *J Inv Cardiol* 1996;8:36.
486. Dangas G, **Mehran R**, Duvvuri S, Cocke TP, Ambrose JA, Sharma SK. Use of the femostop system as an alternative to surgical repair of femoral artery pseudoaneurysm. *Cathet Cardiovasc Diagn* 1996;38:120.
487. **Mehran R**, Mintz GS, Bucher TA, Greenberg A, Satler LF, Hong MK, Kent KM, Griffin J, Pichard AD. Aorto-ostial in-stent restenosis: mechanisms, treatment, and results. A serial quantitative angiographic and intravascular ultrasound study. *Circulation* 1996;94:1165.

488. **Mehran R**, Mintz GS, Pichard AD, Satler LF, Hong MK, Hoffman R, DeForty D, Morgan C, Griffin J, Leon MB. Impact of vessel wall injury on in-stent restenosis: a serial quantitative angiographic and intravascular ultrasound study. *Circulation* 1996;94(8):1535.
489. Hong MK, Kent KM, Satler LF, Wong SC, Buchler T, **Mehran R**, Donovan K, Pichard AD. Are long-term results different when stents are used in de novo versus restenotic lesions? *Circulation* 1996;94(8):1927.
490. Hong MK, Kent KM, **Mehran R**, Tio FO, Foegh M, Wong SC, Cathapermal S, Bramsell O, Leon MB. Continuous subcutaneous angiopeptin reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model. *Circulation* 1996;94(8):3634.
491. Hong MK, Wong SC, Pichard AD, Satler LF, Bucher T, Morgan C, **Mehran R**, Hoffman R, Donovan K, Kent KM. Long-term results of patients enrolled in the antiplatelet treatment after intravascular ultrasound guided optimal stent expansion (APLAUSE) trial. *Circulation* 1996;94(8):4010.
492. Mintz GS, **Mehran R**, Hong MK, Popma JJ, Pichard AD, Satler LF, Kent KM, Leon MB. A sensitive and cost-effective intravascular ultrasound model to study anti-restenosis strategies *in vivo*. *J Am Coll Cardiol* 1996;27(2): 922-948.
493. Hoffman R, Mintz GS, Popma JJ, Pichard AD, Satler LF, Kent KM, **Mehran R**, Leon MB. Distribution of tissue growth in Palmaz-Schatz stents: insights from a serial intravascular ultrasound study. *J Am Coll Cardiol* 1996;27 (2):732-733.
494. Dangas G, **Mehran R**, Wallenstein S, Hollywood J, Kakarala V, Ambrose JA. Braunwald classification of unstable angina correlates with coronary lesion morphology. *J Am Coll Cardiol* 1996;27(2):763-766.
495. **Mehran R**, Mintz GS, Popma JJ, Pichard AD, Satler LF, Kent KM, Wong SC, Leon MB. Excimer laser angioplasty in the treatment of in-stent restenosis: an intravascular ultrasound study. *J Am Coll Cardiol* 1996;27(2):1011-115.
496. Fuessl RT, Mintz GS, Popma GS, Satler LF, Kent KM, Pichard AD, Hoffman R, **Mehran R**, Griffin J, Goldstein A, Donovan K, Leon MB. In vivo validation of lesion length measurements using motorized pullback of intravascular ultrasound transducers. *J Am Coll Cardiol* 1996;27(2):1013-121.
497. Sharma SK, Duvvuri S, **Mehran R**, Dangas G, Lotvin A, Kuthuru M, Cohen AM, Marmur JD, Cocke T, Ambrose JA. What are the best predictors of slow flow after rotational atherectomy? *J Inv Cardiol* 1996;8:36.
498. Sharma SK, **Mehran R**, Duvvuri S, Dangas G, Marmur JD, Cocke TP, Para V, Ambrose JA. A comparison of directional coronary atherectomy (DCA) with balloon angioplasty in recent myocardial infarction (MI). *J InvCardiol* 1996;8:1.
499. Sharma SK, Duvvuri S, **Mehran R**, Dangas G, Lotvin A, Kuthuru M, Cohen AM, Marmur J, Cocke T, Ambrose JA. What are the best predictors of slow flow during rotational atherectomy? *J Inv Cardiol* 1996;8:1.
500. Hong MK, Kent KM, **Mehran R**, Mintz GS, Tio FO, Foegh ML, Wong SC, Bramwell O, Leon MB. Continuous subcutaneous angiopeptin reduces neointimal hyperplasia in a porcine coronary in-stent restenosis model. *J InvCardiol* 1996;8:1.
501. Mintz GS, Popma JJ, Pichard AD, Satler LF, Kent KM, Hong MK, Griffin J, Mackenzie J, **Mehran R**, Leon MB. Reference vessel measurements: systematic differences between quantitative angiography and intravascular ultrasound. *J Inv Cardiol* 1996;8:1.
502. **Mehran R**, Mintz GS, Hong MK, Tio FO, Hoffman R, Popma JJ, Pichard AD, Satler LF, Kent KM, Wong SC, Fuessl R, Harvey M, Roth A, Prunka N, Keers B, Leon MB. In vivo intravascular ultrasound measurements of neointima within stents correlate with *ex vivo* pathology morphometry. *J Inv Cardiol* 1996;8:1.
503. Dangas G, **Mehran R**, Duvvuri S, Cocke TP, Ambrose JA, Sharma SK. Use of the femostop system as an alternative to surgical repair of femoral artery pseudoaneurysm. *Cathet CardiovascDiagn* 1996;38:120.
504. Dangas G, **Mehran R**, Wallenstein S, Hollywood J, Kakarala V, Ambrose JA. Braunwald classification of unstable angina correlates with coronary lesion morphology. *J Am Coll Cardiol* 1996; Suppl A:182A.
505. **Mehran R**, Dangas G, Sharma S, Dube G, Harpel PC, Ambrose JA, Fallon FT. Quantitation of lipoprotein Lp(a) in atherosclerotic plaques: a histologic study of atherectomy specimens. *Eur Heart J* 1996; Abstr Suppl 193.
506. **Mehran R**, Brillantes AM, Jayaraman T, Kobrinsky E, Marks AR. Association of ryanodine receptor and FK-506 binding protein. *Circulation* 1993;88(4): 1624.
507. Marx SO, Jayaraman T, **Mehran R**, Go LO, Wiederrecht J, Marks AR. Identification of a novel FK-506 binding protein in rat aortic smooth muscle cells. *Circulation* 1995;92(8):1297.
508. **Mehran R**, Brillantes AM, Marks AR. Molecular cloning and characterization of FK-506 binding protein from the human heart. *J Cell Biochem* 1993; Suppl17D.
509. Ip JH, Winters SI, Tepper D, **Mehran R**, Gomes JA. Influence of anti-arrhythmic drugs on pace termination and acceleration of ventricular tachycardia. *PACE* 1992;15:585.
510. Berns MJ, **Mehran R**, Terriot P, McKay R, Gillam L. Ablative catheter placement under direct visualization with intravascular ultrasound probe: a potential guide for ablative therapy of arrhythmias. *J Am Coll Cardiol* 1990.